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This PhD project aims to develop a novel polymer-drug conjugate (PDC) via free radical 
polymerisation for extended release and decreased permeation of p-menthane 3,8-diol (PMD) when 
applied topically onto the skin. The rational behind this was the volatile nature of PMD (evaporates 
quickly) and reports of the side effects associated with the topical absorption of the PMD. For this 
purpose, firstly hyaluronic acid (HA) was chosen as a polymer to conjugate PMD but despite 
exploring various synthetic strategies, and changing reaction parameters including the molecular 
weight, drug, reaction time etc, a conjugate could not be produced. After these initial attempts, an 
alternative route was selected for the PDC synthesis based on synthesis of polymerisable PMD 
conjugate and its subsequent co- and homopolymerisation. PMD was conjugated with acryloyl 
chloride via an ester bond to form acryloyl-PMD (APMD), which was subsequently copolymerised 
with acrylic acid (AA) to form a series of copolymers poly(AA-co-APMD). The copolymers were 
characterised by 1H NMR and FT-IR for their structural elucidation, which was then followed by 
molecular weight characterisation, thermal analysis by TGA and DSC, reactivity ratio studies, 
turbidimetric analysis and drug loading. The properties of these copolymers were affected by the 
molar ratios of AA and APMD, where the AA incorporation into the final copolymer was 3´ higher 
than the APMD. In order to assess the amount of drug (PMD) released from the copolymer, an in 
vitro experiment was performed by using porcine liver esterases (PLEs) to cleave the ester bond 
from the substrate (copolymer). It was found that ~45% of the drug was released over five days. To 
investigate the reason for the comparatively modest drug release, two experiments were performed 
to investigate the effect of copolymer molecular weight and enzyme activity on PMD release. It 
was found that molecular weight did impact on drug release whilst addition of fresh enzymes 
showed that ester bond cleavage was not limited by enzyme activity in our study. Penetration and 
permeation of the copolymer and free drug (PMD) through excised full thickness porcine ear skin 
was investigated. The Franz diffusion cell studies showed no permeation of the copolymer as 
compared to the PMD. Moreover, tape stripping revealed that almost ~90% of the copolymer was 
found on the outer surface of the skin as compared to PMD which was found in all the layers of the 
skin. A new model using planaria fluorescence assay was developed as a novel method to pre-screen 
potential irritants such as our copolymer or PMD.  The model was developed using a range of 
known skin irritants to include non-, mild-, moderate- and strong-irritants. The results showed that 
this model was able to successfully differentiate strong irritants from the non-irritants, whilst the 
other irritant classes also showed good correlation between the fluorescence intensity (FI) of the 
 vii 
planaria after irritant and then fluorescent dye exposure and the known literature primary irritation 
index (PII). This test demonstrated that that the copolymer is unlikely to be a significant irritant 
when applied topically. Overall, this project has demonstrated the feasibility of the copolymer 
approach as strategy to develop extended-release insect repellents whilst reducing transdermal 
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Chapter 1. Introduction 
Polymer-Drug Conjugates: A Potential Drug Carrier 














The skin is the largest and one of the most physiologically intricate organs in the human body, 
accounting for 15-16% of the total body mass and has a surface area of 1.7-2.5 m
2
. It is 
responsible for creating a barrier between the host and the external environment as well as the 
maintenance of homeostasis by permitting communication between the endo- and exogenous 
environments (Alberti et al., 2001; N'Da, 2014; Williams, 2003). 
The concept of polymer-drug conjugates (PDCs) began in 1950s, but it was in 1975 when 
Helmut Ringsdorf validated this approach as a mean of realizing drug targeting (Ringsdorf, 
2007). Since then, research in PDCs orientated around their application in cancer to achieve 
delivery of chemotherapeutic drugs to tumor tissues (Kopeček, 2013), with passive 
accumulation occurring by the enhanced permeability and retention effect (EPR) (Natfji et al., 
2017). Later, the application of this approach of conjugating drugs to polymers as carriers was 
extended to develop therapeutic systems for diseases other than cancers including infections, 
inflammation, cardiovascular disease, nervous system disorders, digestive system ailments, 
endocrine disease, eye infections, bone and wound-related problems (Pang et al., 2014). 
At present polymers are widely used in topical formulations, and serve as a vehicle for the skin 
formulations (Park et al., 2005). Selection of polymers depend upon the formulation type, 
ranging from polyethylene and polyacrylates in transdermal patches to thickening or gelling 
agents like cellulose in semisolid systems (Prausnitz and Langer, 2008). The most common 
polymers applied to skin are cellulose derivatives, chitosan, polyacrylates, hyaluronic acid, 
polyvinyl alcohol, polyvinyl-pyrrolidone and silicones. These polymers have varied functions 
in diverse applications from  wound dressings, to anti-nucleants in super-saturated systems and 
lubricants (Valenta and Auner, 2004).  
 
This chapter focuses on the application of PDCs for the skin rather than other routes, with a 
focus on the rationales and the key considerations that have underpinned their design (Table 
1, Table 2), with information summarised according to the therapeutic area. We finish the 




1.2. Skin as a Potential Site for Drug Delivery 
The skin provides an approachable and convenient site for the administration of drugs and can 
be used for both topical and systemic drug delivery (Prow et al., 2011). Drugs are provided to 
various body parts by applying traditional hypodermic needles and metal lancets e.g., 
intramuscular and subcutaneous injections, which produce discomfort and can transmit various 
biohazardous pathogens like Hepatitis-C, HIV and now COVID-19 causing SARS-nCOV-2.  
The skin, on the other hand, offers potential for non- or minimally invasive drug delivery due 
to its large surface area and the trans-dermal route avoids the first-pass impact of the liver. 
Likewise, constant blood pharmacons (biologically active substances other than drugs) and 
drug concentrations can be achieved by the transdermal route, thus reducing variations of the 
drug concentration in the blood, reducing related harm and inefficacy. Additionally, ingesting 
difficulties and drug absorption complications in the gastrointestinal region can be bypassed. 
Due to many immune cells like macrophages, the skin presents potential for delivering different 
vaccines (van der Maaden et al., 2015).  However, the skin, and in particular the stratum 
corneum, presents a formidable barrier to passive absorption of most drugs.  
 
The skin comprises of three layers, the epidermis, dermis and hypodermis (Figure 1.1). The 
outermost layer of the skin is the epidermis which is approximately 180μm thick but is up to 
0.8mm on the hand palms and feet soles (Alkilani et al., 2015). Epidermis, depending upon the 
location is divided into 4-5 layers, from deep to superficial these layers are the stratum basale, 
stratum spinosum, stratum granulosum and stratum corneum, whilst the epidermis of the palms 
and feet consist of a fifth layer called stratum lucidum (Duracher et al., 2009). All these layers 
except the stratum basale consist of specialised cells called keratinocytes made up of a protein 
called keratin (van der Maaden et al., 2015). The stratum basale is the deepest layer of the 
epidermis which connects the epidermis with basal lamina, this is then followed by stratum 
spinosum which got its name due to the spiny appearance of the cells. This layer of the 
epidermis consists of specialised macrophages called Langerhans cells (Honari and Maibach, 
2014). Next layer is the stratum granulosum which got its name from the grainy appearance of 
the cells. Due to the death of the cells of this layer, it gives rise to another layer called stratum 
lucidum, which is a smooth layer of the cell located in between the stratum corneum and 
stratum granulosum. This is then followed by the uppermost layer of the epidermis called 
stratum corneum (SC) which helps to prevent the penetration of the microbes and keep the skin 
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hydrated. The SC is dead, anucleate and so the underlying epidermal layers are sometimes 
referred to as the viable epidermis to distinguish this from the overlying barrier layer (Delgado-
Charro, 2013; Hadgraft and Valenta, 2000; Piérard et al., 2003). 
 
Epidermal layers are site for various diseases (and hence a potential drug delivery site) like 
psoriasis (a disease of stratum basale), atopic dermatitis (associated with depletion of SC lipids) 
(Sahle et al., 2015) and different bacterial and fungal infections (Edlich et al., 2005; Mueller et 
al., 2002). Most of these epidermal diseases, e.g. psoriasis, rosacea, allergic reactions due to 
food, eczema result in the disruption of the SC (Alkilani et al., 2015) and thus should be a point 
of consideration whilst designing the drug delivery system for these diseases. 
 
Underneath the epidermis is the dermis which is typically ~2000μm thick (Figure 1.1).  The 
dermis contains blood vessels,  hair follicles, nerves, nociceptors (pain-sensors), connective 
tissues (collagen and elastin), lymph vessels, sebaceous and sweat glands (Abdo et al., 2020; 
Barcaui et al., 2015; Kolarsick et al., 2006; van der Maaden et al., 2015). Approximately 2.5 
million sweat glands regulate body’s temperature by producing sweat.  The sebaceous glands 
are mostly located on the forehead, scalp and face, and are moderately prominent on the upper 
trunk and secrete sebum which regulate pH and keep the skin moist (Benson, 2012; Rossi et 
al., 2009). Hair follicles are found almost all over the skin with varying densities except on the 
hands, feet and lips. Dermis is a disease site for the diseases like cellulitis, acne vulgaris 
(Boulanger, 2007), fibromatosis (Lebwohl et al., 1990), benign fibrous histiocytoma and 
dermal changes (premature wrinkling) in aging. Moreover, the hair follicles in the dermis offer 
a potential route for non-invasive transdermal drug delivery (Patzelt and Lademann, 2013). 
 
Below the dermis is hypodermis which connects the skin to underlying fibrous tissues of the 
bones and the muscles. The border between the hypodermis and the dermis is difficult to 
distinguish. By some, it is not considered strictly as a part of the skin. Hypodermis is a site for 






Figure 1.1. Illustration representing A) Possible drug delivery routes into and through 
the skin, image adapted from (Williams, 2003) B) Microanatomical configuration of 
Human skin  
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One other important characteristics of human skin is the presence of various enzymes such as 
alcohol dehydrogenase, aldehyde dehydrogenase, Cytochrome P-450 and carboxyl esterases. 
These enzymes act as a first line of defence against foreign substances by transforming and 
thus helping in excretion or elimination of these harmful substances. Moreover, these enzymes 
has been utilised in the drug delivery and various studies have exploited these enzymes as a 
mean for extended as well as the controlled drug release ( Lau et al., 2012; Mizukami et al., 
2017; Pyo and Maibach, 2019). Due to considerable number of cells, the skin retains a 
biotransformation activity equal to approximately one-third of the liver, therefore, the skin is 
an important organ with an elevated enzyme activity and is suitable for designing delivery of 
dermally controlled medications (Alkilani et al., 2015). 
1.3.Polymer-Drug Conjugates 
1.3.1. An Overview 
Since the ground-breaking efforts of Hermann Staudinger (Staudinger, 1920), polymer science 
has substantial impacted on humanity in numerous areas, both positively and negatively with 
over 400 million tons of plastics manufactured yearly world-wide since 2015. Due to rapid 
advances in synthetic instruments and knowledge of biomolecular composition and 
performance, polymer bioconjugates are seen not only in biomedical applications, but can also 
provide inventive concepts in other materials sciences. Different chemistries for site-specific 
conjugation, distinct methodologies to standardize the size, topology, distribution, and role of 
the polymers, alongside adjustable exploitation of bioconjugate structural design were 
introduced. Recent  innovations in polymer bioconjugates focus on nucleic acids, proteins, 
lipids, carbohydrates and even living cells (Chen et al., 2009; Webber et al., 2016).  
 
Since Ringsdorfs early work (Ringsdorf, 1975), extensive research has been reported using 
polymer drug conjugates as drug delivery systems (DDS) for various purposes, starting from 
cancer therapy and later on extending to the treatment of inflammatory, infectious and 
cardiovascular diseases (Larson and Ghandehari, 2012). The polymer is often used as an “inert” 
carrier for covalently bound drug molecules, though in some cases the polymer itself may also 
have some functionality in drug targeting. The benefits of  drug conjugation to polymeric 
transporters, for instance polyethylene glycol (PEG), include improved drug solubilization, 
decreased immunogenicity, controlled drug release, drug targeting, extended circulation, and 
enhanced safety (Ekladious et al., 2019). 
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Polymer-drug conjugates (Figure 1.2) can be regarded as polymer-based prodrugs and are often 
used to improve aqueous solubilization of various drugs, and consequently enhance bio-
accessibility. Polymer-drug conjugate drug delivery system commonly contains a 
biocompatible water-soluble polymer backbone to which a hydrophobic drug moiety is linked 
directly or via a biological responsive linker (“spacer”) (Kim et al., 2012). The spacer is 
typically a ‘bio-reactive’ chemical bond, implicating that it undergoes dissociation in a 
biological setting. These bio-conditions can be in the form of chemical, i.e., change in pH or 
the presence of enzymes such as esterases, lipases or proteases. The selection of the spacer is 
thus dependent on the desired site of action and the physiological conditions of the part of the 
body where delivery of PDC is intended (Seifu and Nath, 2019). 
 
  
Figure 1.2. Schematic description of PDCs. Figure adapted from (Natfji et al.,2017) 
 
On the basis of architecture, there are four common types of PDCs namely linear polymers, 
dendrimers, polymeric micelles and polymeric nanoparticles (Figure 1.3). Examples of linear 
PDCs include polyethylene glycol e.g., N-(2-hydroxypropyl) methacrylamide (HPMA) 
copolymers used in various lysosomally-cleavable PDCs e.g., peptide-polymersomes 
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modernized with anti-EGFR antibody for systemic cancer therapy. Dendrimers are branched 
polymers having star like structures which provides multiple sites for drug conjugation onto 
their surfaces, hence increasing the chances of biological interactions. The most widely used 
dendrimers are poly-amidoamine (PAMAM), polypropylene imine in brain diseases, poly-aryl 
ether dendrimer, and biodegradable poly-lysine dendron in ocular drug delivery. Another form 
of the PDCs are polymeric micelles; these are amphiphilic macromolecules, that in aqueous 
medium form micelles. Examples includes polysorbates and sodium dodecyl sulphate, used as 
a permeation enhancer in transdermal drug delivery. Similarly, polymeric nanoparticles are 
soft colloidal structures in the range 10-1000 nm. They can be synthesised from various 
degradable and non-degradable polymers; examples include but are not limited to hyaluronic 
acid (HA) for targeting cell surface receptor CD44 and chitosan used to entrap nucleic acids 






Figure 1.3. Different types of PDCs 
1.3.2. Mechanism of Action of Polymer-drug Conjugates 
Polymers present exceptional and multipurpose opportunities for  drug delivery, and can be 
“bio-tailored” for therapies such as medical appliances, implants, and application of polymer-
drug conjugates, whilst synthetic polymers have been used to aid delivery of therapeutic small 
molecule drugs  the full benefits of polymer-based drug delivery has not yet been realised 
(Joralemon et al., 2004). Presently, effective uptake of polymeric systems by different isolated 
cancer cell lines persists as a major challenge, predominantly because many of the 
biocompatible polymers are highly hydrophilic with a neutral surface charge, and hence with 
low affinity to plasma membranes.   To mitigate this challenge, ligand alteration and stimuli 
reaction site-specific moieties have been shown to and increase intracellular uptake of the 
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copolymer-drug conjugates, shown by utilizing HPMA-copolymer anticancer drug 
conjugates (Pang et al., 2016).  
 
Recent investigations have led to dynamic release systems, which contain sustained release and 
site-specific targeted drug delivery. Pharmaceutical nanobiotechnology seeks to combine both 
the diagnosis and therapy of diseases using varied drug delivery vehicles e.g.,  liposomes, 
polymeric nanoparticles, niosomes, and curative polymers as “smart,” biocompatible systems 
(Mogoşanu et al., 2016). 
 
For therapeutic impact, a drug must interact with or bind to its target. The bulk (60%) of drug 
targets are proteins stationed at the plasma membranes of various cells. In addition to plasma 
membrane intracellular proteins, ribosomes or DNA are other targets for delivering drugs. An 
ideal PDC should release the drug only at the target location. In the case where an active drug 
target is extracellular, then delivery is relatively easy. Where the drug target is in cytosol 
(intracellular) and the polymer delivery system can easily enter, then drug will be released 
intracellularly. However, if the conjugate does not have the ideal properties to enter a cell where 
the target site may reside, then drug release may be extracellular, but the drug will then need 
to enter the cell and diffuse to its target site.   Fortunately, due to different biochemistry of the 
environment outside (extracellular) and inside of the cells (cytosol), designing and creation of 
linkage between the drug molecule and  polymer that break down under particular conditions, 




Figure 1.4. Illustration showing PDCs drug delivery mechanism to a cancer stem cell 
 
Dependent on the pathophysiology of the target site, the design of PDCs and the mechanism 
of drug release can be tailored as summarised in Table 1.1. 
 
Table 1.1. Rationale for Polymer-Drug Conjugate Design 
Rationale Mechanism of Action Examples 
Controlled and Sustained 
Drug Delivery 
 pH-dependent release HPMA-copolymer Anticancer drug 
conjugates (Pang et al., 2016) 
Release and Enhanced 
Drug Targeting 
 Enzyme-dependent release Tragacanthin-tyramine conjugate 
(Lett et al., 2019) 
  Receptor-mediated      
activation. 
HA-Growth hormone conjugate (Yang 
et al., 2012) 
  Tissue affinity PEG-Adenovirus conjugate 
(Kim et al., 2011) 
  Targeting by increase of 
vasculature 
HPMA-Doxorubicin (Etrych et al., 
2008) 
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Increased water solubility Linking to a water-soluble 
polymer 
8-Aminoquinoline-HPMA conjugate 
(Nan et al., 2001) 
Enhanced stability and 
prolonged half-life (t1/2)  
Reduced renal filtration                PEG-vancomycin conjugates 
(Greenwald et al., 2003) 
  Reduced enzymatic 
degradation 
Sodium-carboxymethylcellulose–
Bowman–Birk conjugate (Marschütz 
and Bernkop-Schnürch, 2000) 
Combination therapy   Polymer and drug have 
therapeutic effects. 
Polyacetal-curcumin conjugate 
(Requejo-Aguilar et al., 2017) 
  Loading two drugs 
simultaneously.  
PGA-paclitaxel+ carboplatinum 
conjugate (Vicent and Duncan, 2006) 
Localised 
effect                               
 Prevention of Blood- Brain 
Barrier penetration 
PEG-haloperidol conjugate (Natfji et 
al., 2020) 
 
1.3.3. Advantages of Polymer-Drug Conjugates 
PDCs offer numerous advantages over traditionally used micro and macromolecule 
formulations including improved solubility and stability in aqueous medium, precise (or rather 
more precise) delivery and an improved pharmacokinetic profile (Zhu et al., 2014). The 
principle difference between other polymeric systems and polymer-drug conjugates is that in 
the later, one or more drug molecules can be linked to a single polymer chain through a linker, 
a spacer or a drug may be directly attached whereas the other polymeric carrier  systems only 
physically encapsulate the drug (Maeda et al., 2001; Pan et al., 2014; Pang et al., 2016). PDCs 
thus possess, and can have tailored, suitable physico-chemical properties (Figure 1.4) to: 
 (1) Increase in water solubility of poorly water-soluble drugs, i.e., by attaching the drug 
to a linear polymer like PEG, which also helps in the rapid excretion of the drug from 
the body.  
(2) Protect the drug from deactivation or degradation e.g., PEG-protein conjugates.  
(3) Improve in the pharmacokinetic profile of the drug, such as prolonging its 
circulation before elimination  
(4) Decrease an immune response to a drug.  
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(5) Allow site-specific targeting of the drugs such as with the EPR effect for tumours.  
(6) Enhance therapeutic outcomes by either attaching two drugs on the same polymer 
chain or where both polymer and the drug have synergistic activity.  
(7) PDCs due to their unique nature are more resistant to the efflux mechanism 
employed by the multidrug resistance bacteria (Pang et al., 2013). 
 
 
1.3.4. Synthesis and Characterisation of Polymer-Drug Conjugates 
 
For the synthesis of PDCs, various methods are used, among which there are two most widely 
used routes; 1) conjugation of the polymer with the drug, 2) polymerisation of the monomer 
drug conjugate to form homo or copolymer, 3) Polymerizable drug. For conjugation of the 
polymer with the drug, different methods are used, the most common is the coupling method. 
This method involves the use of activating agents like N-hydroxysuccinimide esters (NHS), or 
carbodiimides (Hamley, 2014). Another method used for the conjugation of drugs with the 
polymers is the click coupling reaction (a reaction involving high grafting efficiencies) where 
low to medium size (molecular weight) polymers are conjugated with the drugs. Major 
disadvantage of this method includes relatively lower drug loading (Zolotarskaya et al., 2015). 
Similarly, an alternate route for the synthesis of PDCs is the polymerisation of the monomer 
drug conjugate with itself (homopolymer) or with another monomer (copolymer). For this 
purpose, various methods are used, namely, free radical polymerisation, ring-opening 
polymerisation, reversible addition-fragmentation chain transfer polymerisation (RAFT) 
reaction etc. The selection of these method depends upon the requirement, i.e. molecular weight 
and polydispersity index (PDI) etc. Amount of drug loaded can be controlled by the molar ratio 
of the feed mixture whilst the drug release can be controlled by the selection of a rational linker 
in between the drug and the monomer. Disadvantages of this method include uncontrollable 
and inconsistent side conjugation with the polymer backbone whilst the advantages include 
better drug loading than the conjugation of the drug to the polymer backbone (Hasirci et al., 
2017; Nicolas, 2016). Similarly, third method to synthesise a PDC is the use of a polymerizable 
drug, for example 10-hydroxycamptothecin. The use of this strategy includes advantages like 
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better drug loading, whilst disadvantages include; not many drugs fit for such category, 
moreover, as most of these drugs are polymerised through the polycondensation route, so this 
chemistry does not yield high molecular weight polymers. In addition, introduction of 
responsive functional groups is not easy and requires complex chemistry (Feng and Tong, 
2016).  In order to investigate the structure and properties of the PDCs various techniques are 
used, few of them are NMR, FT-IR, UV, TEM, GPC and thermal analysis (Chang et al., 2012). 
 
Figure 1.5. Synthetic strategies for the synthesis of PDCs. Illustration adapted from (Feng 
and Tong, 2016) 
 
1.4. Applications of Polymer-Drug Conjugates for Skin Drug Delivery 
Traditionally PDCs have been used in chemotherapy to optimise the drug delivery profile and 
reduce the adverse drug reactions (ADRs) by exploiting the EPR effect. Till now, there is only 
one commercial example of PDCs which is MovantikRx (a PEG-Naloxol conjugate) used to 
treat opioid induced constipation and is given orally. Beside this, PDCs have also been used 
for other indications including cardiovascular diseases, nervous system diseases and endocrine 
system diseases etc mostly delivered via intravenous route.  Here, we focus on topical 
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application of PDCs.  This may initially appear somewhat counterintuitive as skin is a well-
established effective barrier to drug delivery, and only relatively small molecular weight 
(typically <500 Da) and lipophilic molecules can be delivered to or through the skin to 
therapeutic levels.  However, this is advantageous where the drug to be conjugated should 
remain at the skin surface and not permeate, perhaps where surface action or release at the skin 
surface is desired (as with insect repellents described below), or for use where the skin barrier 
is compromised in conditions such as psoriasis or for wound healing.      
1.4.1. Polymer-Drug Conjugates in Wound Healing  
Wound healing is a complicated, biochemical, molecular and cellular activity including 
inflammation, propagation, and movement of different cell types, resulting in tissue rebuilding 
and transformation as shown in Figure 1.6. This activity is accelerated or hampered by matrix 
production, collagen accumulation, neovascularization, re-epithelialization and formation and 
differentiation of various cells and the interplay with growth factors and cytokines. The 
prominent growth factors which are important modulators of wound healing include fibroblast 
growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), 
transforming growth factor (TGF), epidermal growth factor (EGF) and vascular endothelial 
growth factor (VEGF). The ultimate result of this cellular-molecular cross talk results in tissue 
repair that affect chemotaxis and promote mitosis of inactive cells which then lead to 
angiogenesis (Barrientos et al., 2008; Singer and Clark, 1999).  
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Figure 1.6. Illustration representing the wound healing process a) Beginning of 
homeostasis by the release of erythrocytes and platelets to form a clot, b) Activation of 
platelets by thrombin resulting in the release of growth factors, i.e. EGF, PDGF to attract 
neutrophils and macrophages, c) Fostered by the proangiogenic factors like FGF, there 
is formation of the new blood vessels and capillaries, d) Re-epithelization phase 
characterised by the gradual appearance of the newly formed collagen. 
Wound healing is a highly synchronised process and depends on signalling pathways within 
the cell. Substantial progress has been made in the identification of these signalling molecules 
and the underlying mechanism in both the healthy and diseased states. As a result, there has 
been a significant interest in using these signalling pathways for better therapeutic outcomes, 
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i.e., healing or facilitating the healing process that may otherwise not occur naturally. An ideal 
drug delivery system (DDS) for wound healing would have the following characteristics:  
(1) It should maintain its therapeutic activity throughout the wound bed,  
(2) It must prevent rapid dilution in the wound and associated systemic uptake,  
(3) It would facilitate the release of the drug within the wound at relevant therapeutic 
rate and duration, and  
(4) It would increase the water solubility and stability of the drug (Rădulescu et al., 
2016).  
One approach to achieve the above is the use of PDCs. 
 
Acidic fibroblast growth factor (aFGF), a protein that activates division in the cells of 
mesodermal and neuroectodermal origin, exhibits biological activity in wound healing by 
stimulating the proliferation of fibroblasts and promoting angiogenesis, resulting in wound 
healing. However, use of aFGF is limited due to its instability and short half-life. To address 
these problems Huang and the coworkers reported conjugation of PEG with recombinant 
human acid fibroblast growth factor (rhaFGF) by the site specific PEGylation of rhaFGF with 
mPEG-butyraldehyde (20KDa). The obtained product was purified by using Sephadex-G 25-
gel filtration. In vivo immunogenecity was significantly decreased whilst the in vivo half life 
was significantly elongated, due to which wound healing was much quicker when BALB/c 
mice were treated with PEGylated rhaFGF as compared with the treatment alone with rhaFGF 
(Huang et al., 2011). It was concluded that this was due to the better thermal activity at 
physiological temperature and an improvement in half-life as seen by other researchers 
(Papanas and Maltezos, 2007). 
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Figure 1.7. Illustration showing the synthesis and the advantages of the PEGylated 
rhFGF 
 
In another study Choi et al. (2012) reported the successful conjugation of low-molecular weight 
protamine (LMWP) with recombinant epidermal growth factor (rEGF) to form a rLMWP-EGF 
conjugate. Conjugation was achieved by linking a highly positive charged protamine molecule 
to the n-terminal of EGF and was used to treat diabetic and burn wounds. In both cases, in vitro 
results showed well-preserved cell proliferation activity of the conjugate. Moreover, after the 
application of this conjugate onto the skin of BALB/c mice, the in vivo results showed that as 
compared to controls, i.e. EGF alone, the physical mixture of EGF and LMWP and the 
conjugate itself. The results (Figure 1.9) showed that the conjugate permeability into the mice 
skin was 11 times higher than the free protamine and was responsible for the quicker wound 
closure. These experiments suggest that topically applied conjugate of protamine with EGF 
(rLMWP-EGF) has the potential to be used in diabetic wounds as shown in Figure 1.9 b and c. 
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a)                                                                     b&c) 
Fig 1.8. In vitro permeation through the artificial skin constructs. (a) Time-course of 
cumulative concentrations of epidermal growth factor (EGF) and EGF covalently 
conjugated with low-molecular-weight protamine (LMWP), transactivating 
transcription activator (TAT), and oligo-arginine (R7). Effect of epidermal growth factor 
(rEGF) or low-molecular-weight protamine (LMWP) conjugated EGF (rLMWP-EGF) 
on wound area reduction in the full thickness model. (b) Percentages of wound area were 
measured for 10 days. (c) Lower panels provide typical wound images. The data are 
plotted as mean ± standard deviation (n = 4). *p < 0.05 vs. EGF. **p < 0.05 vs. TAT-EGF 
(Choi et al., 2012). 
 
In an alternative wound repair model, Requejo-Aguila et al. (2017) applied PDCs for spinal 
cord injury (SCI); curcumin, a natural anti-inflammatory, was conjugated to polyacetal (PA) 
in order to increase its water solubility and stability and provide controlled release of the 
drug.  In vitro studies showed pH-dependent release of the drug, i.e., curcumin with increasing 
release at acidic pH.  In vivo studies using Sprague Dawley rats revealed that a single 
administration of the conjugate produced a significant increase in motor activity due to the 
various factors among which top of the list is the elongation of the axon due to the inhibition 
of Rho kinase enzyme. Other factors included a decreased volume of cavitation, decreased 
astrogliosis (glial scar formation) and increased number of neurons fibres after the injury as 
compared to controls or PA as shown in Figure 1.10. Notably, the conjugate treatment offered 
a neuroprotective effect supplemented by reduced levels of apoptosis and inflammation. The 
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combined therapy of PA-curcumin and ependymal progenitor (epSCi) improved functional 
recovery from chronic spinal injury, with a notable reduction in scar area. 
Figure 1.9. Illustration showing the synthesis PA-Curcumin conjugate, and the 
mechanism by which the PDC heals the spinal wound 
Hatanaka et al. (2019) assessed biocompatible polymeric nanosheets for topical and 
transdermal drug delivery by using two-dimensional nanostructures. Their sheets properties 
included high transparency, elasticity, and glueyness. Betamethasone valerate (BV) was used 
as a model drug conjugated to poly (L-lactic acid) or poly (lactic-co-glycolic) acid.  Films were 
constructed by a spin-coating-assisted layer-by-layer technique utilizing a water-soluble 
sacrificial tissue/membrane. These fabricated formulations had higher incorporation and 
release of BV as compared to a commercial ointment and controlled-release membranes 
enabled application to any area of skin for an extended period. The auditors reported that this 
bio-friendly polymeric nanosheet preparation offers a novel and encouraging topical and 
transdermal drug delivery system for pharmaceutical or cosmetic uses including the usage as a 




1.4.2. Topical Conjugates for Local Anaesthetics 
 
Pain management, whether acute or chronic, is a substantial clinical challenge requiring both 
pharmacological and behavioural (e.g. cognitive behavioural therapy) interventions. Local 
anaesthetics disrupt neural transmission by preventing the influx of sodium ions via ionophores 
inside neuronal tissues and are commonly applied to manage post-surgical pain and for acute 
and chronic pain therapy. A range of methodologies are presently applied to extend the duration 
of local anaesthetics, but long term sustained neuronal obstruction (e.g. for >24 hrs) remains 
elusive.  Whilst local anaesthetics have been extensively used in clinical practice,  due to their 
toxicity and short half-lives their benefits are limited and hence are the target of multiple 
research groups attempts to develop innovative  drug delivery systems such as microparticles, 
liposomes, niosomes and nanoparticles (Becker and Reed, 2012). 
 
Hyaluronic acid (HA) is a non-immunogenic polysaccharide naturally found in valves of heart, 
vitreous humour of the eyes, synovial fluid and extracellular matrix. Due to its 
biodegradability, bio-similarity and viscoelastic traits, HA has been extensively used in 
numerous therapeutic products (Abduljabbar and Basendwh, 2016).  One of the important 
drugs used as anaesthetic is bupivacaine (BUP), but its usage has got limitations due to its short 
duration of action. As discussed in Table 1.1, one of the major advantages of the PDCs is the 
increased half-life of the drug.  Thus, by keeping this into consideration Gianolio et al. (2005) 
conjugated BUP to the HA derivative, Hylan B particles; in vitro  BUP drug release was 
extended to ~100 hours  from HA-BUP particles, substantially higher than that of free BUP 
showing approximately 5 hours (Figure 1.10). This translated to extended in vivo efficacy 
where HA-BUP demonstrated a twenty-fold lengthier block time in weakening motor nerve 
functions, as compared to free BUP.  
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Figure 1.10. Figure showing the cumulative release of BUV from the PDC over the period 
of time (Gianolio et al., 2005) 
 
Polylactic acid (PLA) polymerized from lactic acid is a multipurpose material, primarily 
utilized for biodegradable goods such as plastic bags and containers. PLA was conjugated to 
bupivacaine (BUP) and was used as a delivery system to lengthen percutaneous response of 
superficial neurons. Another anesthetic lidocaine (LID) was coated onto poly-L-lactide-
polylactic acid (PLLA) microneedle arrays. Dip-coating permitted LID to only cover the needle 
tips and substantially decreased painkiller loss, so this drug delivery system prolonged the 
duration of anesthesia (Baek et al., 2017). 
 
Among the recombinant proteins, polypeptides are engineered genetically from various cell 
types. Covalent bonding of the peptide and drug via a cleavable linker produces peptide-drug 
conjugates which have been evaluated as drug delivery system. Among these systems, 
transcriptional trans-activator peptide (TAT), is a well-established peptide. Wang et al. (2013) 
produced a liposomal formulation using lidocaine loaded TAT-peptide-conjugates for 
transdermal delivery of the lidocaine. The formulation was tested for its stability and 
encapsulation efficacy, showing better stability and encapsulation efficacy (80.05 ± 2.64%) as 
compared to the conventional liposomal formulation (CLs). In vivo experiments using BALB/c 
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mouse skin penetration of the fluorescent dye calcein (also called as fluorexon) encapsulated 
in liposomes and TAT-conjugated liposomes delivery vehicles showed that the conjugated 
formulation had improved skin permeation, i.e. 4.17 and 1.75 times higher than the LID 
solution and LID-CLs (shown in Figure 1.11) as well as the stability in the mouse model. This 
better permeability profile can be attributed to the TAT, as it is a well-known cell-penetrating 
peptide that can increase the skin delivery of drugs. 
 
Figure 1.11. Figure showing the permeation profile of the Lidocaine from the PDC (Wang 
et al., 2013) 
 
Leu-enkephalin (LENK) is an endogenous opioid peptide neurotransmitter with an amino acid 
sequence of Tyr-Gly-Gly-Phe-Leu.  It is naturally occurring in the brains of several organisms, 
including humans and has been identified as a promising painkiller. It is considered as a strong 
anaesthetic attributed to its strong affinity towards the δ -opoid receptors, however, its 
utilization is restricted due to its instability in the plasma and transport across the BBB. In order 
to address these problems, Feng et al. (2019) conjugated LENK with squalene assembling the 
conjugate to form nanoparticles. In vivo studies using rats with carrageenan-stimulated paw 
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oedema resulting in hyperalgesia (extreme sensitivity to pain) to mimic human pain evaluated 
the therapeutic activity of the formulation. The anti-hyperalgesic impact of LENK-SQ 
nanoparticles was twice as long as that of morphine. Fluorescent images showed the 
biodistribution of the formulation in the rat model paw oedema where, in contrast to LENK 
alone, the majority of the conjugate was observed at the site of application, i.e., is an inflamed 
paw, with relatively little  accumulation within the rat’s brain so overcoming the problems 
linked with the use of the peptide (LENK) only. 
 
 
Figure 1.12. Antihyperalgesic effects of acute treatment with morphine (A and B), 
LENK-SQ-Diox NPs (C and D), LENK-SQ-Dig NPs (E and F), and LENK-SQ-Am NPs 
(G and H) in λ-carrageenan–induced inflammatory pain injected rats. Administration of 
morphine, LENK-SQ NPs, Nal, Nal-M, LENK, blank SQ NPs, or dextrose solution 
(vehicle) was performed (arrows, 0 on abscissa) 3 hours after λ-carrageenan injection into 
the right hind paw. Morphine (A), LENK-SQ-Diox NPs (C), LENK-SQ-Dig NPs (E), and 
LENK-SQ-Am NPs (G) induced an increase in PWL (in seconds, means ± SEM of 
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independent determinations in five to nine animals per group) in the Hargreaves test. 
*P < 0.05, **P < 0.01, ***P < 0.001, compared to dextrose solution or LENK 
solution; ###P < 0.001, compared to morphine; $P < 0.05, $$P < 0.01, $$$P < 0.001, 
compared to LENK-SQ NPs. Two-way analysis of variance (ANOVA) with repeated 
measures, Bonferroni post-test. Nal or Nal-M was administered 15 min before morphine 
or LENK-SQ NP injection. Basal on abscissa: Control (naïve) rats (before λ-carrageenan 
injection). (B, D, F, and H) Bars are the means ± SEM of AUCs (seconds × minutes) of 
the cumulative durations derived from the time course changes (A, C, E, and G) in PWL 
after the various treatments. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA, 
Tukey post-test, compared to dextrose (vehicle) or LENK solution; $P < 0.05, $$P < 
0.01, $$$P < 0.001, compared to LENK-SQ NPs (Feng et al., 2019). 
 
 
Figure 1.13. (A) Biodistribution of fluorescent LENK-SQ-Am NPs in mice with inflamed 
right hind paw. (B) Biodistribution of fluorescent LENK-SQ-Am NPs in mice with non-
inflamed hind paw (saline injected only into the right hind paw). (C) Biodistribution of 
free dye in mice with inflamed right paw. (D) Zoom of group A at 2 hours. (E) Zoom of 
group B at 2 hours. (F) Quantitative analysis of the paws with the same region of interest 
(ROI). R, right hind paw; L, left hind paw (Feng et al., 2019). 
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1.4.3. Polymer-Drug Conjugates for the Treatment of Psoriasis 
Psoriasis (Greek psōriasis, from psōra ‘itch’and psōrian ‘have an itch’) is an inflammatory 
chronic illness facilitated by the immune system with a primarily cutaneous contribution. 
Psoriasis is a lifelong autoimmune disease exemplified by patches of abnormal skin. Affected 
sites are normally red, purple on certain individuals with darker skin, itchy, dry, and encrusted. 
Psoriasis coverage varies from discrete patches to full body coverage. Clinical phenotypes of 
psoriasis are described by the appearances of the disease, patient age at disease commencement, 
degree of coverage and morphology (Raychaudhuri et al., 2014). Plaque psoriasis is the most 
common form of psoriasis which has encrusted (scaly) skin, erythematous plaques, and 
inflammatory cell infiltration (Nestle et al., 2009). It also affects nails, skin and joints, is a 
persistent, agonizing, disfiguring and immobilizing noncommunicable disease (NCD) for 
which there is no appropriate remedy. It adversely effects the quality of living, most common 
among 49-69 years old with a registered prevalence rate of 0.09%  to 11.4% in the world, 
making it a significant health concern (Rendon and Schäkel, 2019; WHO, 2016). 
  
Common first line therapy for psoriasis uses corticosteroids but as the condition resolves and 
the stratum corneum barrier reforms, then decreasing amounts of the drug are delivered at the 
target site. Retention of corticosteroids  within the epidermis can manage skin inflammation, 
erythema and scaling linked with psoriasis, whilst preventing potential side effects associated 
with oral delivery. Dolz-Pérez et al. (2020) used both in vitro and ex vivo assays to show that 
a poly-L-glutamic acid (PGA)-fluocinolone acetonide (FLUO) conjugate (PGA-FLUO) 
suppressed pro-inflammatory cytokine (TNF-α, IL-1β, IL-6, IL-10) released by the leukocytes, 
suggesting this system for the treatment of psoriasis. Furthermore, PGA-FLUO was shown as 
a reservoir within the epidermis by employing ex vivo human skin permeation studies with 
confocal microscopy; negligible conjugate was seen in the dermis, suggesting a reduced 
likelihood of FLUO entering the systemic blood circulation. PGA-FLUO applied within a 
hyaluronic acid (HA)-poly-L-glutamate cross polymer (HA-CP) vehicle successfully 
decreased psoriasis-linked phenotypes in an in vivo mouse model of human psoriasis with 
minimum pro-inflammatory cytokines in body tissue and blood serum. Together, the results 
show that the conjugate combined with a HA-CP penetration enhancer could be an effective 
topical therapy for psoriasis. 
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Figure 1.14. A) Illustration showing the synthesis and the permeation of the PDC, B) 
Histological analysis of mouse tissues after five days of anti-psoriatic treatment in an 
IMQ-induced skin inflammation model. The images demonstrate a marked reduction of 
the epidermal thickening in the group treated with PGA-FLUO compared to free FLUO. 
One representative picture is shown for each treatment regimen (Dolz-Pérez et al., 2020) 
 
Topical anti-inflammatory medications with inadequate percutaneous penetration is a major 
reason restricting their use in psoriatic skin. Although curcumin has demonstrated effectiveness 
in the treatment of psoriasis, its permeation through the stratum corneum remains  a main 
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obstacle to transdermal delivery. Mao et al. (2017) used skin-permeating nanoparticles to 
enable delivery of curcumin to the lower skin layers. Polymeric nanoparticles were synthesized 
from an innovative amphiphilic polymer called RRR-α-tocopheryl succinate-grafted-ε-poly 
lysine conjugates with a diameter of 25.45 nm and a positive Zeta potential of 19.65 mV. The 
particles were evaluated in mouse skin in vivo, (it should be noted that mouse skin is a relatively 
poor and fragile model of human skin). Curcumin was effectively encapsulated in the 
polymeric nanoparticles with an encapsulating efficiency of 78.45%. To prolongation retention 
of the curcumin-nanoparticles (CUR-NPs) in skin, silk fibroin was applied as a hydrogel-based 
matrix which, in vitro, demonstrated slower release of curcumin than the plain CUR-gel, with 
no alteration in the skin penetration ability of CUR-NPs. In vivo experiments on psoriatic mice 
showed that the CUR-NPs-gel displayed a better therapeutic outcome than CUR-NPs alone as 
the former enhanced skin permeation resulting in successful anti-keratinization activity. 
Interestingly, CUR-NPs-gel also prevented the appearance of pro-inflammatory and 





Figure 1.15. Permeation of nanoparticles in mice skin at 24 h and 48 h. Original 
magnification: 20×. (A) Mice skins on the back were exposed to the IMQ suspension for 
8 days (IMQ exposure alters keratinocyte proliferation and differentiation), (B) PASI 
scoring of psoriatic skin after treatment with various formulations: (a) Erythema, (b) 
thickness and (c) scaling of the back skins. The score is presented (Mean ± SD, n = 12) 
(Mao et al., 2017). 
 
Antibodies such as TNF-α–Ab are potent therapeutics for the treatment of psoriasis. Three 
immuno-biological drugs are used to target tumour necrosis factor (TNF-α), with etanercept, 
adalimumab and infliximab authorized to treat mild-to-serious cutaneous psoriasis. These 
biologics are delivered by intravenous infusion or subcutaneous injection but are expensive 
with potential for side effects. The key challenge for topical  delivery of TNF-α–Ab is their 
poor  penetration into and permeation through the stratum corneum (Carrasquillo et al., 2020). 
Korkmaz et al. (2016) used the approach of combining TNF-α–Ab conjugated to hyaluronic 
acid (HA) with tip loaded dissolvable microneedle arrays (TL-dMNAs) for local application, 
i.e. into the skin. The results showed that: (1) TL-dMNAs can be effectively moulded to 
incorporate anti-TNF-α-Ab-HA at the tip of the microneedles whilst maintaining the required 
biological activity for antibody ligand binding; (2) Anti-TNF-α-Ab-HA can be efficiently 
distributed into human skin using TL-dMNAs; and (3) polymer conjugation successfully 
prevented antibody diffusion from the delivery locus. Taken together, these outcomes 
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encourage the development of microneedle array–based delivery system of varying polymer-
antibody conjugates for the treatment of psoriasis. 
 
Figure 1.16. Illustration showing the use of microneedles coated with the conjugated 
polymer in the skin 
 
Tretinoin, also called as all-trans retinoic acid (ATRA), a metabolite of vitamin A is used to 
treat acute promyelocytic leukaemia and skin disorders such as psoriasis. ATRA is used in the 
form of creams or emulsions, delivering the drug as a single bolus which is immediately taken 
up by the skin and contributes to the side effects such as skin irritation and hair loss. To address 
these problems Castleberry et al. (2017) synthesised a polymer-drug conjugate by conjugating 
ATRA with a hydrophilic polymer, namely polyvinyl alcohol (PVA), through an ester bond. 
This resulted in the formation of amphiphilic nanoparticles which were water soluble. In vitro 
drug release studies using pig skin showed that the ATRA from the conjugate was within the 
skin for up to 10 days, thus providing a sustained drug release (as compared to single bolus). 
Moreover, in vivo results showed that the conjugate formulation reduced inflammation at the 
site of inflammation as compared to the free drug and ensured retention of the drug at the site 
of application at detectable concentrations for up to 6 days. 
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Figure 1.17. Figure showing the synthesis and the release profile of ATRA from the PDC 
(Castleberry et al., 2017) 
 
Mycophenolic acid (MPA) is a potent anti-proliferative and immunosuppressant agent with 
anti-psoriatic action and is usually applied as a component of triple therapy involving a 
calcineurin inhibitor (ciclosporin) and prednisolone. Use of MPA for therapeutic purposes is 
restricted due to its poor oral bioavailability, and low aqueous solubility (Kelly and Butch, 
2012). Supasena et al. (2020) reported conjugation of poloxamer 407 (P407) and MPA via an 
ester linkage resulting in a P407-MPA conjugate and was studied for micellization, particle 
size, size distribution, and antipsoriatic activity. 1H-NMR implied that polymeric micelles 
formed from the P407-MPA conjugate showing its polyethylene oxide chain to the aqueous 
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environment while restricting the conjugated MPA within the inner core. Surprisingly, the 
conjugate had over 12-fold lower critical micelle concentration (CMC) compared to the 
polymer alone, i.e.  P407. The conjugate showed an enzyme-dependent sustained-release and 
improved antiproliferation activity in an in vitro psoriasis model, i.e. tumour necrosis factor-α-
induced HaCaT cells. 
 
PDCs have also been evaluated for combination therapy. Mielanczyk et al. (2020) conjugated 
two hydrophobic anti-psoriatic agents, namely methotrexate (MTX) and acitretin (AC), with 
N,N-dimethylaminoethyl methacrylate (DMAEMA) repeating units in the polymethacrylic 
chains. These positively charged (+5 to +10 mV) nano- and microparticles were assessed for 
cytotoxicity in vitro using MTT and Annexin-V apoptosis assays on NHDF, Me45, HaCaT and 
BEAS-2B cell lines. The conjugates showed a novel cytostatic effect in Me45 cells and a pro-
apoptotic effect in HaCaT cells. Epithelial BEAS-2B cells were the most sensitive to the 
polymer conjugates and gave responses via initiation of necrosis. Moreover, using an animal 
skin in vitro assay showed reduced side effects from these conjugates. Similarly, 
histopathological tests confirmed absence of irritation of the animal skin following dosing with 
these conjugates. 
 
1.4.4. Polymer-Drug Conjugates for Treating Skin Infections 
The increasing worldwide prevalence of bacterial infections, principally in persistent wounds, 
is an urgent priority and one in which novel treatments could be highly impactful. To this end, 
Shepherd et al. (2011) established a method where hyperbranched poly-(NIPAM) polymers 
were conjugated with the antibiotics Polymyxin-B and Vancomycin and were tested against 
bacteria in solution culture. Interestingly, attachment of bacteria to the polymers was reported 
which triggered conformational modification including disintegration of the polymer backbone 
and the establishment of polymer/bacteria complexes which upon removal also removed the 
attached bacteria and hence significantly reducing the bacterial load in the culture. The novel 
polymer was also evaluated using a “human burn” tissue engineered skin model infected with 
Gram-negative Pseudomonas aeruginosa and Gram-positive Staphylococcus aureus; 
significant decreases in the bacterial load was detected following use of the hyperbranched 
polymer in the form of polymer gel solution or hydrogel membrane. 
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Figure 1.18. Illustration showing the use of a hydrogel membrane (made up of 
Poly(NIPAM)-Amb conjugate) onto the infected wound 
 
Poly(N-isopropylacrylamide) (PNIPAM) is an extensively used temperature-reactive polymer 
produced originally in 1950s and is currently manufactured from industrially produced N-
isopropylacrylamide. Swift et al. (2019) showed that highly branched poly-(N-
isopropylacrylamide) (HB-PNIPAM), with a chain having solvato-chromic (different colours 
due to a solute when that solute is dissolved in dissimilar solvents) dye Nile red (or Nile blue 
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oxazone), might offer a fluorescence indicator when end groups attach to a bacterium and 
consequently chain sections isolate. In this drug-polymer conjugate, vancomycin was attached 
to HB-PNIPAM chain ends or as suspended groups on linear polymers individually having 
Nile red or Nile blue oxazone. Analysis of both the fluorescence and calorimetric results 
revealed that branched polymers responded to attachment of both the peptide target (D-Ala-D-
Aa) and bacteria in a divergent trend. Results of fluorescence spectroscopy indicated that only 
the outer domain segments of branched polymers reacted to binding of Gram positive bacteria 
Staphylococcus aureus with only a slight reaction when linear analogous polymer or branched 
polymer with Nile red or Nile blue oxazone in the innermost core was exposed to 
Staphylococcus aureus cultured in vitro in chocolate blood agar. 
 
Chromobacterium violaceum a Gram-negative bacterium normally found in water and soil, 
infrequently produces severe pyogenic or septicemic infections in human skin, generally seen 
as skin abscesses. Chromobacterium violaceum is mainly recognized as a violacein (bis-indole 
pigment with anti-bacterial and anti-viral properties) producer and as a reporter for quorum 
sensing molecules discovery. Quorum sensing (QS) is intercellular messaging facilitating 
individual bacteria to modify their activities in response to the resident Gram-positive and 
Gram-negative bacterial inhabitants’ density via molecules described as autoinducers (Batista 
et al., 2020). QS also plays a role in regulation of gene expression of a bacterial population in 
response to chemicals (nutrients and toxins) in an environment. Bacterial quorum detection has 
been associated with several pathogenic bacterial processes, for instance biofilm creation, 
rendering this as an important focus for generating materials with a novel antibiotic action. 
Shepherd et al. (2019) synthesized pol-(N-isopropyl acrylamide) that was covalently connected 
to numerous chain ends to homoserine lactone as a crucial messenger molecule participating 
in quorum sensing and was shown to have anti-QS activity in a Chromobacterium violaceum 
assay.  
 
Turos et al. (2007) successfully conjugated penicillin with polyacrylate, which was then 
formulated into nanoparticles with anti-bacterial activity. These nanoparticles were prepared 
by free radical polymerization in which penicillin-acrylate monomer was dissolved in a 7:3 
(w/w) mixture of butyl acrylate and styrene in the presence of sodium dodecyl sulphate 
(surfactant) and potassium persulphate (radical initiator). In vitro activity was tested against 
methicillin-resistant Staphylococcus aureus (MRSA) and showed encouraging results with no 
cytotoxicity towards human dermal fibroblast (HDF) cell line. Furthermore, the conjugate 
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demonstrated hydrolytic cleavage by bacterial penicillinases, thus expanding the drug's action 
with regard to drug resistant strains such as MRSA. Similarly, these conjugated polymeric 
particles also showed positive results in vivo against a murine model, again with decreased 
cytotoxicity. When applied topically to a dermal abrasion model in vivo, this emulsion 
enhanced wound healing by an average of 3 to 5 days. Thus, this study suggests that 
polyacrylate nanoparticle-containing emulsions may be a promising therapy for treating skin 
infections. 
 
Jeong et al. (2008) synthesized a polymer-drug formulation using Poly(lactic-co-glycolic)-acid 
containing ciprofloxacin particle sizes of 100–300 nm. These drug carriers were evaluated for 
in vitro and in vivo antibacterial activity against an eczema infecting strain of E. coli. As 
ciprofloxacin was released from this polymer-drug nano-system over a period of 14 days, the 
system provided a lower but sustained antibacterial action than free drug. However, in 
vivo antibacterial action was greater than the free drug.  Interestingly, the in vitro experiments 
were conducted for 24-hour time period only, while in the in vivo experiment, BALB/c mice 
were sacrificed after 72 hours demonstrating that studies of sustained release antibiotic 
formulations should use in vitro studies over a lengthy period.  Such a study was also 
undertaken by Toti et al. (2011) for PLGA polymers linked to rifampicin and azithromycin and 
who showed significant antibacterial activity against reproductive tract and groin skin 
epithelial cells infecting Chlamydia trachomatis.   
 
In immunocompromised patients, fungal infections are a significant cause of morbidity and 
death. Presently, three main classes of medicines (azoles, echinocandins and polyenes) are used 
as antifungal agents with distinct mechanisms of action. However, these medications can 
generate adverse reactions due to their minimal specificity, drug–drug interactions and limited 
range of activity. Some of these constraints could be overcome by modifying the properties of 
current drugs through physical and chemical alterations, for example the alteration of the 
polyene antibiotic amphotericin B (AmB), by making a micellar suspension in deoxycholic 
acid (Fungizone®), AmB colloidal dispersion (Amphocil™), non-covalent AmB lipid 
complexes (ABLC™) and most commonly liposomal AmB (AmBisome®) which are now used 
against cutaneous leishmaniasis. Each of these formulations modify and slow the release of 
AmB, reducing plasma levels and consequently reducing its nephrotoxicity. Polymer–drug 
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conjugates of antifungal medications enhance the aqueous solubility of water-unsolvable 
medications, extend shelf life and crucially can reduce the toxicity of these drugs and facilitate 
drug  release at the target sites (Franquet et al., 2004; Low and Rotstein, 2011) 
 
Gurudevan  et al. (2018) conjugated AmB to bovine serum albumin (BSA) via amide bonding 
to provide 6 to 8 weight % drug load. Characterization of the resultant polymer-drug conjugate 
was performed using SDS-PAGE, UV–visible, FTIR and CD spectroscopy. Interestingly the 
resulting conjugate was water-soluble, non-toxic to HEK-293 T cells up to 500 μg/mL i.e., 
~30 μg AmB and demonstrated <5% haemolysis at 200 μg/mL (equivalent to ~12 μg AmB) 
against human RBCc in vitro. At 37 °C this conjugate provided steady release of up to 20% 
AmB from the conjugate in vitro, whereas three times this amount was released in human blood 
plasma over 72 hours. This conjugate gave anti-fungal activity against Candida albicans, C. 
parapsilosis and C. neoformans  showing minimum inhibitory concentration (MIC) of 0.7 to 
1.1 μg/mL of AmB, similar values to  AmBisome® MIC’s of 0.78-1.5 μg/mL. In this study the 
model protein BSA was used as an effective carrier  and implies that human serum 
albumin (HSA) could act as an effective  carrier in future PDCs design. 
 
1.4.5. Polymer- drug Conjugates for Delivering Drugs to Hair Follicles 
Polymer technology has developed rapidly over recent decades and has resulted in the 
expansion of polymer-drug conjugates with a broad array of designs and chemical properties. 
Traditional non-degradable polymeric drug delivery carriers such as N-2-hydroxypropyl 
methacrylamide (HPMA) and poly-ethylene glycol (PEG) copolymers have been widely used 
in formulations and clinical settings but a trend towards biodegradable, stimuli-responsive, and 
targeted drug delivery systems is also seen with recent drug-polymer conjugates (Larson and 
Ghandehari, 2012).  
 
Hair loss also known as androgenetic alopecia (AGA) is a persistent problem seen in both 
males and females. AGA is most common phenomenon reported in 50% of middle-aged men 
and almost 95% of the men between 80-90 years. Hair loss can lead to lowering of self-
confidence, and can contribute to poor mental health including depression (Ellis et al., 2002) 
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The hair follicles and pilo-sebaceous unit provides a site where micro-, submicron-, and nano-
sized material can enter and accumulate (Figure 1.19). The diameter of the hair follicle 
openings varies between 175±75μm in terminal hair follicles while it is 85±36μm in vellus hair 
follicles.  The interaction surface of hair follicle infundibulum (cup or siphon in which a hair 
follicle develops) is estimated to be roughly 0.69 cm2 for empty and 0.069 cm2 for full follicles 
(Vogt et al., 2007: Rancan et al., 2014) so the infundibulum offers not only a potential reservoir 
site but also a significant surface area where contact between collected material and skin might 
arise. If drug-polymer conjugates accumulate in the hair follicle canal and releases their drug 
then this can produce not only local acting effects but also a high drug concentration to drive 
delivery through the tissue and into the systemic circulation (Toll et al., 2004; Shah et al., 
2012).  
 
Figure 1.19. Photomicrograph of human terminal hair follicle. (A) Light micrograph of a 
longitudinal segment presenting the hair follicle hair shaft and infundibulum. The 
infundibulum is full of cell fragments and sebum. Enclosures (b–d) are areas of the hair 
follicle that were examined by using transmission electron microscope (B, C and D 
respectively) (Rancan et al., 2014). 
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Aljuffali et al. (2015) synthesized polymer lipid nanocarriers, termed “squarticles” conjugated 
with anti-platelet-derived growth factor (PDGF)-receptor β antibody to ascertain whether 
targeted minoxidil (MXD) (used for the male-pattern hair loss and an antihypertensive 
vasodilator) distributed to the hair follicles and papilla cells (DPCs). As the matrix of the 
squarticles, squalene and hexadecyl palmitate (HP, also called as cetyl palmitate) were 
employed. The resulting PDGF-squarticles had a mean diameter of 196 nm and zeta potential 
of − 47 mV. Encapsulation in the nanoparticle increased MXD swine skin accumulation from 
0.12 to 0.25 μg/mg. The conjugation of antibody to the nanoparticles enhanced MXD hair 
follicular uptake by 3-fold as compared to that of the control solution in a BALB/c mouse in 
vivo model. Both upright and parallel sections of the porcine skin displayed a wide-ranging 
distribution of nanoparticles in the hair follicles, epidermis, and lower skin layers. This 
effective targeting of PDGF-squarticles to hair follicles might be beneficial better efficacy of 
minoxidil for  alopecia or male pattern baldness. 
Recently, Nagai et al. (2019) prepared polymer-drug formulations with minoxidil  as 
nanoparticles (1% N-MXD) using p-hydroxyalkylbenzoates, methylcellulose and mannitol 
with a bead mill technique. N-MXD (90–300 nm) were applied to examine their impact on hair 
development using a common inbred mouse strain C57BL/6 (frequently termed "C57-
black 6"). Interestingly, minoxidil content in the hair bulbs was greater for N-MXD polymers 
than observed for commercially marketed MXD formulation which translated into greater drug 
efficiency. Notably, the levels of Insulin-like Growth Factor-1 (IGF-1) and vascular endothelial 
growth factor (VEGF) levels associated with hair growth were also more when N-MXD was 
delivered as compared to the commercial control.  
1.4.6. Polymer-drug Conjugates for the Treatment of Cutaneous Leishmaniasis 
Much of the focus has been on the use of PDCs for the treatment of visceral leishmaniasis 
(VL), and there are only very few studies reporting the use of PDCs for CL. One of such study 
has been reported by Silva-Carvalho et al. (2020), where he developed water-soluble Dextrin-
Amphotericin-B (Dex-AmB) nanoparticulate-drug complexes with better therapeutic 
effectiveness and reduced toxicity. These nanocomplexes (214-347 nm) were synthesized by 
dissolving dextrin and Am-B in alkaline borate buffer, followed by dialysis, freeze-drying (FD) 
or nano spray-drying (SD). These nanocomplexes produced by relatively very simple technique 
were very effective against cutaneous leishmaniasis causing Leishmania amazonensis and L. 
infantum parasites respectively in axenic culture (IC50 of 0.056 and 0.096μM for L. 
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amazonensis and 0.030 and 0.044μM for L. infantum, respectively). Interestingly, these 
polymer-drug nanocomplexes had significantly reduce cytotoxicity compared to Am-B alone 
when tested against macrophages using MTT assay. Thus dextran-amphotericin-B polymer-
drug conjugates could be synthesized, so they can be delivered through mannose receptors into 
Leishmania infected macrophages.  
Over the last two decades, the application of PDCs to diseases other than cancer has increased, 
including for topical delivery though this remains a relatively under researched area. As 
macromolecular constructs, passive diffusion through the intact stratum corneum barrier is not 
feasible and hence the focus is on targeting to the follicles or use in conditions where the skin 
barrier is damaged such as psoriasis or wound healing. Thus, opportunities exist for similar 
barrier dysfunctioning conditions such as atopic dermatitis, scabies or cutaneous leishmaniasis 

















Table 1.2. Summary of the potential therapeutic targets for the application of PDCs to 
the skin 
Challenge                       Barrier to overcome      Target                        Possible polymeric 
                                                                                                                            carrier/s  
 
Scabies                               NA                             Lower SC                         HA,Polypeptides 
Cutaneous leishmaniasis    NA                                 Macrophages                               Polysaccharides,e.g.                    
                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                               arabinoglycan, chitosan  
Insect repellent                  NA                           Insects                     Film forming polymers  
                                                                                                           without being topically 
                                                                                                            absorbed e.g., PAA            
Fungal or bacterial            SC                           Target cells                      HA, polypeptide 
 infections                                                                     
Eczema                              NA                           To inhibit the               Any non-irritant polymer              
                                                             inflammatory mediators,         e.g. HA, chitosan, PAA. 
                                                                     e.g. TNF α, IL-1 etc             
                      
Winter Xerosis                  SC               To overcome skin dryness      Polymers that can penetrate                                                                 
                                                                                                        the skin whilst hydrating  
                                                                                                    it as well, e.g. low molecular- 
                                                                                                            -weight HA 
Acne                               SC              To reach hair follicles        Lyso phosphatidylcholine,         
                                                                                                    cyclodextrin and gel forming  
                                                                                                          polymers like PAA 
 
 
1.5. Insect Repellents 
Various infectious and parasitic diseases, i.e. malaria, leishmaniasis, dengue fever etc are 
transferred to humans by the bite of insects and hence are called as insect-borne diseases, 
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causing thousands of mortalities every year. To prevent that, insect repellents are frequently 
used. Insect repellent is a substance that is usually applied to the skin to protect against the 
biting insects like mosquitos, ticks, chiggers etc (Fradin and Day, 2002). 
Common insect repellents are broadly classified into two categories, i.e. natural insect 
repellents and synthetic insect repellents. Some of the commonly used insect repellents are 
DEET (N, N-diethyl-m-toluamide), p-menthane-3,8-diol (PMD), picaridin, nepetalactone, 
neem oil, permethrin. These are briefly discussed in the following. 
 
DEET is a synthetic compound that is considered to be the most effective and commonly used 
in the world. It is a yellowish oil that can be applied onto the skin. Upon topical application, it 
has been reported that it can permeate through the skin into the bloodstream. In one of the study 
serum samples of the people using the DEET (lotion containing 25% of the DEET) on their 
skin as an insect repellent was taken in such a way that it was observed the serum had 1.82 to 
18.84 ng/g of the DEET during the first 8 hours of the skin application (Chen-Hussey et al., 
2014). 
 
Similarly, picaridin is another synthetic repellent which was first made in the 1980s. Picaridin 
has been commonly used in different parts of the world but has only been available in the 
United States since 2005. When applied to the skin of rats, 60% of it was absorbed through the 
skin. In clinical trials it was found that less than 6% of the picaridin applied to the skin was 
absorbed. Picaridin may be broken into various metabolites (Van Roey et al., 2014). 
 
 Similarly, another commonly used insect repellent is nepetalactone, first isolated from the 
plant catnip (Nepeta cataria). It is a bicyclic monoterpenoid, i.e. it is a ten-carbon compound. 
It is a very potent insect repellent and is having ten times higher activity than that of the 
commonly used insect repellent DEET (Birkett et al., 2011). 
 
Permethrin is a broad-spectrum insecticide that has been used for a variety of purposes like 
agricultural and commercial/residential applications. It is also used to control termites, 
ectoparasites on the animals, and head lice or scabies in humans. It is also used for treating the 
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soldier's uniforms in the United States, thus helping to reduce outbreaks of insect-borne 
diseases (Young and Evans, 1998) 
 
Among natural insect repellents, neem oil is a widely used insect repellent an alternative to 
DEET, and it has been tested for repellence against a range of arthropods that are of medical 
importance. It can provide up to 7.2 hours mean protection time against a dengue vector and 
irritating biting mosquitoes (Jilani and Saxena, 1990). 
 
1.5.1. p-menthane-3,8-diol (PMD) 
PMD is a naturally occurring compound that usually exists in two isomeric forms, i.e. cis and 
trans.  In 2005, the centre for disease control (CDC) endorsed the use of topical repellent 
products containing para-menthane-3,8-diol (PMD) naturally obtained from a plant called the 
Eucalyptus citriodora (Lee et al., 2018). Chemically PMD is a monoterpene and can be 
obtained from both sources, i.e. synthetically and naturally. Naturally, it can be obtained from 
the distillation of the leaves of Eucalyptus citriodora (Carroll and Loye, 2006). On the other 
hand, it can be synthesised in the lab by the cyclisation of citronellal with excellent yield and 
purity (Yuasa et al., 2000).  Similarly, in order to see the permeation of PMD into the skin, a 
study was performed in such a way that the pigskin was taken to which PMD lotion was 
applied. After 24 hours they saw that around 3.5% of PMD was able to penetrate the dermis of 
the skin, whilst the remaining dose was found to be evaporated off from the skin (Reifenrath 
et al., 2009). 
 
A)                                                          B) 
 
Figure 1.20. Structure of PMD A) trans isomeric form, B) cis isomeric form 
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1.5.2. Polymeric Carriers for Insect Repellents 
For an effective insect repellent formulation, it is important that the concentration of the active 
compound should remain same over a sufficiently long time period. However, the efficacy of 
an insect repellent can be rendered by various reasons like, volatility and the permeation of the 
compound (Barradas et al., 2016). In order to tackle those, polymeric formulations have been 
developed. Various studies have reported the use of polymeric carriers for the insect repellents. 
Most of these studies have reported polymeric micro or nano capsules to encapsulate the insect 
repellents, e.g. DEET, PMD, citronella oil, picaridin and others (Katz et al., 2008; Salafsky et 
al., 1999). It has been shown that as a result of encapsulation physicochemical properties of the 
repellent like vapour pressure and partition coefficient can be modified. The polymers used for 
the preparation of these micro or nano capsules include chitosan, collagen and gelatine, it is 
because of forming covalent or ionic interactions with the encapsulating drugs beside their 
good safety profile. Similarly other polymers used for this purpose were carboxy methyl 
cellulose and cyclodextrins (Jing et al., 2014; Solomon et al., 2012).  
1.6. Aim and Objectives of the Thesis 
The aim of this project was to explore and develop a PDC for extended release and decreased 
permeation of an insect repellent, i.e., p-menthane 3,8 diol. 
The objectives of this project were: 
a) Synthesis of a PDC having a hydrolysable ester bond 
b) To characterise the PDC for its structure and properties by 1H-NMR, IR spectroscopy, 
thermal analysis (TGA and DSC), molecular weight, drug loading and effect of pH on 
the aqueous solubility of the PDC 
c) In vitro hydrolysis study by using porcine liver esterases (PLEs) 
d) To evaluate the skin penetration and permeation of the free drug as well as the PDC 
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Hyaluronic acid (sodium salt) (MW 1.6 MDa, Batch# 
070815-E1) 
Contipro., Czech Republic 
Citronellal (Lot# 10202671) Fischer Scientific., UK 
n-Heptane (Lot# 1697988)  Acros Organics., UK 
(Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) (Lot# A0374488) 
Acros Organics., UK 
N,N Diisopropyletylamine (DIPEA)(Lot# STBF9469V) Sigma-Aldrich Co., UK 
Dimethylsulfoxide (DMSO) (Lot# 1670195) Fischer Scientific., UK 
Sodium Chloride (Lot# 1557449) Fischer Scientific., UK 
Sodium carbonate anhydrous (CAS# 497-19-18) Fischer Scientific., UK 
Hydrochloric acid (CAS# 7647-01-0) Fischer Scientific., UK 
Dowex ion exchange resin (CAS# 217492, mesh size 50-
100) 
Sigma-Aldrich Co., UK 
4, Dimethylamino pyridine (CAS#1122-58-3) Acros Organics., UK 
Polyacrylic acid (18,00 Da) (LOT#SLBS6469) Sigma Aldrich Co.,UK 
Polyacrylic acid (1.25 MDa) (LOT#MKBT3043V,CAS# 
89-83-8) 
Sigma-Aldrich Co., UK 
Thionyl chloride (LOT#A0372214, CAS#7719-09-7) Acros Organics., UK 
N,N-Dicyclohexylcarbodiimide (LOT#A0385375) Acros Organics., UK 
Thymol (LOT#A0382019) Fischer Scientific., UK 
Triisobutylamine (CAS# 1116-40-1) Sigma-Aldrich Co., Uk 
Polyethyleneglycol dimethylether (dmPEG) (CAS# 
24991-55-7) 
Sigma-Aldrich Co., UK 
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Porcine liver esterases (CAS#39346-81-1) Sigma-Aldrich Co., UK 
Agarose low gelling temperature (LOT#SLBW7267) Sigma-Aldrich Co., UK 
Pur-A-lyzer Mega 1000 Dialysis kit (LOT# g01/17443) Sigma-Aldrich Co., UK 
p-Menthane 3,8 diol (CAS#42822-86-6, 
LOT#BS18U05312, BV18ZJ01182)  
BOC sciences, USA 
Acryloyl chloride (LOT# STBG5526V, STBF9634V) Sigma-Aldrich Co., UK 
Acrylic acid (CAS# 79-10-7) Sigma-Aldrich Co., UK 
2,2-Azobis(2-methyl-propionitrile) (LOT# STBC6554V) Sigma-Aldrich Co., UK 
Triethylamine (CAS# 121-44-8) Sigma-Aldrich Co., UK 
Porcine liver esterases (CAS# 9018-16-1) Sigma-Aldrich Co., UK 
Triisobutylphosphate (CAS# 126-71-6) Acros Organics, Uk 
Glycerol (CAS# 56-81-5) Sigma-Aldrich Co., Uk 
Polyethylene glycol-400 (PEG-400) (CAS# 25322-68-3) Sigma-Aldrich Co., UK 
Tween-20 (CAS# 9005-64-5) Sigma-Aldrich Co., UK 
Toulene (CAS# 108-88-3) Sigma-Aldrich Co., UK 
Ethyl acetate (CAS# 141-78-6) Fischer scientific Co., UK 
Parafluoroaniline (CAS# 371-40-4) Sigma-Aldrich Co., UK 
Benzalkonium chloride (CAS# 63449-41-2) Sigma-Aldrich Co., UK 
Dipropylene glycol (CAS# 25265-71-8) Sigma-Aldrich Co., UK 
Terpinyl acetate (CAS# 80-26-2) Sigma-Aldrich Co., UK 
Linalyl acetate (CAS# 499-75-2) Fischer scientific Co., UK 
Carvacrol (CAS# 115-95-7) Sigma-Aldrich Co., UK 
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2.2.1 Chromatographic methods 
2.2.1.1 TLC 
Thin-layer chromatography (TLC) is a procedure applied in organic chemistry to separate 
compounds in a mixture based on variations in their polarity. In this work, the stationary phase 
was a thin layer of polar silica gel and various mobile phases were employed, typically organic 
solvents. Studies used Merck TLC Silica gel 60 F254 aluminum backed plates (Sigma-
Aldrich). Initially, a line was drawn on the bottom of the TLC plate and mixtures were then 
spotted at this origin using thin capillaries before the bottom of the plate was submerged in an 
organic solvent, i.e. hexane:ethylacetate (4:1); the solvent travelled up the plate by capillary 
action, carrying and separating solutes by their lipophilicity and molecular weights. The TLC 
plates were then visualised using p-anisaldehyde (as an indicator). The p-anisaldehyde stain 
was prepared by mixing 5 mL of concentrated sulfuric acid into 135 mL of absolute ethanol 
and then adding 1.5 mL of glacial acetic acid dropwise in a round bottom flask placed over ice. 
Finally, 3.7 mL of p-anisaldehyde (also known as 4-methoxybenzaldehyde, analytical grade, 
Sigma-Aldrich) was added, and the solution was stirred to ensure homogeneity. The solution 
was refrigerated at 4-7 °C and was wrapped in an aluminum foil until use. 
  
 
2.2.1.2 Column Chromatography 
 
Column chromatography was carried out using silica gel. The column was prepared by taking 
a cylindrical glass column and plugging in with a small piece of cotton and then packing the 
column by a wet packing method; for every 1g of test material, the equivalent of 70g of fresh 
silica gel (60 mesh size) was used. Silica was added to a beaker and sufficient hexane was 
added to produce a slurry. The slurry was then poured into the column. After packing of the 
 59 
column, the material was dissolved in ethyl acetate and was then put into the column with a 
final ratio of hexane:ethylacetate of 4:1. Fractions were collected in the tubes (15 mL) and were 
then analysed by TLC for the purpose of identification. At the end, the solvent system was 
evaporated by using rotary drier.  
 
2.2.2 Infrared Spectroscopy 
Infrared (IR) spectroscopy is widely used to verify chemical structures and to aid identification 
of compounds. IR is a region of electromagnetic radiation ranging between 400 cm-1 and 4000 
cm-1. The principle on which IR spectroscopy is based on is that the molecules that tend to 
absorb (by the bonds) electromagnetic radiation result in the transition between molecular 
vibrational or rational energy levels. The wavelength of the radiation absorbed is the 
characteristic of the bond (including environment) absorbing it. Thus, based upon the nature of 
these bonds (in the molecules) and their surrounding environment different wavelengths are 
absorbed and then emitted by different parts of molecules (Bates, 1976; Gillie et al., 2000). 
The intensity by which a molecule (bond) absorbs radiation depends upon its dipole moment, 
i.e. the order of intensity of absorption will be OH>NH>CH. Similarly, there are different 
factors responsible to predict that where (wavenumber) these peaks can be seen. These include 
bond strength (stiffness of the bond), as a general rule greater the stiffness of the bond higher 
will be the wavenumber. Similarly, other factor is the mass effect, as mass on bond increases 
the wavenumber decreases (McDonald, 1986; Wellner, 2013). 
 
Figure 2.1. Exemplar IR spectra of Nylon (FTIR-Graph- www.microanalysis.com.au) 
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Infrared spectra were recorded using the ATR (attenuated total reflectance) technique on a 
Perkin Elmer (Spectrum 100) FT-IR spectrometer (Perkin Elmer Ltd., UK) from 4000 to 400 
cm−1 with 16 scans averaged and collected at 4 cm−1 resolution. The absorption was obtained 
in wavenumbers [cm-1]. The symbols ν and δ denote stretching and bending molecular modes 
respectively and peak intensities are categorized as s, strong; m, medium and w, weak, while 
br denotes broad peaks.   
2.2.3 Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a highly sensitive and precise analytical 
technique for structural elucidation and material purity. It exploits the principle that when 
radiation in the radiofrequency region is used to excite atoms usually protons or carbon-13 
atoms in such a way that their spin switches from being aligned with to being aligned against 
an applied magnetic field, thus giving a typical NMR spectrum. The spinning of the nuclei of 
certain atoms give them the properties of magnetic vector. Examples of such nuclei are 1H, 13C, 
15N, 19F,29Si and 31P. Now when these nuclei are placed in a magnetic field they will try to align 
with the applied field. The greater the field strength the greater the energy difference (Watson 
and Pgce, 2020) 
There are two types of NMR’s, proton NMR and 13C NMR. Proton NMR is the most commonly 
used form of NMR as it’s a sensitive technique and can yield large amount of structural 
information. NMR spectra is represented in the form of chemical shifts. A chemical shift 
assigned to a proton is determined in relation to the proton of the tetramethyl silane. Here the 
chemical shift assigned to a compound is represented in the form of ppm. Value of 1ppm in 
Hertz (Hz) depends upon the strength of the applied magnetic field. For example, at a field 
strength of 100mHz a shift of 1ppm=100 Hz (Watson and Pgce, 2020). 
In our experiments, we used Bruker DPX 400 (400 MHz) spectrometer to record 1H-NMR 
spectra in either deuterated chloroform (CDCl3) or deuterated dimethyl sulfoxide (DMSO-d6). 
13C- NMR spectra were recorded either in deuterated chloroform (CDCl3) or in deuterated 
dimethyl sulfoxide (DMSO-d6). Chemical shifts (δ) are given in parts per million (ppm) using 
the subsequent abbreviations for splitting patterns: s, singlet; d, doublet; t, triplet; app. t, 
apparent triplet; dd, doublet of doublets; dt, doublet of triplets; q, quartet; m, multiplet.  
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2.2.4 Mass Spectroscopy 
Mass spectrometry works on the principle of detecting the molecular weight of a molecule in 
such a way that it works by generating charged molecules or molecular fragments either in high 
vacuum or immediately before the sample enters the high vacuum. The most common source 
of generating these charged molecules is the electrospray ionisation (ESI). Upon the generation 
of these charged or fragmented molecules they are then detected by a detector (Glish and 
Vachet, 2003). 
Mass spectrometry data were recorded on a Thermo Fisher LTQ Orbitrap XL instrument using 
ESI. Where possible, high-resolution mass spectroscopy (HR-MS) data are provided for the 
molecular ion or appropriate adduct, fragmentation patterns are also provided. 
2.2.5 Melting Point 
Melting points were determined using an Electrothermal Digital Melting Point apparatus (A-
9000, Electrothermal Ltd, UK) with samples held in a capillary tube. 
2.2.6 Thermogravimetric Analysis (TGA) 
TGA is a thermal analysis technique in which the change of mass loss is measured concerning 
changing temperature. TGA uses a temperature ramp, shows weight loss that can provide 
information related to certain physical (evaporation) and chemical (decomposition or oxidative 
degradation) phenomena. The results from a thermogravimetric run may be presented by 
weight versus temperature (or time) curve, referred to as the thermogravimetric curve or rate 
of loss of weight versus temperature curve, referred to as the differential thermogravimetric 
curve. Depending upon the nature of the material (to be analysed) a thermogravimetric curve 
may undergo solvent evaporation followed by the decomposition or degradation (nature of 
which depends upon the type of the material) (Carrier et al., 2011). 
TGA experiments were conducted with a Q50 thermogravimetric analyser (TA Instruments, 
UK). The TGA’s temperature calibration was established with reference samples of nickel, 
zinc and iron. The weight calibration was established with certified Troemner 100 mg standard 
weight. TGA was conducted in an inert nitrogen atmosphere with a flow rate of 30 mL min-1. 
All temperature transitions were assessed at a constant temperature ramp of 5oC min-1. Samples 
weighing between 2-9 mg were placed in aluminium pans. The samples were subjected to these 
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conditions and heated at 5oC min-1 from 35oC to 590oC (depending upon the material, e.g. for 
PMD the maximum temperature was 100oC), and then cooled from 590oC to 35oC. Then the 
data were analysed by using the universal analysis thermal software. 
2.2.7 Differential Scanning Calorimetry (DSC) 
DSC is primarily method used for determining the energetics of the phase transitions within a 
macromolecule. It works on the principle of measuring the heat capacity of thermally induced 
events as a function of temperature. Though there are multiple applications of DSC ranging 
from determining the melting point, purity and the temperature of crystallisation but in 
polymers its mostly used to determine the glass transition temperature (Tg) (Chiu and Prenner, 
2011). 
DSC analysis of the samples used a DSC Q1000 (TA, Instrument, UK). The instrument was 
calibrated with indium (156.6oC). Experiments were carried out in an inert nitrogen atmosphere 
with a flow rate of 50 ml min-1. Samples were subjected to different heating rates ranging from 
10-50oC min-1. Samples weighing between 3-9 mg were sealed (having a small hole to prevent 
the explosion of the volatile compounds). The samples were generally subjected to two cycles 
of heating and cooling: (i) samples were held at 35oC for 5 minutes, (ii) ramped from 35oC to 
200oC, (iii) held at 200oC for 5 minutes, (iv) gradually cooled down from 200oC (at the rate of 
10-50oC min-1) to 35oC. Thermograms were analysed for melting events and for glass transition 
temperatures (Tg). 
2.2.8 Elemental Analysis 
CHN elemental analyses were obtained from MEDAC LTD, analytical and consultancy 
services. An elemental analyser (FLASH EA 1112 series, Thermo-Finnigan, Italy) was used 
for C (carbon) elemental analysis. For the analysis, combustion and reduction tubes 
(PerkinElmer) were used. The combustion reaction was run at 975oC in the presence of pure 
helium and oxygen as a carrier gas. For the determination of the carbon content, carbon in our 





2.2.9 Liquid Chromatography-mass spectroscopy (LC-MS) 
LC-MS analysis used an LC system coupled to an Apex-Q FTICR mass spectrometer (Bruker 
Daltonics) with a phenyl column (0.25 mm thickness). Spectra were obtained by electron 
ionization at 70 eV. 2μL of the sample was injected. Compounds (PMD and acryloyl-PMD 
(APMD) were quantified by using the external standards of the same compound, i.e. PMD and 
APMD at different concentrations. Five to six concentrations of the compounds were prepared 
from a stock solution of 1mg/mL (r2=0.98). 
2.2.10 Culturing Dugesia lugubris (Planarian) in the Laboratory 
Dugesia lugubris (Schmidt, 1861) a planarian species is a useful organism in various 
laboratories for studying neurological development to toxicology. Planarians are freshwater 
flatworms which are inexpensive and simple to grow and maintain in the laboratory. Dugesia 
lugubris (catalogue LZC-030) was purchased from Blades Biological Limited (Cowden, 
Edenbridge, Kent TN8 7DX, UK). 
 
2.2.10.1 Materials for the Culture 
Materials used to culture and maintain planaria included glass beakers, large Petri dishes 
(26 cm × 15 cm × 8 cm), sterile plastic transfer pipettes, paper wipes, waste storage containers 
containing acetone:ethanol (1:1 v/v) (to store the dead or used planaria), chicken meat to feed 
the planaria, disposable gloves, ice, blender/food grinder, steel strainers and scalpels. 
 
2.2.10.2 Culture Expansion 
 
Planaria (Dugesia lugubris) (Figure 2.2) were retained in artificial pond water (APW) made by 
adding 0.5 g of instant ocean salt in 1000 mL of Milli-Q water (having 18.2 MΩ/cm resistivity) 
at ambient temperature. They were fed with uncooked chicken meat that was finely chopped 
at a quantity sufficient for nourishing planaria once a week. The APW was changed every 48 
hours. The planaria were kept in a large beaker at a density of 50-100 worms with 3–15 mm 
body length in 2500 mL of prepared APW. It was important to ensure that the container had 





Figure 2.2. Swimming Dugesia lugubris in APW. Scale bar is 2mm 
 
Planaria were cultured in a dark room (to avoid algal growth in pond water and the natural light 
reluctance (negative phototaxis) of planaria) at room temperature. The culture was regularly 
examined to monitor the condition of the planaria. For culture development and expansion, 
planaria were fed once per week. Any mucus or residues accumulated inside surface of the 
beakers were wiped off by using a paper towel, especially in the regions where the worms were 
located. In cases where the culture generated a foul smell, colour changes or water degradation 
(worms twisting, wriggling and spinning in a corkscrew-like fashion was an indicator of culture 
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Chapter 3. Synthesis of p-menthane-3,8-diol (PMD) 

















p-Menthane-3,8-diol (PMD) was synthesised in order to develop a polymer-drug conjugate. 
The rationale for the synthesis of conjugate was; primarily to develop a system for prolonged 
drug release as compared to the conventional use of free PMD. The hypothesis was that the 
drug (PMD) would conjugate with the polymer through an ester bond. Then, under the action 
of naturally occurring esterase enzymes on the skin, the drug would be released over an 
extended period. Numerous studies have reported the use of enzymes to cleave the ester bond, 
followed by the release of the drug (e.g.,Natfji et al., 2017). Secondly this approach would 
minimize drug uptake into and absorption through the skin and hence reduce systemic PMD 
uptake. The hypothesis for this was that the molecular weight of the polymer would prevent 
(or certainly minimise) absorption since in general, molecules with relatively low molecular 
weights (<500 Da), and that are lipophilic tend to permeate through skin as evidenced by drugs 
such as oestradiol, nicotine and fentanyl which are successfully administered from patches (Bos 
and Meinardi, 2000). Various studies raise specific concerns over the systemic absorption of 
insect repellents such as N,N-Diethyl-meta-Toluamide (DEET) and consequent side effects, 
especially regarding their use in pregnant women and the neonates (Tavares et al., 2018). 
 
PMD, also ascribed as 1-(2-Hydroxy-4-methylcyclohexyl)-1-methylethanol and P-Menthane-
3,8-diol, is a biochemical pesticide derived in small amounts from the essential oil of an 
Australian plant Corymbia citriodora (Eucalyptus citriodora) leaves. This active ingredient is 
used to make products that are applied to human skin and clothing to repel insects, such as 
mosquitoes and sandflies (Pandey et al., 2009). It is used in two types of consumer insecticide 
products: a spray and a lotion. It is a monoterpenoid alcohol with a formula of 
(CH3)2CHC6H10CH3. It is a colourless liquid with a fragrant fennel-like odour. It occurs 
naturally, especially in exudates of Eucalyptus fruits. The molecular weight of the PMD is 
172.27 g/mol, whilst its water solubility is poor having a logP value of 1.88 showing its high 
lipophilicity.  The compound is generally encountered as a mixture of two cis and trans isomers, 
which have similar properties (Maia and Moore, 2011). 
Polymer-drug conjugates have been extensively researched for more than 40 years (Elvira et 
al., 2005).  There are various means to link the polymer with the drug covalently; the work 
presented here is focused on polymer-drug ester conjugates. Various examples have been 
reported in the literature for the successful conjugation of the polymers with the drugs through 
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esters bond (Larson and Ghandehari, 2012), using different chemical strategies (Avendaño and 
Menéndez, 2008; Halpern et al., 2014). Some of these are coupling through N,N-
dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
making polymer or drug/ammino acid a better leaving group (Jung and Theato, 2013). 
 
This chapter will focus on the synthesis of PMD followed by the chemical challenges involved 
in the synthesis (preliminary attempts), which lead to the final approach resulting in successful 
conjugation and characterization (described in chapter 4). Though PMD is commercially 
available, however, for this project the materials were synthesised in house to ensure purity 
and minimise batch-to-batch variability. 
 
3.2. Materials 
Hyaluronic acid (sodium salt) (MW 1.6MDa) was obtained from Contipro, Dolní Dobrouč, 
Czech Republic (Contipro obtains hyaluronic acid from cell walls of Streptococcus 
zooepidemicus bacterial culture), citronellal, dimethylsulfoxide (DMSO), sodium chloride, 
sodium carbonate anhydrous, Hcl and thymol were obtained from Fischer Scientific Co., UK. 
n-Heptane, (benzotriazol-1-yloxy)-tripyrrolidinophosphonium hexafluorophosphate (PyBOP) 
4-dimethylamino pyridine, thionyl chloride and N,N-dicyclohexylcarbodiimide were obtained 
from Acros Organics., UK. N,N diisopropyletylamine (DIPEA), dowex ion exchange resin 
(mesh size 50-100), poly (acrylic acid) (1,800 Da and 1.2 MDa), polyethyleneglycol 











3.3.1. Synthesis of PMD 
PMD was synthesized by the method described by Yuasa et al. (2000). Briefly, 116g of 
sulphuric acid aqueous solution 0.25% (w/w) was first heated at 55°C with stirring. Then to 
this 100g of citronellal (the starting material) was added slowly and was stirred at the same 
temperature for the next 11 hours. Then 1.4 g of sodium hydroxide aqueous 25% (w/w) solution 
was added to it. After this, 120 mL of n-heptane was added in such a way that two layers, i.e., 
an organic and an aqueous layer, were created. The reaction was monitored by TLC analysis 
using formaldehyde solution (4:1 v/v, hexane: ethyl acetate, used as mobile phase). The organic 
layer was collected and distilled to remove any water. The organic solution was then cooled to 
-50°C with continuous stirring for 20 h. After 20 h time period, transparent crystalline material 
was filtered. The yield was 38%.  
3.3.1.1. Choice of Polymer for the Selection of Conjugation 
The selection of the polymer was based upon two main criteria, one was that polymer should 
be non-immunogenic and should not have any adverse reactions such as irritation on skin and 
the other was presence of suitable group, i.e., COOH to form an ester bond. The first polymer 
selected based on these criteria was hyaluronic acid (HA). HA is a natural polymer that acts as 
a skin emollient and is used in various dermatological products (Huang and Huang, 2018). HA 
is a naturally occurring glycosaminoglycan found all through the connective tissues. It is a 
nonimmunogenic and biodegradable polymer (Alaniz et al., 2002). Various research papers 
have reported successful conjugation of HA with drugs (Chen et al., 2014), including 
paclitaxel, Oncofid-S, biphosphonates, doxorubicin and cisplatin (Arpicco et al., 2014). Based 
on these reasons, it provided us with a base for the selection of hyaluronic acid as a first choice 
for the conjugation. 
Another critical parameter for the selection of the polymer was to prevent absorption of the 
drug through the skin. Since in general, molecules that have relatively low molecular weight 
(< 500 Da) and that are lipophilic tend to permeate through the skin. Thus, based on this we 
selected the polymers with high molecular weight to prevent topical absorption, hence initially, 
we choose the HA with high molecular weight (Essendoubi et al., 2016). Additionally, HA is 
humectant, and retains water molecules onto the exterior of skin to maintain it pleasant and 
hydrated state. 
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3.3.2. Preliminary Attempts for the Conjugation  
3.3.2.1. Synthesis Using the Method of Sahoo et al. (2008) 
Several attempts were made to conjugate HA with PMD. The first method used was the one 
reported by Sahoo et al. (2008) with some modifications. Briefly, Dowex ion exchange resin 
(12.5g) was washed three times with 250 mL of water and then treated with 25 mL of TBA and 
left to react at room temperature for 1 hour. The resin was then filtered and collected. Then 1g 
of hyaluronic acid was dissolved in 100 mL of distilled water to which 10g of the Dowex-TBA 
resin was added, and the reaction was allowed to proceed at room temperature for 18 hours. 
The reaction mixture was filtered through a 0.45 μm sterile filter, the supernatant collected and 
freeze-dried for three days to yield HA-TBA mixture (Figure 3.1-a). Almost 500 mg of this 
mixture was dissolved in 60 mL of anhydrous DMSO, to this HA-TBA mixture, 0.5 mL of 
DIPEA and 0.9g of PyBop were added and left stirring at room temperature for 1 h. Finally, 
1g of PMD was added, and the mixture was left stirring for another 24 h at room temperature.  
 
3.3.3.2.  Synthesis Using Fischer Esterification Reaction 
The Fischer esterification theory and use of this theory on some polymers/compounds have 
been reported previously (Kantlehner, 1991; Wassei et al., 2011). Based upon this theory the 
first step was to convert the supplied HA into free HA which was then followed by the 
conversion of the hyaluronic acid to a hyaluronic acid chloride and then reacting it with PMD 
(Figure 3.1). For this, the following protocol was used. Firstly, sodium hyaluronate was 
dissolved in water to make a solution (1% w/v). To this, 1.0 mL of an acid (HCl, 4M) was 
added to generate a pH of 2.0. Then this solution was enclosed in a dialysis membrane 
(Medicell International Ltd., UK) having a molecular cut off value of 12-14,000 Da. The 
medium (distilled water) was changed periodically until the pH stabilized at 5.0. After this, it 
was subjected to freeze-drying for 3 days to obtain free hyaluronic acid. After the production 
of free hyaluronic acid, it was then refluxed with thionyl chloride at 75°C for 3 h, after which 




a) Conversion of HA to acid chloride form making it a better leaving group 
 
Figure 3.1. Steps used in Fischer Esterification Reaction for the generation of HA.  
 
3.3.3.3.  Synthesis Using the Method of Lee et al. (2008) 
In this technique, the authors successfully reported conjugation of HA with paclitaxel (PX) 
through an ester bond by using dicyclohexylcarbodiimide (DCC) an activating agent for the 
carboxylic groups of HA (Lee et al., 2008). Briefly, for a desalting process, 1.0 g of HA (1.6 
MDa) was dissolved in 100mL of deionized water, dialyzed (MWCO: 10-12k Da) for 24 h, 
and lyophilized. A blended mixture of desalted HA and dmPEG was added in 25mL of 
deionized water. The solution was well-stirred and lyophilized to obtain a dry HA/dmPEG 
complex powder. A total of 300mg of lyophilized HA/dmPEG complex was added in 5mL of 
anhydrous DMSO under an inert environment (using argon) with vigorous stirring at 80°C for 
2 h. To this then DCC and DMAP were added and the solution was stirred for 1.0 h to activate 
carboxylic groups of HA. To the above solution, a solution of PMD (prepared by dissolving 
100 g of PMD in 5mL of anhydrous DMSO) was slowly added using a syringe under an inert 
environment. The mixture was then stirred for 2 days at 40°C. The resultant solution was 
dialyzed against DMSO for one day and deionized water for three days using a dialysis 






3.3.4. Changing the Approach: From High Molecular Weight to Low Molecular Weight 
The main aim of this study was to convert the high molecular weight HA into low molecular 
weight in an attempt to increase the reactivity of the polymer. For this purpose, the method 
reported by Tømmeraas and Melander, (2008) was applied (Tømmeraas and Melander, 2008). 
Briefly, 1g of HA was dissolved overnight at room temperature in 100 mL of deionized water. 
The solution was prewarmed to 60°C before adding 1.0 M HCl under vigorous stirring for 1 
minute to give an acid concentration of 0.10 M. The total HA concentration was adjusted to 10 
mg/mL. The mixture was left without agitation at 60°C (in an oil-filled thermostatic water bath) 
for a total of 52 h. Samples (5 mL each) were withdrawn over 52 h time. Each sample was 
immediately cooled on an ice-bath and neutralized with equimolar amounts of NaOH (1.0 M 
solution) before freezing and lyophilization. 
3.3.4.1. Use of Poly(Acrylic Acid) as a Polymer 
Due to the failure of the above methods, as an alternative approach, HA was replaced by 
another polymer, namely poly(acrylic acid) (PAA). PAA is a hydrophilic polymer, 
commercially available with an excellent safety profile (Ritthidej, 2011). PAA is used in topical 
formulations, i.e., Lubrizol’s Carbopol® applied in pharmaceutical industry as rheology 
convertors, suspension solidifiers, mucoadhesive facilitators, pill binders, extended release 
polymers, and bio-accessibility garnisher.  PAA has suitable groups, i.e., COOH to form an 
ester bond between the polymer and the PMD (Ritthidej, 2011). For the reasons mentioned 
above, a high molecular weight PAA was selected. 
 
3.3.5. Synthesis Using the Method of Shin et al. (2014) 
In this technique, the authors productively reported the conjugation of hyaluronic acid with 
methotrexate through an ester bond by using dicyclohexylcarbodiimide (DCC) as an activating 
agent for the carboxylic groups of hyaluronic acid. The basic principle of this method was first 
the activation of the carboxylic group (by making it a better leaving group) and then reaction 
with an alcohol to form a polymer-drug conjugate. The reaction was performed according to 
the basic scheme as outlined in the article (Shin et al., 2014). In brief, 100 mg of PAA (1.2 
MDa; 0.083 micromoles) was dissolved in 33.33 mL of formamide to give a concentration of 
3 mg/mL. Then, the solution was further diluted with 25 mL of dimethyl sulfoxide (DMSO) 
and allowed to stir at room temperature. To this DCC (15 mg) and DMAP (9 mg) were added 
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and stirred for a further 30 mins to activate the carboxyl group of PAA. Then to this an excess 
amount of the alcohol (10mg of PMD, to increase the chances of esterification) was added and 
the resulting solution was mixed under vigorous stirring at room temperature for 24 h, in the 
dark (by wrapping an aluminium foil around the flask). After that, the product was centrifuged 
at 3000 rpm for 5 min to remove any unreacted dicyclohexylurea residue, followed by 
purification using a dialysis membrane (MW cut-off = 12,000 ~14,000) against deionized water 
for two days, and lyophilization. 
 
3.3.6.  Synthesis Using the Procedure of Madgey et al. (2012) 
The authors successfully reported conjugation of poly(acrylic acid) with salicylic acid. In this 
method, first of all, poly(acrylic acid) (both high molecular weight and low molecular weight 
were used) was converted into poly(acryloyl chloride) by using thionyl chloride (to provide a 
better leaving group) before attempting conjugation with PMD. Briefly, about 1.4 mole of 
thionyl chloride was added dropwise to 1.0 mole of polyacrylic acid in a round-bottom flask. 
The reaction mixture was stirred for 1 h at 60°C and left to cool at room temperature. The 
unreacted thionyl chloride was collected by filtration. The obtained product (PAA reacted with 
thionyl chloride) was washed with anhydrous methylene chloride and dried overnight in a 
vacuum at 40°C. A solution of 0.25 mole of PMD and 0.75 moles of triethylamine in 300 mL 
acetonitrile was added dropwise to 0.3 moles of poly(acryloyl chloride) pre-soaked in 100 mL 
acetonitrile for 6 h. After complete addition, the reaction mixture was stirred further for 6 hours 
at 25°C. The product was filtered off and washed with methanol, 1M HCl and distilled water 
one after another to remove the formed triethylamine hydrochloride and finally with diethyl 
ether. The obtained product was dried overnight under vacuum at 40°C. 
 
3.3.7. Change of the Drug 
It is well known that secondary and tertiary alcohols (PMD) are sterically more hindered hence 
tend to be less reactive than primary alcohols (Watile et al., 2019). So, to increase the reactivity 
of the compound towards the polymer a primary alcohol with somewhat structural similarities 
with PMD as well as some insect repellent properties was selected, specifically thymol (Pandey 
et al., 2009; Sharma and Anand, 1997). Both of the above approaches in 3.3.6 and 3.3.7 were 
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repeated with thymol (of converting the polymer into an acyl halide and then reacting with 
alcohol and DCC coupling) and PAA but in neither case products could be produced. 
 
3.4. Results and Discussions 
3.4.1. Transformation of Citronellal to PMD 
The preparation of para-menthane-3,8-diol isomers from (+)-citronellal uses an acidic medium, 
as shown in Figure 3.2. The acidic medium acts as a catalyst for the cyclization of (+)-
citronellal into para-menthane-3,8 diol (primary step in the synthesis of the said compound). 
Here HCl acted as an acidic medium in order to carry out the desired reaction. 
 
Figure 3.2. Schematic presentation of acid-catalysed cyclisation of (+)-citronellal into 
para-menthane-3,8-diol. 
 
In this study, we evaluated different parameters as reported by Yuasa. et al. (2000) namely the 
acid concentration, the temperature of the medium and the reaction time. All these parameters 
were optimized and contributed to improving the conversion of citronellal to generate the 
highest yield of PMD during the reaction. The parameter with the highest yield was selected 















Time (hours) Conversion of 
(+)- citronellal 
into PMD (mol 
%) 
1 0.25% 50°C 24 44.8 
2 0.5% 55°C 20 42.3 
3 1% 60°C 16 43.1 
4 1.5% 65°C 12 44.6 
5 2% 70°C 8 43.5 
6 2.5% 75°C 4 41.9 
 
 
Table 3.1 shows clearly the change in the conversion of (+)-citronellal as a function of different 
parameters. The period for the conversion changed significantly by varying the acid 
concentration (acidity). It was necessary to stir it in a 50°C bath for 15 h, which is conceivable 
for a mass production perspective. The synthesis was reproducible (with a mean value of yield 
= 44 ± 5.2 %, n=6). Conversion of citronellal was calculated as: 
Conversion (%) = citronellalt=0 - citronellalt=t /mol citronellalt=0 
 Reaction progress was monitored by using thin layer chromatography (TLC) analysis, which 
provided two clear spots (citronellal and PMD) using 20% ethyl acetate in an 80% hexane v/v 
solvent system. Purification was done on a silica gel column (230 − 240 mesh) using the same 
eluent system as above. NMR analysis was done to identify the final product (Figure 3.4). It is 
clear from 1H-NMR spectra of PMD, giving characteristics peaks for CH3 and for the secondary 
and tertiary OH groups (Figure 3.4-A and 3.4-B) signifies the IR spectra for PMD.  
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From the TLC chromatogram indicated in Figure 3.3, it can be observed that over the period 
of time the side products are diminishing, and the final product (PMD) is obtained. The TLC 
chromatogram clearly indicate the starting materials, intermediate product and the final product 




Figure 3.3. TLC chromatogram showing the gradual conversion of the citronellal into 












Figure 3.4. 1H-NMR spectrum of (A) PMD, having characteristics peaks for CH3 and for 
the secondary and tertiary OH groups (B) IR spectrum of PMD.  
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3.4.2. Preliminary Attempts to Synthesise a Polymer-Drug Conjugate Following 
Sahoo et al.  (2008) 
The preparation of polymer-drug ester conjugates was not as straightforward as expected. 
Although the majority of reported polymer-drug conjugates (with HA or PAA) are largely 
prepared through amide bonds, a limited number of ester drug conjugates have also been 
reported. The published synthetic methods failed to produce desired polymer-drug ester 
conjugate. 
The first method used for the conjugation between HA and PMD was described by Sahoo et 
al. (2008). PyBop is a phosphonium salt derivative. There have been reports suggesting the use 
of PyBop (a coupling agent) for the conjugation reaction between the carboxyl group and the 
amine group of peptides. The principle involved in this reaction is the activation of the carboxyl 
group by the PyBop coupling agent (Al-Warhi et al., 2012). Thus, based upon this, in this 
experiment, we used PyBop as a coupling agent between the COOH group of HA and OH 
group of the PMD. The first step in this reaction was the exchange of hyaluronan sodium salt 
to tert-butyl ammonium salt (TBA) in order to increase its solubility in DMSO. For the 
attachment of TBA with HA, first Dowex ion exchange resin was used (which facilitated the 
exchange of sodium ions from the HA with TBA) (Cerroni et al., 2015). The last step in this 
reaction was the addition of diisopropylethylamine (DIPEA) which acts as a base and is an 
essential ingredient in PyBop based synthesis (Singh and Argade, 2012). 
There could be various reasons for the failure of the above-used method. The first can be the 
problems associated with human handling; for this, the reaction was repeated several times 
with as much care as possible regarding the handling of the experiment. The second reason can 
be the HA unable to react with the TBA but as seen from the Figure 3.5-D there are peaks 
related to TBA hence indicating that both of these reacted. Other two possible parameters that 
could have affected the said reaction would be the duration and the temperature of the reaction 
allowing the mixing of PMD with the rest of the reaction medium, i.e., the temperature we used 
was ambient temperature while the duration of the reaction for which it was allowed to react 
was 24 h. In order to rule out the temperature the reaction was carried out at 30°C and the 














Figure 3.5. 1H-NMR spectra collected from attempts to conjugate PMD with HA 
following the method of Sahoo et al., 2008.  (A), spectrum of HA starting materials 
showing characteristic peaks for H of glucosamine and CH3 of N-acetylcysteine. (B), 
spectrum of TBA showing characteristic peak for NH2. (C), spectrum of PMD showing 
characteristic peaks for the secondary and tertiary OH groups.  (D), spectrum of the final 
product indicating absence of PMD.  
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For the above outcomes, the most likely reason for this unsuccessful reaction may be a 
decreased affinity of the PyBop towards the hydroxyl groups of alcohol (PMD), though as 
indicated above, there are few examples of the successful conjugation. However, most of them 
account for the formation of the amide bond (between the carboxy and the amine groups) rather 
than the ester bond (Al-Warhi et al., 2012). Similarly, another possibility can be the formation 
of the side products during the chemical reaction that may hinder the conjugation of the said 
polymer and drug (Valeur and Bradley, 2009). 
3.4.3. Synthesis Using Fischer Esterification Reactions 
Another method that has been reported for the conjugation via an ester bond is to react an acyl 
halide with alcohol. In this method first, the carboxylic acid is reacted with a better leaving 
group, i.e., chloride, etc. which is then reacted with alcohol in the presence of a base to form 
an ester (Ouellette and Rawn, 2014). Here, firstly we needed to attach a better leaving group, 
i.e., chloride with the polymer. For this purpose, here, we have used thionyl chloride, which is 
a standard reagent used for the introduction of the chloride group (a leaving group) as shown 
previously by Petten et al. (2015). 
There are several potential reasons for the failure of this reaction. The first could be the inability 
of the hyaluronic acid sodium salt to convert into free hyaluronic acid. Moreover, as it has been 
reported that the above certain temperatures there is a significant degradation/denaturation of 
HA (Mondek et al., 2015) which in our case was indicated by the change of colour of the HA 
solution (possibly indicating the degradation of HA). Consequently, instead of refluxing the 
reaction mixture at 65°C it was reacted at 50°C for 4 h. After changing the temperature, though 
there were no signs of the degradation of the polymer at the same time, there was also no 
conjugation between the HA (polymer) and the PMD (drug) as indicated in Figure 3.6-C. Thus, 
it can be concluded that although this decrease of the temperature was important to prevent the 
degradation of the polymer, it appears likely that this temperature was insufficient to cause the 
reaction between the HA and the PMD and hence can be the key factor in the unsuccessfulness 












Fig 3.6. 1H-NMR spectra collected from attempts to conjugate PMD with HA following 
the Fischer esterification method.  (A), spectrum of HA starting materials showing 
characteristic peaks for H of glucosamine and CH3 of N-acetylcysteine. (B), spectrum of 
PMD showing characteristic peaks for the secondary and tertiary OH groups.  (C), 
spectrum of the final product indicating absence of PMD. 
Synthesis Using the Method of Lee et al. (2008) 
An alternative method to conjugate a polymer with the drug is by using DCC coupling. This 
method is based upon the activation of the carboxyl group (COOH) and then the subsequent 
conjugation with the drug. The first step for this reaction was converting the sodium 
hyaluronate into a free acid form. After that, in order to dissolve the free acid form of HA in 
DMSO, it was conjugated to polyethene glycol (dimethyl ether), for this reaction, DMAP 
added, which is required at 5 mol % for the efficient formation of esters ("Stiglich-esterification 
@ www.organic-chemistry.org," n.d.). From the results presented in Figure 3.8, it can be seen 
that the conjugation did not occur. 
Again, there are several potential reasons for the unsuccessful reaction; the first one can be the 
unsuccessful reaction of dmPEG and the free HA. This was unlikely since the HA was able to 
dissolve in DMSO, as the solubility of free HA is very low in DMSO. Another possibility can 
be the unavailability of the dry conditions in the reaction as this reaction is very moisture 
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sensitive. Whilst the reaction uses dry conditions it is feasible that moisture could have entered 
the said reaction. Another reason for the failure of the reaction could be the not all of the 
carboxy groups of the HA were activated which may be due to the use of the very high 
molecular weight of HA; the high molecular weight could have hindered the access to all of 
the carboxy groups within the polymer which coupled with the sterically hindered hydroxy 
















Figure 3.7. 1H-NMR spectra collected from attempts to conjugate PMD with HA 
following Lee et al. (2008) (A), spectrum of HA starting materials showing characteristic 
peaks for H of glucosamine and CH3 of N-acetylcysteine. (B), spectrum of PMD showing 
characteristic peaks for the secondary and tertiary OH groups.  (C), spectrum of the final 
product indicating absence of PMD. 
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3.4.4. Changing the Approach: From High Molecular Weight to Low Molecular Weight 
Initially, the HA that was used had a molecular weight of 1.6 MDa. As it has been reported that 
by decreasing the molecular weight, the reactivity of the polymer can be increased (Bernal et 
al., 2003), so to break the long chains of the polymer harsh conditions in the form of high 
temperature (60°C) and acidic environment (1M HCl) were provided. Upon following the 
indicated procedure (Bernal et al., 2003), the obtained solutions were subjected to gel 
permeation chromatography (GPC) in order to evaluate molecular weights. Results showed 
that various fractions of different molecular weights were found. To separate these fractions, 
they were passed through the dialysis membranes of various molecular weight cut-offs from 
3000-12000 Daltons. After that, low molecular weight HA was reacted with that of PMD by 
using the DCC coupling method as described above, but it failed in the desired conjugation. 
Possible reasons for the failure may be the; 
a) Degradation of the polymer during the procedure to form low molecular weight 
HA. 
b) Inability of the HA to react with PMD.  
The first potential reason was unlikely because there were no signs of the degradation of HA 
in the NMR spectra of the sample as the spectra was in accordance with the data of Tømmeraas 
and Melander (2008). Similarly, other reasons can be the inability of HA to react with the PMD, 
which may be due to the inability of the DCC to activate the carboxylic groups of the polymer; 













Figure 3.8. 1H-NMR spectra collected from attempts to conjugate PMD with HA 
following the change of approach, using high to low molecular weight HA.  A), spectrum 
of low molecular weight HA showing characteristic peaks for H of glucosamine and CH3 
of N-acetylcysteine. B), spectrum of the final product indicating absence of PMD. 
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3.4.5. Synthesis Using Procedure of Shin et al. (2014) 
Given the lack of reactivity or conjugation with either high or low molecular weight HA, using 
varied synthetic routes, it appears that it is the polymeric carrier that was problematic.  
Consequently, attempts switched from HA to PAA, a polymer with excellent safety profile and 
has been used in topical formulations with the required chemical structure (possessing 
carboxylic groups) (Calixto et al., 2015). The technique opted here for the conjugation was as 
accomplished by Shin et al.  (2014). 
The main principle of this conjugation was based upon the formation of the ester bond by the 
DCC coupling method. However, this reaction also failed to produce the desired results. From 
experimental parameters possible reasons for this failure may be: 
a)  The amount of drug added 
b) Reduced appropriate dark conditions to the solvent (formamide) 
c) The temperature of the reaction 
d) Unavailability of dry conditions 
In order to ensure that the reaction did not fail because of the drug (PMD) availability, an excess 
amount of the drug was added. Similarly, it was ensured that during the reaction the round-
bottomed flask (in which the reaction was taking place) was adequately covered with the 
aluminum foil. On the other hand, though in this case we did not further increased the 
temperature, but the possibility of the desired conjugation by increasing the temperature cannot 
be high, as previously described where HA did not give the desired results. Nevertheless, 
though this factor cannot be ruled out as there is possibility of the successful conjugation by 
increasing the temperature. Perhaps the most likely explanation was that there was some 















Figure 3.9. 1H-NMR spectra collected from attempts to conjugate PMD with PAA 
following the method of Shin et al. 2008 (A), spectrum of PAA showing characteristic 
peak for COOH. (B), spectrum of PMD showing characteristic peaks for the secondary 
and tertiary OH groups.  (C), spectrum of the final product indicating absence of PMD. 
3.4.6. Synthesis Using the Method of Madgey et al. (2012) 
Madgey et al. (2012) reported conjugation of PAA with salicylic acid through an ester bond by 
converting first PAA into poly(acryloyl chloride) and then subsequently reacting it with 
salicylic acid to form the said conjugate. Here, for the conversion of PAA into poly(acryloyl 
chloride), thionyl chloride was used, which after the required processing as outlined in the 
method was reacted with PMD. Though this method in the first attempt did produce good 
results but upon replicating the method was not reproducible. Possible reasons for the failure 
can be the inability of poly(acrylic acid) to be converted into poly(acryloyl chloride). The most 
probable reason for this failure can be as this method involved few steps after the reaction of 
PAA with thionyl chloride and during those steps most likely it was quite difficult to protect 
the converted polymer from the environmental moisture, hence, making it nearly impossible 











Figure 3.10. 1H-NMR spectra for (A), PAA showing characteristic peak for COOH (B), 
PAA after treatment with thionyl chloride, showing reaction of COOH group of 
polyacrylic acid (C) PAA+PMD, having no signs of conjugation occurring 
3.4.7. Change of the Drug 
After these initial unsuccessful attempts, one of the proposed reasons for the failure of these 
reactions was the drug (PMD) has secondary and tertiary hydroxy groups making it difficult 
for them to react with the polymer. Based upon this, in order to see what will be the effect of 
the replacing PMD with a compound with the primary hydroxy group, we chose thymol. The 
reasons for choosing this compound was that it has a maximum resemblance to the PMD (in 
the structure) and also belongs to the same class of the compounds as that of PMD, i.e., both 
are terpenoids, and also it has got some insect repellent properties (Pandey et al., 2009).  
 
After selecting the new drug, i.e., thymol, we employed the most commonly used methods in 
the literature for the formation of an ester bond, i.e., conversion into an acyl halide. For this 
purpose, we followed previously described methods. The first in this list was by first converting 
poly(acrylic acid) into poly(acryloyl chloride) and then the reaction with thymol to form the 
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conjugate. In the first step, poly(acrylic acid) was successfully converted to poly(acryloyl 
chloride) which was indicated by the loss of the hydrogen for the carboxy group of poly(acrylic 
acid) which further indicated the presence of the Cl (Figure 3.11 C) after that conjugation was 
tried with the thymol. In this case, there was the appearance of one peak that was related to the 
drug, but the results were not reproducible (though being tried thrice under the same 
conditions). Moreover, the peak was for the OH group of thymol that in case of successful 
conjugation should have not been there (Figure 3.11 C). 
In the second step as described before based on activation of the carboxylic group (by making 
it a better leaving group) and then reacting it with an alcohol to form a polymer-drug conjugate, 













Figure 3.11. 1H-NMR spectra for (A), PAA spectrum of PAA showing characteristic peak 
for COOH (B), Thymol, having a characteristic peak for primary OH group at 9.2 ppm 
(C) PAA+thymol showing no signs of conjugation 
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3.5. Conclusion 
Due to the high molecular weight polymer initially used and the low reactivity of the PMD 
(because of secondary alcohol) the esterification of PMD was not that straightforward. The 
reported methods and our modifications to those procedures failed to yield the desired results. 
Despite changing the polymer, polymer molecular weight, solvents and the drug itself, the 
desired polymer-drug conjugate could not be synthesised.  This led to the change of approach, 
i.e., from polymer-drug conjugate to the monomer drug conjugate and then subsequent 
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Paramenthane-3,8-diol (PMD) is a biochemical pesticide derived from eucalyptus plants. This 
active ingredient is used to make products that are applied to human skin and clothing to repel 
insects, such as mosquitoes (Pandey et al., 2009). There have been concerns over the use of 
insect repellents, notably in pregnant women as well as the infants; although there isn’t 
sufficient data available on the use of PMD in these groups, nevertheless it is advised not to 
use it (for example “insect-repellent-usage @ www.infantrisk.com,” n.d.). 
 
Polymer-drug conjugates (PDCs) have been used as a tool for drug delivery and their usage is 
increasing because of enhanced drug solubility, targeted delivery of the drug and a decreased 
adverse effect profile (Malathi et al., 2020). There are various polymers that are commonly 
applied to the skin both in topical medicines and cosmetics, e.g. chitosan, hyaluronic acid, 
polyacrylates etc (Valenta and Auner, 2004). Selection of a polymer for topical drug delivery 
is based upon numerous parameters but the prime requirement  is good safety profile, i.e. 
minimal irritation (Sugibayashi and Morimoto, 1994). 
 
Polymers can be in the form of homo- or copolymers. Copolymers are systems in which 
macromolecules are obtained by the polymerisation of two different types of monomers 
(Hagiopol, 2016). Copolymers provide many advantages as compared to homopolymers, 
notably that copolymers have hybrid properties arising due to the individual monomers; these 
properties can then be tailored to meet the specific uses (Shukla, 2020).  For example, poly 
(lactide-co-glycolide) uses  poly(glycolide) which has a low glass transition temperature (Tg), 
and when combined with poly(lactide) (having higher Tg) the resulting copolymer has a stable 
Tg (Francois et al., 2015; Klein and Wojcik, 2001). Alongside the unique therapeutic properties 
(active targeting, enhanced stability etc) that copolymers may possess, copolymerisation also 
gives rise to tailored rheological and mechanical properties, i.e. flow, viscosity, softening point 
etc (Li et al., 2015). 
 
Acrylic acid copolymers have been traditionally used for various purposes like ophthalmic drug 
delivery (Ma et al., 2008) whilst their application in topical and transdermal drug delivery is 
also well established (Don et al., 2008). As copolymers exhibit various physico-chemical 
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properties, it is important to characterise them fully (Contreras-López et al., 2013), commonly 
for thermal stability, Tg, molecular weight, composition of the polymer and  reactivity ratio of 
the monomers (Srivastava and Kumar, 2013). Depending upon the usage, various specific tests 
can be performed, e.g. for hydrogels, copolymers are tested for their swelling properties 
(Shahzamani et al., 2020). 
 
Here, a novel poly(acrylic-co-acryloylPMD) ester copolymer has been synthesised and 
characterised by 1H NMR and IR spectroscopy. The copolymer thermal stability was assessed 
by thermogravimetric analysis (TGA), Tg by differential scanning calorimetry (DSC), 
molecular weight by gel permeation chromatography (GPC), reactivity ratio by liquid-
chromatography mass-spectroscopy (LCMS), and drug loading by elemental and titration 
assay. Moreover, turbidimetric analysis was also performed to see the effect of pH on aqueous 
solubility of the copolymer. 
 
4.2. Materials 
PMD (p-Menthane-3,8-diol) was used as received (BOC, USA) (from this chapter onwards the 
PMD used was purchased commercially). Acrylic acid (AA) in liquid form (99%, Fisher 
Scientific, UK) was passed through the aluminium oxide column to remove the inhibitor prior 
to be used in copolymerization. Azobisisobutyronitrile (AIBN) was used as initiator and was 
recrystallized twice in methanol (Sigma-Aldrich, UK). Sodium hydroxide (Fisher Scientific, 
UK), acryloyl chloride and anhydrous triethylamine (Sigma-Aldrich, UK) were used as 
received. Poly(acrylic acid) (Mw=5000 Da) was purchased from Polysciences, Germany. All 
the solvents used were obtained from the Fisher Scientific, UK and were used as such without 
purification. TLC plates were obtained from Merck, Germany. 
 
4.3. Methods 
 4.3.1. Synthesis of Monomer Drug Conjugate (APMD) 
3.54 g of PMD was dissolved in 4 mL of anhydrous THF and stirred for 10-15 minutes until a 
clear solution was obtained. Then to this 3.44 mL of anhydrous triethylamine was added to de-
protonate the PMD and was allowed to further stir for 5 minutes. Then, to this solution mixture, 
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1.8 mL of acryloyl chloride was added dropwise. As this is a highly exothermic reaction, the 
round bottom flask was placed over ice. Then this mixture was allowed to stir at room 
temperature for 4 h. After that, the solvent was evaporated under vacuum followed by silica 
column chromatography using mixtures of ethyl acetate and hexane (1:4) and the product 
determined by thin layer chromatography (TLC). The final product was a viscous oil (2.1 g). 
Yield (53%). The yield was calculated as: (Amount of pure product recovered/Amount of 
chemical used) *100)   
1H NMR, (DMSO, 400 MHz): δ 6.40 ppm (1H, d), 6.25 ppm (1H, q),5.90-6 ppm (1H, d), 5.30 
ppm (1H, s), 4.20 ppm (1H, s), 0.90 ppm (6H, s), 0.80 ppm (3H, d). IR data 3221 cm-1= OH of 
PMD, 2840-2970 cm-1= C-H stretch, 1719 cm-1 = Ester linkage, 1017-1048 cm-1 =C-H 
bending. m/z = 242.19 Da which corresponds to C13H22O3Na. 
 
4.3.2. Synthesis of poly(AA-co-APMD) Copolymer 
The poly(AA-co-APMD) copolymer was synthesised via free radical polymerisation (with 
varying molar ratios). All the magnetic stirrers and glassware used in the experiment were dried 
at 110 °C for 6-8 h prior to the experiment. Briefly, (depending upon the molar ratio of the 
monomers used) in a typical reaction (7:3 APMD:AA)  APMD (300 mg), acrylic acid (285 
mg) and azobis(isobutylronitrile)(AIBN) (0.005 mol/L) were added into a flask together with 
ethanol (5 mL) as a solvent. After degassing the solution with nitrogen for 20 mins, the mixture 
was stirred under the inert environment at 65 °C for 16 h. Then, the flask was cooled to quench 
the reaction and the product obtained was dialysed using a regenerated cellulose membrane 
(suitable for ethanol, Sigma Aldrich, UK, MWCO 2000 Da) against ethanol for 2 days with 6 
times change of the solvent to remove unreacted monomers and oligomers. The final product 
poly(AA-co-APMD) was obtained by using a rotary vacuum for 20-30 mins at 50 °C. The yield 
of copolymer after the purification was 18-50% for different molar ratios except 1:9 
(AA:APMD), where the yield was extremely low (2%), and attempts to obtain a homopolymer 
of APMD failed. Yield of the poly(AA-co-APMD) was calculated by: 




4.3.3. Turbidimetric Measurements  
The turbidity of polymer solutions at different molar ratios, i.e. 9:1 and 3:7 (AA:APMD) was 
investigated at 1 mg/mL with a Shimadzu UV/VIS-2401 PC spectrophotometer (Japan) at 400 
nm. For this experiment, poly(acrylic acid) (PAA) was used as a control. The experiment was 
performed at room temperature. The pH of the solutions was changed by adding 0.1 N sodium 
hydroxide (NaOH) and determined using a digital pH-meter (JenWay, UK). All the 
experiments were performed in triplicate. 
4.3.4. Molecular Weight and Molecular Weight Distribution of the Polymers 
Molecular weight of the copolymers and its distribution was determined using a gel permeation 
chromatography (GPC) instrument equipped with an Agilent 1100 series RI detector, 
quaternary pump and Waters Ultra hydrogel columns with pore sizes of 250, 500 and 1 000 A, 
respectively. The mobile phase consisted of THF with a flow rate of 0.75 mL /min. The eluent 
was DMF containing Bu4NBr (0.1% w/v). In this experiment copolymers of varying ratios of 
acrylic acid (AA) and acryloyl PMD (APMD) were used ranging from 1:9, 3:7, 5:5, 7:3, 9:1 
(AA:APMD). PAA was used as a control.  
 
4.3.5. Reactivity Ratio Experiment 
4.3.5.1. Method Development 
The first step in the reactivity ratio experiment was to develop a method for the analysis of both 
AA and APMD. For this purpose, LCMS was used. Briefly, for the purpose of constructing a 
calibration curve for both AA and APMD, a stock solution of 1000 µg/mL (1mg/mL) was 
prepared by dissolving 14.2 mg of AA and 17.8 mg of APMD in 14.2 and 17.8 mL ethanol 
respectively. This was then serially diluted to make 200, 100, 50, 25, 10, 5 and 1 µg/mL 
dilutions (by using following formula): 
Concentration (start) x Volume (start) = Concentration (final) x Volume(final) 






 4.3.5.2. Reactivity Ratio Experiment 
Monomer mixtures of AA and APMD were dissolved in ethanol. Five monomer mixtures were 
investigated with the AIBN concentration was kept constant in all cases (0.005 mol/L). The 
polymerization, carried out at 60 °C, was allowed to proceed to low conversions (below 10%). 
For this purpose, reactions were stopped before 2 h. The obtained product was subjected to 
liquid chromatography mass-spectroscopy (LCMS) for analysis. The analysis was performed 
for both AA and APMD 
 
4.3.6. Drug Loading 
Two methods were used for the calculation of drug loading, i.e. titration method and elemental 
analysis. 
 
4.3.6.1. Titration Method 
In this method, firstly PAA (5,000 Da, Polysciences, Germany) was used and 5 different 
solutions of PAA in water:ethanol (7:3 v/v) were prepared (1,2,3,4 and 5 mg/mL).  All solutions 
were flushed with nitrogen to remove any dissolved carbon dioxide (as during the reaction it 
may form carbonic acid which may give false results). Then, 3mL of PAA solution from each 
of the stock (1, 2, 3, 4 and 5 mg/mL) was taken and to this 3 drops of phenolphthalein indicator 
was added. Then 0.1M NaOH solution was added dropwise until a faint pink colour appeared 
(at this point the reaction was stopped) and the volume of NaOH used was recorded. Similar 
data obtained from the copolymer system (volume of 0.1M NaOH used) was correlated with 
the data obtained from the PAA. For example, in the case of 5 mg/mL of copolymer solution, 
the volume of 0.1M NaOH used was 3mL and the % of PAA was calculated as: 
Volume of NaOH used in PAA-volume of NaoH used in copolymer/ Volume of NaoH 
used in PAA*100 (Soto et al., 2014) 
4.3.6.2. Elemental Analysis 
An elemental analyser (FLASH EA 1112 series, Thermo-Finnigan, Italy) was used for C 
(carbon) elemental analysis. Samples were prepared by the method as described earlier at four 
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different molar ratios, i.e. 3:7, 5:5, 7:3 and 1:9 (AA:APMD). After the product was obtained, 
it was dried overnight in a vacuum oven (Thermo Fischer, UK) at 40 °C to ensure complete 
removal of the moisture. A total of 2-3 mg samples was sealed in HPLC vials (Thermo Fischer, 
UK) and were subjected to analysis. For the analysis, combustion and reduction tubes 
(PerkinElmer) were used. The combustion reaction was run at 975 °C in the presence of pure 
helium and oxygen as carrier gas. 
 
4.3.7. Thermal Analysis 
Thermal analysis was performed by using two techniques, i.e. thermogravimetric analysis 
(TGA) and differential scanning calorimetry (DSC). 
 
4.3.7.1. TGA 
TGA was carried on copolymer poly(AA-co-APMD) samples of different molar ratios with  
PAA and PMD used as controls, as described in chapter 2. In this experiment we used non-
Hermetic pans. 
 
4.3.7.2. DSC Study 
In order to determine the glass transition temperature (Tg) of the copolymers (of varying molar 
ratios) and the PAA (as a control). Procedure described in chapter 2 was followed. Here we 
used Hermetic pans. Moreover, this experiment was carried out by the technician. 
 
4.4. Results and Discussion 
4.4.1. Synthesis of Monomer Drug Conjugate (APMD) 
After the initial failed attempts to synthesise a polymer-drug conjugate, an alternative route of 
conjugating PMD with a monomer (that can be polymerised) was explored, i.e. producing an 
acryloyl-PMD monomer (APMD) and then subsequently polymerising this conjugate alone 
(homopolymer) or with another monomer (in our case acrylic acid) to form a copolymer. This 
synthesis route for copolymers has been reported previously in various studies (Chytil et al., 
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2010; Liu et al., 2015) and is considered to be a good alternative if the conventional polymer-
drug conjugation approach is unsuccessful. There are various advantages of this method, 
notably in drug loading as in this method the percentage of drug loading is typically higher 
than for conventional PDCs whilst the drawbacks include that the approach often involves more 
synthetic steps and depending upon the monomer used, water solubility may be decreased, e.g. 
if the methacrylic acid monomers are used there are reports of a decrease in the water solubility 
of the obtained product (Bozorg et al., 2020). 
Here we chose acryloyl chloride as a precursor for the conjugation due to two reasons; the first 
was that the chloride group provides a platform for the formation of an ester bond between the 
PMD and the acryloyl chloride. The other was the acrylic acid itself, as it is the precursor of 
the poly(acrylic acid)-based polymers, which are commonly used in topical drug delivery and 
have an excellent safety profile (Ritthidej, 2011). 
A typical nucleophilic reaction synthesised the monomer drug conjugate (acryloyl-PMD). This 
involves a nucleophilic attack by alcohol, i.e. OH, followed by the removal of the leaving 
group, i.e. Cl. Triethylamine (TEA) was used as a base to convert the HCl (formed during the 
reaction) into a salt (triethylamine hydrochloride, a by-product). The chemical structure of the 
APMD was verified by 1H NMR, shown in Figure 4.1. By comparing the NMR spectra of the 
PMD alone and acryloyl chloride alone, we identified two main parameters for the verification 
of successful conjugation. First was the loss of one (δ 3.38 or 4.42 ppm) of the OH groups from 
PMD (due to the formation of an ester bond between the PMD and the acryloyl chloride) and 
the other was the appearance of the peaks indicating the presence of  CH2 and CH groups of 
the acryloyl chloride at around δ6 ppm. From the 1H NMR spectra of the APMD (Figure 4.1) 
it can be seen that both of these criteria were fulfilled such that the peak indicating the presence 
of one of the OH group in PMD, was lost. Moreover, new peaks were found in the region of 
δ6 ppm, indicating the presence of acryloyl moiety and, hence indicating a successful reaction. 
Further confirmation was from mass spectroscopy that showed the presence of a strong peak 
corresponding to a mass of 242 Da, which is in agreement with the molecular formula 
















Figure 4.1 1H-NMR spectra of (A) Acryloyl chloride, having characteristics peaks for CH2 
and CH groups at around δ6 ppm. (B) PMD, having characteristics peaks for CH3 and 
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for the secondary and tertiary OH groups. (C) Acryloyl PMD, showing successful 
conjugation indicated by the appearance of characteristic peaks for acryloyl chloride. (D) 
Comparative spectra of acryloyl chloride, PMD and APMD. 
 
 
4.4.2. Synthesis of Poly(AA-co-APMD) 
In this study, a novel hydrolysable (by esterases) copolymer poly(AA-co-APMD) was 
synthesised through free radical polymerisation. Briefly, the copolymer was synthesised by 
free radical polymerisation of two monomers, i.e. acrylic acid (AA) and acryloyl PMD 
(APMD) using AIBN as a free radical initiator. The 1H NMR confirmed chemical structure of 
the copolymer. Verification of the polymerisation was affirmed (Figure 4.2) by the loss of the 
peaks corresponding to the double bonds of the acryloyl moiety of APMD, as these double 
bonds are the point of attack by the initiator (AIBN) during free radical polymerisation (Mota-
Morales et al., 2018). 
Along with this, another indicator was the broadening of NMR peaks, as 1H NMR peaks of the 
copolymer are usually broader (due to the repetitive units) and a common phenomenon 
observed with the macromolecules (Paulsen et al., 2017). Moreover, GPC analysis showed a 
peak with a polydispersity index (PI) of 2.9. The Mw of the copolymer was 6,200 Da. In order 
to prove the presence of the ester bond, C NMR and infra-red (IR) spectroscopy were used. In 
C NMR, we expected to have a peak between 170-190 ppm (indicating the presence of carbonyl 
carbon). In Figure 4.2, the C NMR spectra showed a faint peak at 175 ppm that could be related 
to the carbonyl carbon.  Moreover, the IR spectra showed the presence of the ester bond in both 















Figure 4.2 1H-NMR spectra of (A) Poly(AA-co-APMD) showing peaks for COOH group 
of the AA, OH, CH and CH2 groups of APMD. (B) 13C-NMR spectra of Poly(AA-co-
APMD) showing a faint peak for carbonyl carbon. (C) Comparative spectra of PAA and 
Poly(AA-co-APMD) showing the presence of extra peaks in the copolymer corresponding 
to APMD. (D) IR spectra (overlapped), showing PMD with characteristic peaks for OH 
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(3217 cm-1), CH stretching (2840-2970 cm-1 region), APMD showing a prominent peak at 
1716 cm-1 indicating formation of ester bond and the copolymer, poly(AA-co-APMD). 
 
4.4.3. Copolymer Composition 
 
The first step to calculate reactivity ratios is to know the composition of the copolymer. For 
this purpose, it is essential to have an analytical method that can detect the monomer(s) 
concentration. In our case, we had two monomers, i.e. acrylic acid (AA) and acryloylPMD 
(APMD). The most commonly used method for the detection of a monomer during a 
polymerisation reaction is 1HNMR, but due to the overlapping peaks from the acrylic groups, 
it was not possible to use this method. Further, due to the absence of a chromophore, we could 
not use the HPLC or UV spectroscopy. Therefore, we used LCMS to detect the monomers 
during the polymerisation. Here, we were only able to detect APMD and could not detect the 
acrylic acid (most probably due to the volatile nature of the monomer).  
The first step in the validation of a method (LCMS) is to assess whether it can quantitatively 
detect a compound or not and how accurate the detection is. For this purpose, a calibration 
curve was constructed, shown below. 
 
 
Figure 4.3 Calibration curve for the APMD by using LCMS (n=3) 






















Figure 4.4 Composition of the copolymers as the function of the feed mixtures (APMD).  
Black line indicates the partition between the lower and upper halves of the graph. 
 
4.4.4. Calculation of Reactivity Ratio 
During the synthesis of a copolymer, usually, one monomer is more reactive than the other 
monomer or (rarely) both the monomers may have same reactivity towards each other. Thus, 
in order to know the reactivity of one monomer towards another, the reactivity ratio is 
calculated. A reactivity ratio can be defined as the difference between the ratio of the monomers 
in the copolymer system to the ratio of feed mixture (Ebnesajjad, 2003). 
In order to calculate the reactivity ratio various parameters, need to be calculated, including 
monomer feed ratio composition, monomer copolymer composition and conversion of the 
monomer. The mole fractions (in mol%) of APMD in the feed as well as the copolymers (at 
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five different molar ratios) were calculated by using LCMS. The data is presented in Table 4.2. 
Reactivity ratios of APMD and AA were determined by the application of conventional 
linearization methods such as the Finemann–Ross (FR) and Kelen–Tüdós (KT) methods.  The 
Finemann–Ross (FR) method is one of the commonly used method for determining reactivity 
ratios, where G and H  (numerical values obtained through the initial feed and final copolymer 
composition of that monomer, in our case APMD) have a linear relationship with each other 
according to the following equation:  
G= rAPMDH-rAA  (Erbil et al., 2009). 
The FR plot obtained by linear regression analysis for APMD/AA copolymers is in Figure 4.5. 
For obtaining the FR plot certain parameters needs to be calculated which are summarised in 
Table 4.1. 
 
Table 4.1. Compositional FR Parameters for Poly(AA-co-APMD) Copolymer System 
F                                      f                                f2/F (H)                        f(1-F/f) (G) 
0.11                                0.063                              0.036                                0.5 
0.42                                0.176                              0.073.                              0.24 
1                                     0.449                              0.201                                 0 
2.33                                1.38                                0.81                                -0.78 
9                                     8.09                                7.27                                -7.19 
  
Where F=%APMD in monomer mixture/total %APMD, i.e. 1/9=0.11, 3/7=0.42 





Figure 4.5. FR method for determining monomer reactivity ratios in the copolymerisation 
of APMD and AA by using LCMS data (for APMD). 
Kelen and Tüdós (KT) applied these two parameters, i.e. G and H in the linearized 
copolymerization equation, along with new parameters such as α, η and ζ. The intercepts 
at ζ = 0 and ζ = 1 of the η versus ζ plots yield – rAPMD/α and rAA, respectively (Erbil et al., 
2009). 
 
Table 4.2. Compositional KT Parameters for Poly(AA-co-APMD) Copolymer System 
F                          f                      f2/F (H)           f(1-F/f)(G)         η                     Ξ 
0.11                   0.063                  0.036                 0.5                 0.89                  0.06 
0.42                   0.176                  0.073                 0.24               0.40                  0.12 
1                        0.449                  0.201                   0.                      0                  0.27 
2.33                   1.38                    0.81                  -0.78              -0.58                 0.60 
9                        8.09                    7.27                  -7.19              -0.92                 0.93 
 
Where α = 0.52 
η= G/(α+H) and ξ= H(α+H) 

















Figure 4.6 KT method for determining monomer reactivity ratios in the copolymerisation 
of APMD and AA by using LCMS data (for APMD). 
Table 4.3. Comparison of reactivity ratios by various methods for AA/APMD copolymers 
 r1 (AA) r2 (APMD) 
FR method 1.03 0.28 
KT method 1.9 0.71 
 
Various studies have reported that as a monomer becomes bulkier the reactivity of it decreases, 
for example when acrylic acid was copolymerised with methyl methacrylate the reactivity ratio 
of the acrylic acid was found to be 1.5 and for the methyl methacrylate it was 0.48  (Ekpenyong, 
1985).  
From the values summarised in Table 4.3 (for the reactivity ratios of both monomers, i.e. AA 
and APMD) it can be seen that reactivity ratio values are different by the two methods, i.e. FR 
and KT method. As discussed earlier in FR method a plot of G as ordinate and H as abscissa is 
plotted resulting in a straight line whose slope is r1 and intercept is r2. The slope of the line of 
best fit is influenced greatly by the points which are closer to the origin, hence giving a non-
uniform weightage to the points and thus errors in the results are produced. The validity is only 
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qualitative and the estimates of r1 and r2 can change with each experiment by analysing the 
data in different ways. Moreover, the high and low experimental composition data are 
unequally weighed, which produces large effects on the calculated values of r1 and r2. To 
overcome these issues KT introduced refinement of linearization by adding an arbitrary 
constant ‘’ α’’ into FR equation, which helps the data to spread more evenly over the entire 
composition range ultimately giving equal weightage to all the data. Thus, we suggest that the 
inclusion of the ‘’ α’’ accounts for different values.  
However, in both calculations it is clear that AA is more reactive than APMD, and interestingly 
by 1.03/0.28 = 3.7 times by FR method and 1.9/0.71 = 2.7 times by KT method so in both cases 
showing AA about 3 x more reactive than APMD. Thus, it is expected that copolymers will 
contain greater levels of AA than APMD than anticipated, simply from their feed composition.  
So, loading of PMD on the copolymer will be lower than anticipated, as discussed in section 
4.4.9. 
 
4.4.5. Turbidimetric Study: 
In the present work, we studied the turbidity of poly(AA-co-APMD) copolymers with varying 
monomer ratios. The main aim of this was to study the effects of adding APMD (non-ionic) 
monomers into the copolymer system on the aqueous solubility at different pH’s by observing 
changes in opacity. Here PAA was used as a control. For such copolymer systems, a term called 
critical pH of complexation pH(crit) is used below which  the solution becomes turbid which 
is an indication of the phase separation in the system due to the formation of insoluble 
complexes (Khutoryanskiy et al., 2004). Hydrogen bonded interpolymer complexes (IPC) are 
formed between the proton donor (weak polyacids like PAA) and proton acceptor (non-ionic 
polybases like polyethylene glycol) polymers in the aqueous solution. An important limitation 
of such polymer systems is that they are usually soluble only within a narrow pH window. 
Normally, at pH values higher than 4-5, interpolymer complexation via hydrogen bonding is 
not possible due to the increase of ionised sites (carboxylate groups) in the polyacids chain, 
whilst on the other hand, at pH values lower than 3-3.5, the hydrogen bonded IPC precipitates 
(forming a turbid solution) because the fraction of the carboxylate anions in the polyacid chains 
(responsible for the solubility of the complex) decreases significantly (Khutoryanskiy and 
Staikos, 2009; Mun et al., 2003). From the results (Figure 4.7) it can be seen that the copolymer, 
i.e. poly(AA-co-APMD) mixture turns very turbid at lower pH, whilst it remains clear at higher 
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pH, this behaviour can be best explained by the formation of the hydrogen bonded IPC in 
between the AA and the APMD chains. Moreover, the PAA solution (control) remains 
practically transparent throughout the pH region. This behaviour can be attributed to the 
negative charge of the PAA (due to AA units), implying that either no interpolymer 
complexation is formed due to the negatively charged AA units or the IPCs formed are more 
hydrophilic and soluble in water.   
  
 
Figure 4.7. Effect of pH on the turbidity of the solution of PAA and the copolymers with 
varying molar ratios (of AA:APMD) 
 
4.4.6. Molecular Weight Characterisation 
 GPC analysis results demonstrated that poly(AA-co-APMD) copolymer with a relatively high 
molecular weight distribution (Mw/Mn >3.5) was obtained. Table 4.4 shows the molecular 
weight, PDI and molar percentage of monomers in the feed. Based on the results, it can be seen 
that increasing incorporation of AA units into the copolymer system resulted in higher 
molecular weights. This confirms the earlier findings that (from the reactivity ratio data) that 
AA is more reactive than APMD since higher reactivity’s of monomers produce high molecular 
weight polymers (Abbasi et al., 2020). A further factor affecting polymer molecular weight is 
the kinetic chain length which is (in the case of free radical polymerisation) the approximate 
number of monomers that are consumed by each radical; the greater the kinetic chain length, 
the larger will be the molecular weight. The kinetic chain length depends upon the initiation 

























www.wiley.com), and bulky cyclic groups tend to terminate polymerisation (Tüdo and Földes-
Berezsnich, 1989) resulting in the decrease kinetic chain length and ultimately decrease 
molecular weight.  Given the large discrepancies in molecular weight with addition of 
increasing amounts of APMD, it is likely that both the reactivity ratio (approximately three-
fold higher for AA) and the kinetic chain length affects the molecular weight of the resulting 
copolymers. The PDI (Mw/Mn) is relatively high (quite common for free radical 
polymerisation) and could be controlled by the terminating the polymerisation reaction at low 
conversion rates (Krivorotova et al., 2015). 
 
Table 4.4. Molecular Weight Data for Copolymer Poly(AA-co-APMD) System 
Molar feed ratio                        Mw                                   Mw/Mn 
(AA:APMD)                                        
 
1:9                                              1800                                     2.1 
3:7                                              6200                                     2.9 
5:5                                              11500                                   3.1 
7:3                                             29200                                    3.3 
9:1                                             53100                                    3.4 




4.4.7. Thermal Study 
4.4.7.1.Thermogravimetric Analysis (TGA) 
TGA investigated thermal stability of the copolymer poly(AA-co-PMD) at different molar 
ratios and PAA along with the PMD (both as controls). The primary purpose of this experiment 
was to explore the stability of the poly(AA-co-APMD) copolymer and monitor thermal events. 
From Figure 4.8, it can be seen that the control, i.e. PMD, the weight loss starts at 40 °C and 
the material is essentially lost at 60°C, which is according to the literature. Moreover, this loss 
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in weight is attributed to high vapour pressure rather than the degradation of the material itself 
(Drapeau et al., 2011). Purpose of making it into a copolymer was to slow and extend the 
release, as the Figure 4.8 shows that it is rapidly lost when applied as a single compound to the 
skin. PAA is a widely used and suitably stable polymer showing minimal weight loss up to 
~150 °C, with perhaps the slight decrease due to loss of surface adsorbed water. Beyond this it 
starts to degrade. From the Figure 4.8, it can be seen that there two significant stages of the 
degradation in PAA; one at 190 °C and the other at 336 °C, whilst there is an initial weight loss 
below 100 °C which can be attributed to the loss of moisture. The first stage of the degradation 
(in PAA) till 336 °C accounts for most of the weight loss (70%), whilst the second stage after 
336 °C accounts for remaining of the overall weight loss, i.e. almost 91% at 590 °C. The data 
obtained for PAA is in correspondence with the literature. However, there are few deviations 
which can be attributed to the impurities within the polymer sample (McNeill and Sadeghi, 
1990). Complexing PMD in the copolymers clearly stabilises the weight loss. With 
3AA:7APMD, some weight loss (approx. 3.2%) at 40 degrees is seen but is likely the adsorbed 
moisture or the PMD from the relative smaller APMD chains (oligomers) within the 
copolymer. Weight loss at about 250 °C, can be attributed to decarboxylation (release of CO2) 
process. Similarly, above 350 °C the weight loss can be due to the chain scission, as at high 
temperature, the release of fragments within the acrylic acid sequence is possible (Maurer et 
al., 1987). 
 




























4.7.2. DSC Analysis 
DSC analysis was performed on PAA alone followed by the copolymer poly(AA-co-APMD) 
at different molar ratios to determine the glass transition temperature (Tg) - the temperature 
below which a polymer’s physical properties change to those of a glassy state (Ebnesajjad, 
2016). DSC determined the Tg of the copolymers (at two molar ratios) under a nitrogen 
atmosphere (at 40 °C /min). For synthesised PAA, the Tg value was around 101°C which is in 
agreement with the literature (Wong et al., 2007), whilst the copolymers poly(AA-co-APMD) 
showed Tg’s varying from 48-59 °C for different molar ratios. It was found that increasing the 
amount of APMD in the copolymers results in decreased Tg, i.e. for 7:3 (AA: APMD), the Tg 
onset was at 51.9 °C, whilst for 3:7 (AA: APMD) it was 48.2 °C. Two main parameters can 
affect the Tg, firstly the strength of the bond between the molecules, and secondly the stiffness 
of the polymer chain (Hobson, 2001). The results, showing PAA has a higher Tg than the 
copolymers, can be best explained by the higher polarity of  PAA due to which there is increase 
dipole interaction between the molecules hence it has rigid chains, whilst the addition of the 
APMD monomer decreases the polarity and the dipole interactions leading to decreased 





Figure 4.9. DSC thermograms of poly(AA-co-APMD) at two different monomer ratios 
and PAA  
 
4.4.8. Drug Loading Study 
The most commonly used technique for determining drug loading in polymer-drug conjugates 
is 1H NMR (Zhang et al., 2004). Unfortunately, due to the overlapping of the peaks of CH2 and 
CH groups of both the drug (PMD) in the APMD monomer and the AA it was not feasible to 
use this method. Therefore, in order to determine the amount of drug-loaded in the copolymer 
system, other methods were explored; two methods were used namely the titration method (for 
determining free carboxylic groups) hence indirectly showing the amount of PMD present 
while the second technique used was the elemental analysis in which the percent carbon content 
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           4.4.8.1.  Titration Study 
Different types of the complexometric titration methods have been used to quantify 
certain functional groups, including carboxylic groups (Fras et al., 2004). Most titration 
methods use spectrophotometric analysis and commonly employ solvents in which our 
copolymer was insoluble or use conditions that might result in the breakage of the ester 
bond in the copolymer (van Houwelingen et al., 1980). Therefore, a conventional 
method was used by titrating the copolymer against an excess amount of base (NaOH) 
in the presence of a pH indicator (phenolphthalein). The prime concern during this 
process was to ensure that the ester bond of the copolymer do not hydrolyse. For this 
purpose, the whole reaction was performed over ice in order to prevent the hydrolysis 
of the ester bond in the copolymer as the hydrolysis of an ester is slower at a lower 
temperature than the neutralisation reaction. 
 The titration calibration curve for the PAA control showed an excellent correlation 
(r2=0.99) between the concentration of the PAA and the volume of the NaOH (0.1 M) 
used for neutralisation, thus indicating the suitability of this method for quantification 
of the free carboxylic groups. Moreover, previous studies have also reported the 
titration of PAA by the same method (Bensacia and Moulay, 2012) thus giving 
confidence in the approach. 
 
Figure 4.10. Calibration curve for PAA by using titration method. Data are 





























Concentration of PAA (μmol)
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From this calibration curve, the volume of 0.1M NaOH used to neutralise the copolymer 
systems was used to assess the PAA content. For example, for 0.8. μmol of copolymer (3:7, 
AA:APMD) solution was neutralised by 8.9 mL of 0.1M NaOH. From this the percentage of 
free carboxylic groups were calculated by using the following formula: 
Volume(NaOH used in PAA)-Volume (NaOH used in copolymer)/ Volume (NaoH used in PAA)*100. 
From the above equation the amount of free carboxylic groups (AA,) was 89.8% and so the 
assumption is that the remainder of the material (10.2%) was APMD  
Table 4.5. Drug loading calculation at various molar ratios of the monomers by the 
titration method 
Monomer ratio       Volume of 0.1M NaOH             %AA content       %APMD content 
3:7 (AA:APMD)               8.9 mL                           89.8                             10.2 
5:5 (AA:APMD)               9.25 mL                         92.5                             7.5 
7:3 (AA:APMD)               9.62 mL                         96.2                             3.8 
 
4.4.8.2.Elemental Analysis 
Elemental analysis is a technique that provides information on the composition of any chemical 
entity at an elemental level, i.e. C, N, H etc. This technique is commonly employed to determine 
the composition of polymers (Hu et al., 2019). Here, the amount of PMD (drug) within the 
copolymer was determined through elemental analysis. The drug percentage was calculated by 
using carbon (%) via the carbon (content) analysis. The rationale for using carbon content was 
that both APMD and AA have carbon atoms in their structures. For calculating the amount of 
drug-loaded, first it was necessary to determine the percentage of carbon in PMD alone and 
PAA alone. It is understood that by changing the molar ratio of the copolymer will have 
different carbon content (%C) in the final product. The drug content was calculated through 
the following equation. 
Weight (%) Drug= %C(copolymer)-%C(PAA) / %C(PMD)-%C(PAA)*100 (Hu et al., 2019). 
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For the copolymer 3:7 (AA:APMD), the total weight(%) of the APMD was calculated to be 
9.7%, in close agreement with the titrimetric value of 10.2%. 
Table 4.6. Drug loading calculation at various molar ratios of the monomers by the 
elemental analysis method 
Monomer ratio                       %AA content                       %APMD content 
3:7 (AA:APMD)                       91.3                                          9.7 
5:5 (AA:APMD)                       92.9                                          7.1 
7:3 (AA:APMD)                       96.8                                          3.2 
 
 
4.4.9.   Correlation of Drug Loading with Reactivity Ratio 
The composition of a copolymer is usually different from the composition of the monomer 
feed from which copolymer is synthesised because different monomers have different 
reactivities to undergo copolymerisation (Ayranci et al., 2016). Here it can be seen that 
initially, APMD concentration in the mixture feed during the 3:7 (AA:APMD) synthesis 
was 70% whilst acrylic acid was 30%. However, after the synthesis of the copolymer, the 
percentage of incorporated acrylic acid is 85-88% (obtained from titration and elemental 
analysis), far higher than the initial composition, i.e. 30%. This indicates that APMD is far 
less reactive than the AA. This observation is in agreement with the data obtained from the 
reactivity ratio experiment. It can be due to the bulky nature of the APMD as there have 
been reports that when the structure is bulky, it can lead to decrease in reactivity ratio 
because bulky groups promote termination of the reaction hence inhibiting polymerisation 







        Free radical polymerisation of AA and APMD resulted in the formation of poly(AA-co-
APMD) ester copolymer with low to medium molecular weight (depending upon the 
monomer ratios).The reactivity ratio study revealed that the AA is much reactive than the 
APMD, probably due to the presence of bulky cyclohexane ring in the APMD. The 
properties of the copolymer were dependent upon the monomer ratios in the feed mixtures. 
Higher content of APMD in the monomer mixture results in the formation of a turbid 
solution in water. Thermal analysis revealed the thermal stability of the copolymer as 
compared to the free drug (PMD) whilst the DSC study revealed a decrease in the Tg by 
the addition of APMD into the mixture feed, most probably due to the decrease in the 
rigidity of the polymer chain. Drug loading was calculated by two methods; titration 
method and elemental analysis. Both were showing comparable results. These results were 
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Chapter 5. In vitro Hydrolysis and Skin Penetration 













Insect repellents are widely applied to prevent bites and associated rash that are caused by 
insect bites. They are also commonly used as a protective measure against insect-borne 
diseases. Current insect repellent formulations have various shortcomings, thus requiring 
strategies to improve their performance (Maia and Moore, 2011; Rodriguez et al., 2015).  
 
Polymers are widely used in pharmaceutical dosage form including covalently attaching the 
drug with the polymer backbone (D'Souza and Topp, 2004). Therapeutically, PDCs have been 
used for various purposes that include cancer (Greco and Vicent, 2008) and for other diseases. 
One (of various) reason for attaching the drug to a polymeric backbone is to enable long-lasting 
drug delivery (Zhu et al., 2014); for this purpose, they are conjugated via various degradable 
linkages (Dong et al., 2019; Lau et al., 2013). There are several mechanisms for the release of 
the drug from degradable linkages, including pH mediated drug release, enzymatic drug release 
and temperature-mediated drug release etc (de la Rica et al., 2012; Deng et al., 2009). Among 
enzymatic drug release, various enzyme sensitive linkages have been synthesised, one of which 
is the ester linkage that can be hydrolysed by the addition of esterases (Zhang et al., 2017). 
Human skin contains naturally occurring esterases, which can hydrolyse the ester compounds 
(Findlay, 1955). Pigs have multiple forms of carboxylesterases, with the highest levels being 
in the liver. These enzymes are readily available as porcine liver esterases (PLEs)  whereas 
human skin esterases have limited and expensive commercial availability and so PLEs are 
widely used in enzymatic drug release studies (Zhou et al., 2019). 
 
As discussed earlier in chapter 3, various studies raise specific concerns over the systemic 
absorption of insect repellents such as diethyltoluamide (DEET) and subsequent side effects, 
especially regarding their use in pregnant women and the neonates (Tavares et al., 2018).  
Therefore, it is important to minimise the systemic absorption of the repellent, for which we 
have employed the conjugation of the drug to the polymer backbone. To achieve this objective, 
a Franz diffusion cell approach was used to assess the penetration and permeation of the active 
ingredients (Wiechers, 2005) using pig ear skin which is a common skin model to study topical 
penetration and permeation of compounds (Abd et al., 2016). This chapter examines the 
hydrolysis of the copolymer poly(AA-co-APMD) with the addition of porcine liver esterases 
followed by studies into the penetration and permeation of the copolymer and PMD alone into 
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the pig ear skin. In order to monitor penetration and permeation, in vitro experimental 
conditions mimicked in vivo use as closely as possible 
 
5.2. Materials 
 p-menthane-3,8-diol (PMD) was purchased from BOC Sciences (USA), D-Squame tapes were 
obtained from Clinical & Derm, USA. Parafilm ® (Bemis Flexible Packaging (AMCOR), 
USA), porcine liver esterases (PLEs), acryloyl chloride and ammonium acetate were acquired 
from Sigma-Aldrich (Merck, UK), acetonitrile (ACN), ethanol and all other solvents used were 
of LCMS grade and were procured from Fischer Scientific, UK. 
5.3. Methods 
5.3.1. Method Development for the Analysis of PMD 
Certification of an analytic technique used throughout the drug development and drug 
production is required to prove that the procedures are appropriate for their proposed objective. 
Consequently, for the analysis of PMD, liquid chromatography-mass spectroscopy (LC-MS) 
was used. The sensitivity of the method was tested by determining the limit of detection (LOD) 
and limit of quantification (LOQ) for PMD. For accomplishing this objective, the following 
method was used: 
 
Device calibration is a critical stage in most measurement processes. It is a set of procedures 
that determine the correlation between the yield of the measurement system (e.g., the reaction 
of an apparatus) and the recognized values of the calibration requirements (e.g., the quantity of 
analyte present). The first step in the analysis of PMD was to construct a calibration curve. In 
order to prepare a sample for the calibration curve, a stock solution of 1000 µg/mL (1mg/mL) 
was prepared by dissolving 10 mg of PMD in 10 mL of acetonitrile.   This was then serially 
diluted to make 200, 100, 50, 25, 10, 5 and 1 µg/mL dilutions (by using the following): 
Concentration (start) x Volume (start) = Concentration (final) x Volume(final) 
(abbreviated as C1V1 = C2V2 ) 
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with solutions prepared in water: acetonitrile ratio of 4:6 v/v. The main reason for using water: 
acetonitrile (4:6 v/v) was to have equivalence with the final solution (with or without enzymes) 
after adding acetonitrile to quench the aqueous enzyme hydrolysis solution. 
 
5.3.2. In vitro Hydrolysis of the Copolymer by Using Porcine Liver Esterases (PLEs) 
For these experiments, 5mg/mL of copolymer containing 3:7 (AA:APMD) was dissolved in 
water: acetonitrile mixture (9:1 v/v) and the pH was adjusted to 7 by ammonium acetate buffer 
(10 mM of the buffer was prepared by dissolving 77 mg of ammonium acetate in 100 mL of 
LCMS grade water). Then, 35 mg of PLEs (1 unit of enzyme per µM of the copolymer) was 
added and the solution was stirred at 32±1°C (to mimic the skin temperature). Experimental 
samples (0.75 mL) were systematically withdrawn and quenched with equivolume of 
acetonitrile (0.75 mL). They were then subjected to centrifugation (Sanyo MSE Micro Centaur 
MSB010.CX2.5) at 13000 rpm for 12 minutes; the supernatant was collected and was analysed 
by LCMS. In this study, the control used was of the same copolymer but without PLEs. All 
experiments were performed in triplicate, and representative data are shown. The concentration 
for the unknown samples was calculated as: 
Concentration (µg/mL) of unknown= Peak area*Dilution factor. 
Dilution factor was calculated as Df= Vf/Vi where Df stands for dilution factor, Vf for final 
volume and Vi for initial (original) volume. 
 
5.3.3. In vitro Hydrolysis of Monomer Drug Conjugate (APMD) by Using PLEs 
Initially, 1.2 mg/mL of monomer drug conjugate (APMD) was dissolved in acetonitrile (ACN) 
followed by the dropwise addition of water with continuous stirring until a clear solution was 
obtained with a final proportion of water: acetonitrile of 9:1 (v/v). The pH of the solution was 
adjusted to 7 by adding ammonium acetate buffer (10 mM of the buffer was prepared by 
dissolving 77 mg of ammonium acetate in 100 mL of LCMS grade water). Then to this, 54.3 
mg of PLEs (1 unit of enzyme per micromole of APMD) were added, and the solution was 
stirred at 32 ± 1°C (corresponding to the skin temperature). Experimental samples (0.75 mL 
each) were regularly taken and quenched with an equivolume of ACN (0.75 mL) and were then 
subjected to centrifugation at 13000 rpm for 12 minutes, after which the supernatant was 
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collected and was subjected to analysis by LCMS. In this study, the control used was of APMD 
without PLEs. All experiments were completed in triplicate, and representative numbers are 
displayed. The concentration for the unknown samples was assessed by using the following 
calculation: 
Concentration (µg/mL) of unknown= Peak area*Dilution factor 
Dilution factor was calculated as Df= Vf/Vi where, Df stands for dilution factor, Vf for final 
volume and Vi for initial (original) volume. 
 
5.3.4. In vitro Hydrolysis by Adding Continuous Supply of PLEs 
In order to assess long term release of PMD from the copolymer, a continuous (replenished) 
supply of the enzyme was provided. Briefly, the same procedure as reported earlier (5.3.2) was 
followed but with a minor modification, i.e., after every 24 h, a fresh aliquot of the enzyme 
was added (at the above concentration). In this study, the control used was copolymer without 
PLEs. The experiment was performed in triplicate. The concentration of the liberated PMD 
was calculated as: 
Concentration (µg/mL) of unknown= Peak area*Dilution factor 
Dilution factor was calculated as: Df= Vf/Vi   where, Df stands for dilution factor, Vf for final 
volume and Vi for initial (original) volume. 
 
5.3.5. Evaluation of the PMD Release Profile 
Evaluation of the PMD release profile was done by using  
Zero-order kinetics F=K0 t where F is the fraction of drug release at time t and K0 is the zero-
order release constant. 
First-order kinetics Ln (1−F) = −K1t where K1 is the first order release constant. 
 Higuchi model F=−K2t1/2 where K2 is the Higuchi constant. 
Korsmeyer-Peppas Model MtM∞=K3tn where MtM∞ is the fraction of drug release at 
time t, K3 is the release rate constant, and n is the release exponent. The different release 
mechanisms were characterized using the calculated n value. When n < 0.5, the diffusion 
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mechanism is quasi-Fickian, n = 0.5 is Fickian diffusion, 0.45 < n < 1 refers to non-Fickian 
diffusion, n = 1 is case-II transport, and n > 1 refers to super case-II transport (Wong and 
Dodou, 2017). 
 
5.3.6. In vitro Skin Penetration and Permeation Study 
5.3.6.1. Preparation of Skin Membranes 
Although human skin is the most relevant membrane for percutaneous drug absorption, due to 
its limited availability for experimental use, a wide range of animal models has been 
investigated as a replacement. Porcine skin was found to be a good alternative for human skin 
in several in vitro studies (Lau et al., 2010; Rizi et al., 2011). Pig ears obtained from a local 
slaughterhouse (within 6 h of animal sacrifice) were kept at -20°C before membrane 
preparation (frozen skin was used within two months). The ears were defrosted before 
preparation and cleaned under cold running tap water. Hair was trimmed with a trimmer 
(Panasonic, Japan). Full-thickness skin containing dermis and epidermis was harvested from 
the underlying cartilage by using a scalpel (Swann-Morton, UK). 
5.3.6.2. Skin Permeation Study 
The permeation of PMD and the copolymer were compared to determine the amount of each 
that may potentially be taken up by the systemic circulation.  For this, firstly the integrity of 
the skin was checked by physical inspection of the skin. The skin was then mounted on six 
glass Franz-type diffusion cells, with nominal diffusion area of 3.14 cm2 and the receptor 
volume of 15 mL. Thickness of the skin was 70μm. Skin samples were positioned between the 
donor and receptor chambers of the cell, with the dermis in contact with the receptor medium. 
Finite doses (15mg/5 mL, 3mg/mL) of each PMD and the copolymer prepared in water: ethanol 
(8:2 v/v) were applied to the donor chamber. For the preparation of solutions, the volume of 
ethanol was kept at 20% (v/v) to prevent the increase in permeation by the ethanol itself as per 
Williams and Barry (2004). The Franz-cells were placed in an incubator set at 32±1°C. The 
permeation studies were performed under occlusion with Parafilm to ensure hydration and 
equilibration of the stratum corneum. Samples (1 mL) were taken periodically from the 
receptor compartment at 0.25, 0.5, 1, 1.5, 3, 6, 12, 24,48 and 72 h and were replaced with 
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equivolume of the water: ethanol (8:2 v/v) receptor medium. For each PMD and copolymer, 
six replicates were used. 
5.3.6.3. Skin Penetration Study 
At the end of the permeation study, i.e., 72 h, a skin penetration study was performed. For this, 
a tape stripping method was used to collect the test compound from the skin in such a way that 
twenty tape strips were used. The first two tape strips were assumed to account for the solution 
remaining on the skin surface of each donor chamber, tape strips 3-10 accounted for the upper 
stratum corneum, while from 11-20 accounted for the lower stratum corneum. The strips of 
adhesive tapes were cautiously attached to the marked skin location to prevent wrinkles, with 
continuous weight application. For the extraction process, the tape strips were immersed in 
ethanol and were subjected to sonication for 15 minutes at room temperature. Any remaining 
skin particulates were removed via filtration using 0.45μm filter (ThermoFischer, UK) and the 
extraction liquid was subjected to analysis by gel permeation chromatography (GPC). For 
GPC, we used THF as a solvent with an injection volume of 100 μL and a flow rate of 1mL/min. 
Here, PMD was used as control and was analysed through LCMS. 
5.3.6.4. Data Analysis for Skin Permeation and Penetration Study 
Permeation was evaluated by plotting the cumulative amount (!") of the PMD or copolymer 
permeated per unit surface area of the membrane against the collection time for each diffusion 
cell.  For this study, a steady state flux (#$$) was calculated by linear regression using Microsoft 
Excel software within the first two hours. 
5.3.6.5. Statistical analysis 
Statistical analysis was carried out using MS Excel 2016 Data Analysis Add-In programme. 







5.4. Results and Discussion 
5.4.1. Analysis of PMD 
5.4.1.1. Method Development for the Analysis of PMD 
One of the major concerns for this study was to develop an accurate and sensitive method to 
detect PMD. Commonly used methods for the detection of a drug are HPLC and UV. Here, 
these methods were not suitable as PMD does not have a chromophore to be detected and a 
synthetic approach to attach a chromophore risks loss of this volatile analyte. Thus, a mass 
spectroscopy related technique was sought. Previously gas chromatography-mass spectroscopy 
(GCMS) has been used as an analytical method to analyse PMD (Tian et al., 2005), but we 
were unable to accurately quantify low levels of PMD through this method. Thus, liquid 
chromatography-mass spectroscopy (LC-MS) was used to analyse and quantify PMD. The first 
step (to develop a method for the detection and quantification of PMD) was to optimise 
conditions/setting (selection of column as well as the other parameters such as the amount of 
acid to be used). Initially, we used a C-4 column with 1% formic acid, but this gave excessive 
tailing. Likewise, a cyano column (CN columns with cyanopropyl groups) with 1% formic acid 
also resulted in excessive tailing as well as poor peak separation. The chromatogram for this is 
shown in Figure 5.1.  
 
Subsequently, a phenyl column with 2% formic acid gave better peak separation (Figure 5.2) 
and no significant tailing was found in the peaks as compared to the preliminary attempts; the 
shape of the peak is important because if the baseline of the peak or overall shape of the peak 
is distorted, the calibration curve can be compromised since the software calculates the 
concentration by overall area of the peak. The best possible explanation for the success of 2% 
formic acid and phenyl column can be that the formic acid ‘’buffers’’ the eluent system well 
away from the pka of the analyte leaving the analyte in the ion suppressed form. Moreover, 
phenyl column has got affinity towards the OH groups thus leading to a good retention and 









Figure 5.1. Preliminary attempts for the method development to analyse PMD, showing 
chromatogram A (using C-4 column) & B (using cyano column). 
 
Figure 5.2. Chromatogram showing two separate peaks for PMD corresponding to 155 
and 137 Da using the phenyl column with 2% formic acid 
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The chromatogram obtained showed two peaks that accounted for PMD, one with molecular 
mass of 155 Da at the retention time of 3.11 mins and the other with molecular mass of 137 Da 
at 3.25 mins. The one with the molecular mass of 155 Da indicated removal of one OH group 
from the PMD and other with the molecular mass of 137 Da indicated removal of two OH 
groups from the PMD plus a negative charge due to the loss of an electron. Data can be analysed 
by considering either of these two peaks (depending upon the calibration curve). The selection 
of the peak (corresponding to a particular molecular mass) was done on the basis of best 
regression value obtained. In our case, the peak corresponding to 155 Da gave best results and 
hence was used for the analysis. Moreover, this phenomenon (removal of OH groups from the 
PMD)  can be possibly explained by the fact that in mass spectroscopy due to the electron 
impact ionisation conditions homolytic cleavage of the hetero atoms like oxygen, nitrogen and 
sulphur is very common and often leads to the loss of the largest possible radical, in this case 
a hydroxyl (OH) group (Conda-Sheridan et al., 2014). 
 
 
Figure 5.3. Calibration curve for different concentrations of PMD using the peak at 155 
Da, due to the loss of one -OH group. Data are represented as mean ± standard deviation 

























5.4.1.2. Limit of Detection (LOD) and Limit of Quantification (LOQ) for the Analysis of 
PMD 
LOD and LOQ provides a measure of sensitivity and precision of an analytical method. Several 
methodologies can be used to calculate the LOD and LOQ. One of such method is to estimate 
LOD and LOQ from the signal to noise ratio (S/N) of the lowest calibrator. This method was 
not selected owing to the variability in its reproducibility (as S/N ratio varies during different 
experiments). Values were thus determined by testing various concentrations and to 
experimentally see that what LOD and LOQ an instrument can detect, and how reproducible 
the data is (Conda-Sheridan et al., 2014). So, based on this experiment we found the limit of 
detection (LOD) for PMD at 1μg /mL, while limit of quantification (LOQ) for PMD was 5μg 
/mL. 
5.4.1.3. Inter-day and Intraday Precision 
Inter and intraday precision is an important parameter used to determine the accuracy and 
exactness of the method. In this case, inter and intraday assay accuracies were expressed as the 
percent difference between the measured concentration and the nominal concentration. The 
percentage accuracy of the method was expressed by the following formula: 
% Accuracy = (Measured concentration)/(Nominal concentration)x100  (Bhadra et al., 2011).  
 
The intra-day assay used replicate (n=3) determinations for each concentration of a sample 
during each analytical run while inter-day assay was carried out by using replicate (n=3) 
determination of each concentration made on three separate days. 
 
By using the above formula, it was found that percentage accuracy for the intraday results were 
91% (Table 5.1) while for the inter day results it was found to be 94.3% (Table 5.2). ICH 
guidelines require an analytical method to have a linearity (R2) of >0.999 (here was found to 
be 0.9986) with an accuracy of 100 +/- 2% and intra- and inter-day precision of ≤2% as residual 
standard deviation. Whilst the assay developed only partially met these criteria, given the 
challenging nature of the analyte and that this was used for a developmental rather than a 
commercial project, the method was suitable for use without further extensive refinements.    
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Table 5.1. Intraday Assay for the Determination of Accuracy (n=3) 
Nominal 
concentration 




1              2   3 
      
      Mean 
   (μg /mL)             SD 
5.0 2.9 2.8 3.5 3.06 0.37 
10.0 9.6 8.1 7.9 8.5 0.92 
25.0 25.0 25.0 25.0 25.0 0 
50.0 50.0 48.7 49.0 49.2 0.68 
100.0 100.0 98.0 99.0 99.0 1.0 
200.0 200.0 198.0 199.0 199.0 1.0 
 
 







   Mean 
(μg /mL)             SD 
              1          2                     3 
5.0 3.06 5.8 1.4 3.4 2.1 
10.0 8.53 11.6 8.6 9.5 1.7 
25.0 25.0 22.6 26.6 24.7 2.0 
50.0 49.23 47.4 55.3 50.6 4.1 
100.0 99.0 101.5 113.6 104.7 7.8 





5.4.2. In vitro Hydrolysis Study of the Copolymer 
Conjugation of the acryloyl chloride with PMD to form acryloyl-PMD (APMD) was through 
an ester bond in such a way that the APMD was subsequently copolymerised with acrylic acid 
(AA) to form the final copolymer. Hydrolysis of the ester bond was investigated by incubating 
with PLEs to confirm that the copolymer was indeed a substrate for the enzyme. Thus, the 
copolymer and PLEs were incubated at 32±1°C (to mimic the skin temperature) with the 
control copolymer incubated without PLEs (and to evaluate the stability of the ester bond). The 
results were plotted from the data obtained by using the following equation 
Concentration (μg/mL) of unknown= Peak area*Dilution factor 
Dilution factor was calculated as shown previously: 
Df= Vf /Vi 
Df= 1.5/0.75 = 2 
From the equation of the calibration curve (for 155 Da) shown below, we were able to calculate 
the unknown concentration. 
x= (y- 3E+06)/1E+06 
where x= Concentration and y=Area 
By putting the value of area (y) for unknown samples (collected at different time intervals) into 
the above equation and then multiplying the obtained results with the dilution factor, i.e. 2, the 
following results were obtained which were plotted as a cumulative concentration (μg /mL) vs 




Figure 5.4. Release profile of PMD from the co-polymer with or without PLEs. Data are 
represented as mean ± standard deviation (n = 3). 
In this experiment 5mg/mL of the polymer containing approximately 0.4 mg of PMD was used 
(calculated from titration study and elemental analysis). From the Figure 5.4 it can clearly be 
observed that as compared to control (without enzyme) there has been a significant hydrolytic 
release of the drug indicating that the copolymer is a substrate for PLEs. Moreover, it can also 
be seen that during the initial 6 h there is rapid release of the drug (showing that the enzymes 
are still binding to the substrates) followed by a slower sustained release (shown by the plateau 
in the graph) although this remains above that when no enzymes are present. The initial release 
phase liberated 85 μg /mL of the PMD, almost which was almost 50% of the total amount of 
drug released over 5 days (176 μg /mL).  Total release at the end of the experiment accounted 
for around 45% of the total drug load. There can be several explanations for this relatively low 
amount of drug release.  Drug release from the polymeric backbone is governed by multiple 
factors, i.e., molecular weight, hydration of a polymeric prodrug, steric hindrance and 
distribution of the drug along the polymeric chain (D’Souza and Topp, 2004). It has been 
reported by Tallury et al. (2008) that drug release rates decrease with increasing molecular 
weight, due to chain entanglements which increase with increasing molecular weight and 
impede the diffusion of drug molecules (or the enzymes) through polymer matrix leading to a 


































role in drug release in such a way that greater the extent of hydration then greater will be the 
drug release; as a general rule, the greater the hydrophilicity of a polymer then the greater will 
be the hydration and vice versa (Pitt and Shah, 1996). Another reason for this relatively low 
drug release can be steric hindrance; which basically indicates the ability of an 
enzyme/compound to access the centre of a target compound (Larsen, 1989; Seeman et al., 
1984). Moreover, distribution of the drug along the polymeric chain also plays an important 
role such that PDCs having pendant drugs distributed uniformly along the backbone release 
faster than those that have them in clustered blocks (Shah et al., 1990).   Interestingly, with the 
control experiment and no enzymes then there is also an initial burst release over the first 6 
hours with approximately 10 µg of the PMD released (approximately 2.5% of the loaded drug) 
followed by a slow but sustained minor release of a further 7 µg over the following 114 hours 
(approximately 0.015% release per hour over this period). Again, the burst release is 
approximately half that of the total release and could be attributed to rapid release of accessible 
“surface exposed” PMD after which the ester linked repellent is stable for extended periods.   
From the above, two different hypotheses were tested to assess the relatively low PMD release; 
(a) measuring release from a lower molecular weight (monomer-drug conjugate, i.e. APMD) 
to determine if steric constraints or chain entanglement was the prime reason and (b) by 
periodically adding more enzymes to the co-polymer after every 24 h to determine if the 
enzyme was inactive after a period of time  (Wang et al., 2002). 
 
5.4.3. In vitro Hydrolysis of Monomer-drug Conjugate (APMD) by Using PLEs 
To determine the effects of molecular weight in our system and the role of chain entanglement 
or steric constraints on drug release, the monomer drug conjugate (APMD) having a molecular 
weight of 224 Da was used (1.2 mg/mL) in a hydrolysis study. 
 150 
 
Figure 5.5. Release of the drug over 5 days from the monomer-drug conjugate (APMD) 
by using PLEs. Data are represented as mean ± standard deviation (n = 3). 
Figure 5.4 confirms that molecular weight plays an important role in the release of the PMD 
from the copolymer.  Over five days, almost 90% of the drug was released and it is clear that 
the initial burst phase extends to 24 hours by which time nearly 80% of the release has occurred. 
There are several reasons for molecular weight to affect drug release, the most likely of which 
is chain entanglements, which hamper the diffusion of drug molecules and enzymes through 
the polymer matrix leading to a decrease in drug release (Tallury et al., 2008).  The above 
results strongly suggest that restricted access of the enzyme to the ester bond in the copolymer 
resulted in the relatively low drug release seen in Figure 5.4.  
 
5.4.4. In vitro Hydrolysis of the Copolymer by Adding Additional PLEs 
One of the other possible reasons for the relatively low drug release from the copolymer could 
have been exhaustion of the enzymes decreasing drug release. In order to test this hypothesis, 
we choose to constantly add additional enzymes to the system to assess the impact on drug 
release. For this purpose, fresh enzymes were added after every 24 h over the five days period. 
From Figure 5.6, and in comparison, to the original study (Figure 5.4), it is clear that the release 
of PMD has not been significantly improved by the addition of further fresh enzyme. In the 
initial study, following 5 days treatment with PLE’s 178 µg of PMD was released whereas 





























enzymatic activity was not a factor in the modest release profiles. Consequently, the most 
probable reason for the observed release profile is that all conjugated PMD molecules are not 
readily accessible for the enzymes to hydrolyse as there are reports suggesting that the 
orientation of the polymer chain plays an important role in the accessibility of the enzymes to 
hydrolyse the bond and release the drug (Kawai et al., 2019). 
 
 
Figure 5.6. Release of the drug over 5 days time from the copolymer by adding PLEs. 
Data are represented as mean ± standard deviation (n = 3). 
 
5.4.5. Study of Kinetics and Mechanism of Drug Release 
In order to distinguish which type of mechanism is followed by the release of drug from the  
polymer matrix, the kinetics of drug release study can be assessed (Fu and Kao, 2010). To 
study the kinetics of the drug release, initial 2 h drug release data from the initial enzyme 
experiment (Figure 5.4) was used. The release constants were calculated from the slope of 
appropriate plots, and the correlation coefficient (R2) by linear regression analysis using 
Microsoft Excel 2016. The representative drug release kinetics plots were plotted for zero 





























correlation coefficient was selected as a criterion to evaluate the appropriate kinetic model and 
the corresponding release kinetic data for the synthesized copolymer. The value of R2 closest 
to 1 (0.98 for zero order, 0.83 for first order, 0.91 for Korsmeyer-Peppas model and 1.0 for 
Higuchi model) indicated the best fit of drug release data. Though the zero-order model gave 
a very high best fit correlation, it can be clearly seen from Figure 5.10 that the best linearity (r2 
= 1.0) was detected in Higuchi’s equation plot signifying the release of drug from polymer 
follows the square root of time.  
Different factors controlling the release of drug include the material matrix (composition, 
structure, swelling and degradation), release medium (pH, enzymes) and nature of the drug 
(solubility, stability and interaction with matrix) (Costa and Sousa Lobo, 2001). According to 
the Higuchi model, and inherent assumptions, it was concluded that the polymer upon contact 
with the water does not swell (indicating dissolution of the matrix is negligible) suggesting the 
release of drug from an insoluble matrix by a time-dependent diffusion process based on Fick’s 
law.  
The data of initial 60% drug release was incorporated to Korsmeyer-Peppas model to determine 
the mechanism of drug release from the Poly (AA-co- APMD) copolymer. In this model “n” 
is the release exponent, indicative of the mechanism of drug release. The values of “n” 
(calculated from the slope of the graph) for the polymer was found to be 0.655 indicating non-
Fickian or anomalous diffusion mechanism. 
 
 
Figure 5.7. Zero order release plot derived from a PLEs hydrolysis experiment with 































Figure 5.8. First order release plot derived from a PLEs hydrolysis experiment with 























































Square root of time (t1/2)
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Figure 5.9. Higuchi’s release plot derived from a PLEs hydrolysis experiment with 
copolymer as substrate (n=3) 
 
 
Figure 5.10. Korsmeyer-Peppas release plot derived from a PLEs hydrolysis experiment 
with copolymer as substrate (n=3) 
 
Table 5.3.  The r2 and k values for the copolymer by applying different drug release 
models (k was obtained through the slope of the individual graph). 
 
Drug Release Model r2 value k value (h
-1) 
Zero order 0.97 0.4426 
First order 0.82 0.0078 
Higuchi’s model 1.00 1.00 





























5.4.6. In vitro Skin Penetration and Permeation Study 
5.4.6.1.  Method Development 
Before performing any study, one of the prerequisites is to identify an analytical technique for 
the laboratory analysis of the compound of interest. Therefore, the main challenge here was to 
develop an appropriate technique for the analysis of the copolymer. As described above, due 
to the lack of a chromophore in our compound, we were unable to use methods such as HPLC 
and UV, hence the alternative was to use mass spectroscopy-based techniques. For this 
purpose, LC-MS was evaluated but unfortunately this did not give any definitive peaks. The 
most probable reason for this is the cut off molecular weight limit for this instrument was 5,000 
Da, whereas the copolymer is 6,000 Da. An alternative approach that is commonly used in the 
analysis of polymers is matrix assisted laser desorption/ionization-time of flight (MALDI-
TOF) (Schwarzinger et al., 2012).  Again, this was tested here, to analyse and quantify our 
copolymer but regrettably this also did not give any reliable result. The most probable reason 
for this might be the presence of bulkier groups (PMD) in our copolymer and it is known that 
polymers with bulkier groups are difficult to be analysed by MALDI-TOF (Montaudo et al., 
2006). Another method evaluated was a calorimetric method based upon the previous results 
(described in previous chapter) but this method wasn’t sufficiently sensitive to detect 
concentration changes at the micrograms level. 
 
5.4.6.1.1.  Use of Gel Permeation Chromatography (GPC) 
After the initial attempts to develop an analytical method for the detection and quantification 
of the polymer, gel permeation chromatography (GPC) was selected as there are reports for 
this method to not only to identify polymers but also to quantify them (Chen et al., 2003). 
Based upon this technique, a calibration curve (Figure 5.11) was prepared but unfortunately 













Figure 5.11. A) GPC traces for the analysis of the copolymers. B) Calibration curve for 





































Figure 5.12. Various methods opted for the detection of the copolymer 
5.4.6.1.2.  Design of Experiments for Skin Penetration and Permeation  
The design of this experiment sought to determine both the penetration and retention in the 
skin as well as permeation through the tissue for both the copolymer and PMD alone.   For this 




A)                                                                                      B) 
 
Figure 5.13.   Exemplar images representing the experimental set up of A) Permeation 
study; (B) Penetration study. 
5.4.6.1.3. Solubility and Stability in Receptor Phases  
Maintenance of sink conditions during the permeation study is crucial to maintain the maximal 
concentration gradient across the membrane throughout the experiment. The selection of an 
appropriate receptor solution was thus essential. As a rule, in order to maintain sink conditions 
throughout the experiment, the concentration of the penetrant in the receptor phase must not 
exceed 10% of its saturated solubility, and the receptor solution should not affect the membrane 
integrity (Williams and Barry, 2004).  
5.4.6.1.4. Solubility and Stability of PMD and Copolymer in Water-Ethanol Mixture  
Both copolymer and PMD were virtually insoluble in water. There are different means to 
improve the solubility of the test compounds, one of which is the addition of an organic solvent 
and so ethanol was added with a final ratio of 8:2 (v/v) for water:ethanol.  The volume of 
ethanol was kept at 20% (v/v) in order to prevent ethanol itself from increasing the permeation 
according to Williams and Barry (2004) . 
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5.4.6.1.5. Solubility in Extraction Solvent  
To extract compounds from skin samples and from tape strips, an extraction solvent is required 
to allow the test compounds to partition from the skin/strips into the solvent. For this purpose, 
the test compound should be stable within the solvent during the whole process (Weerheim and 
Ponec, 2001). Due to the stability and solubility of both the copolymer and PMD, ethanol was 
selected as the extraction solvent.  
5.4.6.2.  Permeation Study 
A permeation study was carried out to investigate whether the copolymer could permeate the 
skin or not, in comparison with PMD alone. Due to the limited availability of fresh skin, frozen 
porcine ear skin (frozen for less than 2 months) was used in this study.  
When applied alone to the skin, the permeation for PMD followed the typical profile for a finite 
dose application (Figure 5.13-a), with rapid initial permeation over the first 6 hours before the 
donor depletion. Over the first 6 hours, 246 μg /mL permeated accounting for 8% of the applied 
dose (3mg/mL) which is low; there might be two reasons for this low amount of the drug 
(PMD) permeating, first, can be the volatile nature of PMD (Lee et al., 2018) and the second 
reason can be the penetration of the drug into the skin (more than the permeation). Although 
PMD is volatile in nature and there is high probability of the evaporation of the drug but as we 
performed the experiments in an occluded environment (Franz cell), therefore, the probability 
of the analyte escaping out was low and hence this reason was ruled out. On the other hand, 
the possibility of the presence of the drug within the skin layers was confirmed from the results 
of the penetration study (Figure 5.15) indicating the presence of bulk of the PMD and thus 
indicating near steady state permeation throughout the stratum corneum after 72 h exposure. 
On the other hand, in case of the copolymer, the concentration of the copolymer in the reservoir 
medium was below the limit of detection (Fig 5.14-b) which was expected due to higher 
molecular weight which is expected to hinder or indeed prevent permeation.  
It was interesting to see that when the copolymer was dosed, PMD was also found to be below 
the LOD. Although we expected that there should be some PMD in the receptor phase (released 
as a result of the hydrolysis of the ester bond of the copolymer, though the concentration should 
be significantly less as compared to the same amount of PMD applied alone, i.e., without being 
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conjugated to the polymer), this could be the result of the use of frozen skin in which the freeze-
and-thaw process might have damaged the activity of the skin enzymes and other proteins, as 
explained by Kolarsick et al. (2006); others have shown frozen porcine ear skin to be 
metabolically active. However, there may not be enough enzymes to rapidly hydrolyse the 




Figure 5.14.   Permeation data for A) PMD and B) Exemplar retention peak showing 











































In short, the results show that PMD alone is able to permeate through porcine skin but that the 
amount of PMD (from the copolymer) and the copolymer itself permeating into the receptor 
phase was below the LOD. This could be advantageous as one of the aims of synthesising this 
system was to minimise side effects by minimising permeation through the skin and localising 
the copolymer to the outer skin layers. To investigate the distribution of the drug across the 
skin, a depth profile study was then carried out following the skin permeation study.  
5.4.6.3 Skin Penetration Study 
In this experiment, both PMD (as a control) and copolymer retention within the skin after the 
72 h permeation study was assessed by removing the skin from the Franz cell and placing in a 
Petri dish. In order to determine the penetration of the drug (PMD) and the copolymer within 
the skin, a tape stripping technique was used. There are several factors e.g. tape stripping force, 
skin hydration and position of the tape, which can influence the quantity of stratum corneum 
(SC) that is removed by each tape-strip leading to high variation in the results. Thus, the tape 
stripping study is a technique to estimate the distribution of compounds in different layers of 
the SC and can be used comparatively.  
From the results shown in Figure 5.15, it can be seen that in the case of the copolymer, tape 1-
2 represents the surface adsorbed materials containing the highest amount of copolymer.  3-10 
represents the outer stratum corneum of the skin with some copolymer detected.  Tape strips 
11-20 arise from the lower stratum corneum, and Figure 5.14 shows that no copolymer was 
detected in these lower layers.  These results reinforce the permeation data showing that no 
copolymer could pass through the intact skin.  Although quantitation is inexact due to assay 
difficulties, from figure 5.13, 93% of the total copolymer was detected in the surface adsorbed 
(strips 1-2) layer with only 7% in the outer stratum corneum (and likely towards the surface of 
the outer stratum corneum). 
During the copolymer study, PMD release was also expected; due to the activity of naturally 
occurring esterases it was assumed that there would be hydrolysis of the ester bond and some 
of the PMD may penetrate the skin.  However, analysis of the samples (extracted through the 
tape strips by ethanol, evaporated and then reconstituted by adding water: acetonitrile (4:6) (for 
the detection by LCMS) showed no evidence for the presence of PMD.  This may be the result 
of the use of frozen skin in which the freeze-and-thaw processes might have a damaging effect 
on the skin enzymes and other proteins. 
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The control use of PMD alone showed that PMD was distributed throughout the different skin 
layers.  Of the total PMD detected, 37% was in the superficial adsorbed sample (strips 1-2), 
33% in strips 3-10 and 30% in strips 11-20.  Near uniform distribution of PMD in the upper 
and lower stratum corneum implies that the PMD had, in fact, reached near steady state 
permeation throughout the stratum corneum after 72 h exposure. 
 
Figure 5.15.  Skin penetration data for PMD (control) and copolymer in frozen-thawed 
porcine skin. Data is expressed as mean ± SD (n=6). 
 
5.5. Conclusion 
The results from the porcine liver esterases (PLEs) incubation suggest that the ester bond in 
copolymer is susceptible to hydrolysis by PLEs, so this can be a model for cutaneous esterases, 
under the conditions employed in the present experiments. The amount of the parent compound 
(PMD) liberated from the control experiments was approximately 45% of the loading, and thus 
it can be concluded that the hydrolysis of the copolymer was predominantly enzymatic with 
minor hydrolysis in water of the exposed PMD groups. The amount of the drug released from 
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parameters, i.e., exhaustion of the enzymes and different molecular weights different 
experiments were performed, indicating that molecular weight does have an effect whilst 
adding of new/additional enzymes didn’t have any effect on amount of PMD released. 
Permeation of insect repellents into the systemic circulation is associated with side effects, 
thus, to assess the permeation and penetration profile of our copolymer and PMD alone 
(control), skin permeation and penetration experiments were undertaken. It was found that as 
compared to PMD, copolymer only penetrated the upper epidermal layer and did not permeate 
the skin (pig ear), indicating that this approach (polymer-drug conjugation) can be used to avoid 
permeation of the parent compound into the general circulation and hence the side effects 
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Chapter 6. Planarian Toxicity Fluorescent Assay: A 
Rapid and Cheap Pre-screening Tool for Potential 












This chapter has been published as: 
Syed Ibrahim Shah, Adrian C.Williams, Wing Man Lau, Vitaliy V.Khutoryanskiy.2020. 
Planarian toxicity fluorescent assay: A rapid and cheap pre-screening tool for potential 
skin irritants 
6.1. Introduction 
The design of formulations that contact human tissues requires toxicological testing and, in 
particular, topically applied formulations require skin irritation testing. Numerous methods 
have been used to evaluate the irritation potential of chemicals towards human tissues such as 
eyes, skin, nose or vagina. The classical Draize test used rabbits to assess the ocular and skin 
irritation of cosmetics and personal care products (Draize et al., 1944). Due to ethical as well 
as scientific concerns  (Callens et al., 2001; Sharpe, 1985), alternative tests have been sought. 
For skin irritation testing, in vitro methods are available including the commercially available 
Episkin, Epiderm and Zenskin cell culture models (Ahn et al., 2010; Graham et al., 2018) 
although such tissue equivalents do not entirely recapitulate the in vivo tissue – for example 
lacking blood or lymph circulation or providing an incomplete tissue physiology. Numerous 
guidance documents exist for skin irritation testing, for example from the European Centre for 
the Validation of Alternative Methods (ECVAM) or the Organisation for Economic 
cooperation (OECD).  Typically, the guidance specifies the skin equivalent to be used and its 
integrity testing, the numbers of replicates, duration of study etc., which requires specialist and 
relatively expensive laboratory services. Contrarily, planaria are readily available at a low cost 
and are easily cultured and maintained in a laboratory in artificial pond water (Gentile et al., 
2011a) and thus may offer a low cost in vivo alternative model to rapidly screen potential skin 
irritants prior to undertaking extensive regulatory studies. 
 
Alternative in vivo tests have been previously sought, typically employing lower order models. 
For example, Adriaens and Remon. (1999) reported a slug mucosa irritation test (SMIT) to 
characterise toxicological and irritation properties of various pharmaceutical materials and 
formulations for ocular, nasal and vaginal drug delivery, as well as some consumer products 
(Callens et al., 2001; Dhondt et al., 2005; Lenior et al. 2011, Lenior et al. 2013).  The SMIT 
has also been adapted by others; for example, Forbes et al. (2011) tested silicone elastomer gels 
for vaginal drug delivery and in a series of studies; we have previously used a SMIT to evaluate 
the irritation potential of ocular formulations (Khutoryanskaya et al., 2014; Al Khateb et al, 
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2016), mucoadhesive polymers for nasal drug delivery (Porfiryeva, 2019) and mucoadhesive 
nanoparticles for intravesical drug delivery (Kaldybekov et al., 2019). Other invertebrate in 
vivo models used in toxicological testing include Brachionus calyciflorus rotifers for screening 
the toxicity of various penetration enhancers on ciliated epithelium (Adriaens et al., 1997) and 
Caenorhabditis elegans nematodes (Hunt, 2017). As with our present study, these models were 
proposed as a pre-screening tool prior to a time-consuming and relatively costly regulatory 
study. 
 
Planaria are a freshwater-living flatworms commonly used as a model in developmental and 
regeneration research (Gentile et al., 2011b). As advanced invertebrates with a primitive brain 
having features similar to the vertebrate nervous system, planaria are used in  
neuropharmacology to predict the neurotoxicity of test substances (Hagstrom et al., 2016). 
They have a well-developed enzymatic system and so have been used to study 
organophosphorus pesticide toxicity (Hagstrom et al., 2018),  the cytotoxic, genotoxic and 
mutagenic effects of metals (Pra et al., 2005) and for environmental toxicological studies (Li, 
2008; Wu and Li, 2018). Importantly for the current work, planaria have a simple but well-
characterised epidermal membrane (made of ciliated cells) that acts as the first point of contact 
between the worm and a foreign substance (Azimzadeh and Basquin, 2016). 
 
The Globally Harmonised System (GHS) aims to consolidate global differences by classifying 
hazardous materials according to their health, environmental and physical hazards (Winder et 
al., 2005). For skin irritants, the GHS system draws on human experience, structure-activity 
models or the Primary Irritation Index (PII) caused by a chemical, derived from in vivo studies 
following OECD guidelines. The PII test applies 0.5mL or 0.5g of test substance to intact 
animal skin for up to 4 hours. For each animal, the dermal response scores (sum of the scores 
for erythema formation and oedema formation) at 24, 48, and 72 hours post exposure are 
recorded to generate a mean irritation score per time point (Bagley et al., 1996; Marzuki et al., 
2019). PII scores < 1.5 are considered as non-irritant, PII ≥ 1.5 < 2.3 corresponds to mild 




The purpose of this study was to develop a rapid and cheap pre-screening tool to reduce the 
use of complex cell culture, organ and animal models. Here, we have used Dugesia lugubris 
as a model to predict human skin irritation of test substances by measuring the uptake of a 
fluorescent marker (sodium fluorescein) into the flatworms following exposure to various 
irritants; our hypothesis is that increasingly toxic substances will disrupt the barrier function of 
the planarian epidermis hence leading to greater accumulation of sodium fluorescein inside the 
worm. 
6.2.  Materials and Methods 
6.2.1. Chemicals and Reagents 
Benzalkonium chloride (BKC), glycerol, parafluoro aniline (PFA), polyethylene glycol-400 
(PEG-400), carvacrol, isopropyl alcohol, decanol, tri-isobutyl phosphate, terpinyl acetate, 
sodium fluorescein and agarose were purchased from Sigma-Aldrich (UK). Benzyl alcohol, 
citronellal, linalyl acetate, 1-bromohexane and methyl palmitate were purchased from Fischer 
Scientific, UK. Instant ocean salt was from Aquarium Systems (UK).  
Table 6.1. Test articles with CAS number, GHS classification and in order of PII values 
Test article CAS number GHS classification PII* 
Polyethylene glycol-400 (PEG-
400) 
 25322-68-3 Not classified (Non-Irritant) 0.0 
Dipropylene glycol  25265-71-8 Not classified (Non-Irritant) 0.33 
Isopropyl alcohol  67-63-0 Not classified (Non-Irritant) 0.78 
Benzyl alcohol  100-51-6 Category 3 (Mild Irritant) 1.56 
Terpinyl acetate  80-26-2 Category 3 (Mild Irritant) 2.0 
Tri-isobutyl phosphate  126-71-6 Category 3 (Mild Irritant) 2.0 
Decanol  112-30-1 Category 2 (Moderate irritant) 3.33 
Parafluoro aniline (PFA)  371-40-4 Category 2 (Moderate irritant) 3.5 
Linalyl acetate  499-75-2 Category 2 (Moderate irritant) 3.67 
Citronellal  106-23-0 Category 1B (Strong irritant) 4.0 
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1-Bromohexane  111-25-1 Category H315 (Strong irritant) 4.0 
Carvacrol  115-95-7 Category 1B (Strong irritant) 4.2 
Methyl palmitate  112-39-0 Category H315 (Strong irritant) 4.56 
Benzalkonium chloride (BKC)  63449-41-2 Category 1B (Strong irritant)  6.54 
*PII < 1.5 = Non irritant, PII ≥ 1.5 < 2.3 = mild irritants, PII ≥ 2.3 < 4.0 = moderate irritants, PII ≥4 as strong irritants. 
 
6.2.2. Test Organisms 
Planaria (Dugesia lugubris) were purchased from Blades Biological Ltd (Kent, UK). The 
animals were maintained in artificial pond water (APW) (0.5 g of instant ocean salt in 1 L of 
Milli-Q water), prepared by the method of Cebrià and Newmark (2005) at room temperature. 
Animals were fed raw chicken (cut into small pieces), at a quantity sufficient to feed the 
planaria once a week. The pond water was changed every 48 hours. 
 
6.2.3. Mobility Assay 
Planarian mobility was assessed using the method previously described by Mei-Hui-Li (2012). 
Five concentrations of each test substance were prepared (0.1, 0.05, 0.025, 0.01 and 0.005 % 
w/v) by dissolving the test substance in APW. Where the irritants were not directly soluble, 
these compounds were first dissolved in dimethylsulphoxide (DMSO) before adding to APW 
followed by vigorous stirring until a clear solution was obtained. For these, the final volume of 
DMSO was maintained at 1% (v/v) to avoid irritation from the solvent itself (Pagán et al., 
2009). An individual planarian was placed into a glass Petri dish containing 15 mL of the test 
solution or into APW or APW with 1% (v/v) DMSO as a control. The petri dish was placed 
over 1 cm grid graph paper and a video recorder was used from above. After 5 minutes’ 
equilibration, planarian mobility was recorded as the number of times they crossed a grid line 
over the next 5 minutes. For each solution, mobility was assessed for 3 planaria and data are 




6.2.4. Acute Toxicity Assay 
The toxicity of the test substances to planarian was assessed by the method previously 
described by Mei-Hui-Li (2012) with some modifications. Five concentrations of each test 
substance were prepared (0.1, 0.05, 0.025, 0.01 and 0.005 % w/v). For each concentration, five 
animals were added to a Petri dish containing 25 mL of the test solution and each study was 
conducted in triplicate.  Acute toxicity was assessed over 96 hours with planaria inspected 
every 24 hours; those without detectable movement were assumed dead and removed from the 
test solution.  Again, APW or APW with 1% (v/v) DMSO was used as a control. 
 
6.2.5. Fluorescence Intensity (FI) Test 
The protocol was informed by the mobility and toxicity studies and so test substances at 0.1% 
(w/v) were employed with planaria exposure of 1 min followed by washing with APW for a 
further 1 min. The planaria were then placed in a 0.1% (w/v) solution of sodium fluorescein in 
APW for 1 min. Finally, the planaria were washed with APW (15 mL) for 1 min to remove 
excess sodium fluorescein adsorbed to the outer worm surface. The test animal was then 
immobilised by embedding it in 2% agarose solution following the protocol of Shen et al. 
(2018) with minor modifications. In brief, a planarian was transferred onto a microscopic slide 
(VWR, UK), after which few drops of agarose solution were carefully added to cover the whole 
animal. The slide was immediately placed on ice leading to gelling of the agarose solution, 
immobilising the test animal. Fluorescence images of individual planaria were collected with 
a Leica MZ10F stereomicroscope (Leica Microsystems, UK) with Leica DFC3000G digital 
camera, 1.6´ magnification with 160 ms exposure time (gain 2.6´), Gamma = 0.7 and 
wavelength=519 nm (excitation wavelength). The negative controls were planaria treated only 
with sodium fluorescein in APW for water-soluble test compounds and sodium fluorescein in 
1% DMSO solution (v/v) in APW for the poorly water-soluble test compounds. To quantify 
sodium fluorescein inside a planarian, the fluorescence of the whole animal was measured 
using ImageJ (version 1.8.0_112) software and the value obtained normalised by dividing by 





6.2.6. Statistical Analysis 
Statistical significance for the fluorescence intensity test was determined using one-way 
analysis of variance (ANOVA), followed by Bonferroni correction using Graphpad Prism 
software (version 7.0). To correlate the experimental fluorescence intensity values with 
literature data for skin irritants, a Pearson correlation test was performed.  
6.3. Results and Discussion 
6.3.1. Mobility Assay 
A planarian mobility assay has been previously used to assess neurotoxicity of several 
substances (Hagstrom et al., 2015) and hence we extrapolated the approach as a tool to assess 
skin irritants. For this purpose, a range of compounds was selected, spanning known non-, 
mild-, moderate- and strong-irritants along with control groups in APW alone (for water 
soluble compounds) or APW with 1% (v/v) DMSO (for poorly water-soluble compounds).  
 
Locomotion was plotted as a function of the concentration of irritant (Figure 6.1). Planaria 
movement was invariant with increasing concentrations of the non-irritant PEG-400.  
Conversely, exposure to the strong irritant carvacrol stopped planaria mobility entirely and at 
the lowest tested concentration (0.005% w/v).  The response to the mild irritant benzyl alcohol 
indicated some dose-response behaviour, but the locomotion inhibition was more pronounced 
and at lower concentrations for the other test materials. Indeed, the profiles for benzalkonium 
chloride (strong irritant) and linalyl acetate (moderate irritant) were indistinguishable over the 
selected concentration range, and the profiles for tri-isobutyl phosphate (mild) and parafluoro 
aniline (moderate) were contradictory. Given these confounding results, the mobility test 
appears unreliable for determining irritation from different classes of irritant and so was not 
developed further.  However, given the sensitivity of planarian mobility to these agents, this 




Figure 6.1. Effect of test compound concentrations on planaria locomotion. Cumulative 
movement = Number of times a planarian crossed the 1cm gridline during the 5-minute 
study. Data are represented as mean ± standard deviation (n = 3).  The dashed/dotted 
lines are for the guidance of the eye only. 
 
6.3.2. Acute Toxicity Assay 
Acute toxicity was assessed every 24 hours for up to 96 hours of exposure to non-irritants 
(dipropylene glycol and PEG-400), a mild irritant (tri-isobutyl phosphate), a moderate irritant 
(linalyl acetate) and a strong irritant (carvacrol). Again, APW alone was used as a control for 
test compounds soluble in water while APW with 1% (v/v) DMSO was used as a control for 
those poorly soluble in water and the data was normalised against these; for both controls, all 
planaria survived the test.  As with the mobility assay, the planaria showed no adverse effects 
on exposure to the non-irritants (dipropylene glycol and PEG-400) whereas exposure to the 
strong irritant carvacrol was lethal at the lowest dose (0.005% w/v). However, the data for the 
mild (tri-isobutyl phosphate) and moderate (linalyl acetate) irritants were confounding with 
planaria not surviving low dose exposure to the mild irritant but were more robust on exposure 
to higher concentrations of the moderate irritant. It was notable that the effects of exposure to 
the irritants did not change beyond the first 24-hour exposure period. 
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The above results illustrate a generic issue of seeking a lower order animal model to screen 
irritants for human use. Clearly the planarian membrane is extremely simple and fragile 
compared to, for example, human skin with its robust outer stratum corneum barrier. Whilst 
tri-isobutyl phosphate is a mild irritant on human skin, as an organophosphorus compound it is 
used in herbicides and fungicides and is listed by the European Chemicals Agency (ECHA) as 
“acutely harmful to aquatic organisms” (Eto, 1997; Hendriks et al., 1994). Indeed, an LC50 
(96h) of 18-22 mg/L is reported for fish and an EC50 (48h) of 24 mg/L for aquatic invertebrates 
(as are planaria), equivalent to 0.0024% w/v and in a similar range to the results shown here in 
Figure 6.2.  Linalyl acetate is a naturally occurring phytochemical and a principle component 
of lavender essential oil (Batool et al., 2020). Toxicity data towards marine invertebrates is 
limited as the compound is volatile (though our experiments were conducted under occlusion) 
and there is potential for hydrolysis of the ester to liberate some linalool. Notwithstanding these 
issues, an EC50 of 59 mg/L has been reported towards aquatic invertebrates (Daphnia) (Silver 
Registration Dossier ECHA @ www.echa.europa.eu) indicating that linalyl acetate would be 
expected to be less harmful to our test animal than tri-isobutyl phosphate, in accordance with 
the trend in Figure 6.2.      
  
Figure 6.2. Acute toxicity study showing the effects of selected irritants on planaria 
survival. Data are represented as mean ± standard deviation (n = 15).  
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As with the mobility assay, the planaria acute toxicity assay was unsuitable to predict human 
skin irritation of our test compounds, other than to potentially identify chemicals that are non-
irritant.   
 
6.3.3. Fluorescence Study 
The above results clearly demonstrate that both concentration and exposure time to irritants 
impact the viability of planaria (Hagstrom et al., 2015). Thus, a method was required that is 
simple, rapid and discriminating and hence short-term exposure (1 min) to low concentrations 
(0.1% w/v) of irritant followed by 1 min exposure to sodium fluorescein was selected.  It is 
known that sodium fluorescein can penetrate damaged tissue and has been used to assess the 
extent of injury to human vaginal and eye tissues (Ayehunie et al., 2011; Morrison et al., 2017). 
Here, we assume that irritation to planaria causes damage to its outer membrane and that such 
damage will allow sodium fluorescein to enter the animal, with concentrations related to 
severity of damage from the irritant. To normalise the results, total fluorescence is expressed 
as per cm2 of the planaria surface area.  The protocol used to evaluate penetration of fluorescein 





Figure 6.3. Illustrative diagram depicting the planaria fluorescence assay: (a) planarian 
in a solution of test substance (0.1 % w/v) for 1 min; (b) planarian washed in fresh APW 
for 1 min; (c) planarian in a solution of sodium fluorescein (0.1 % w/v) for 1 min; (d) 
planarian washed in fresh APW for 1 min to remove surface absorbed dye; (e) planarian 
placed on microscopy slide and covered with agarose sol; (f) slide placed on ice for 5-10 
mins to allow agarose to solidify; (g) fluorescence assessed microscopically. Scale bar is 









Fourteen test substances were evaluated, five strong irritants and three from each class of  
moderate-, mild- or non-irritants, alongside controls of 1 minute exposure to APW with or 
without DMSO, and an untreated planarium to determine autofluorescence. Autofluorescence 
was negligible and fluorescence uptake into the control planaria was minimal following short 
term exposure to the dye; uptake of 4 a.u./cm2 from APW with DMSO indicates no substantive 
damage to the outer membrane. Following exposure to the non-irritants, fluorescence was not 
signficantly different to that of the control animals, with greatest intensity seen for PEG-400 
exposure at 5.0 ± 2.3 a.u./cm2.  Data for the mild-irritants was also not signficiantly different 
Figure. 6.4. Exemplar fluorescent images of  auto fluorescence (a), negative control without and with 
DMSO in sodium fluorescein solution (b and c) and after planaria being exposed to PEG-400 (d), 
dipropylene glycol (e), isopropyl alcohol (f), terpinyl acetate (g), tri-isobutyl phosphate (h), benzyl 
alcohol (i), linalyl acetate (j), decanol (k), para-fluoroaniline (l), citronellal (m), carvacrol (showing 
disintegration of lower part of the planaria body) (n), benzalkonium chloride (also showing evidence 
for catastrophic membrane damage) (o), 1-bromohexane (p), and methyl palmitate (q). Scale bar is 





to that of the controls, with benzyl alcohol causing fluorescence of 4.6 ± 3.9 a.u./cm2 which 
rose to 10.0 ± 5.8 a.u./cm2 with tri-isobutyl phosphate. The increasing trend in fluorescence 
intensity continiued with the moderate irritants, ranging from decanol (9.5 ± 3.2 a.u./cm2) to 
linalyl acetate (20.0 ± 3.0 a.u./cm2).  It is notable that in our acute toxicity assay (Figure 6.2), 
linalyl acetate appeared less harmful to the planaira than expected from its GHS classification 
or PII value (Table 1) but in the fluorescence assay is shown to be a moderate irritant close to 
the borderline with the strong irritant classification. As a strong irritant, citronellal (18.0 ± 6.2 
a.u./cm2) gave similar fluorescence to linalyl acetate, whilst methyl palmitate and bromohexane 
showed similar F.I’s, (24.8 ± 4.1 a.u./cm2 and 22.6 ± 6 a.u./cm2 respectively). Both  
benzalkonium chloride (53.0 ± 11.2 a.u./cm2) and carvacrol (48.0 ± 12.5 a.u./cm2) caused 
catastrophic damage to the membrane resulting in significantly higher fluorescence intensities 
than all other tests. The result show that all the strong irritants gave significantly greater 
fluorescence intensities (P at least <0.05) than the non irritants and controls.    
 
Figure 6.5. Fluorescence intensity (per cm2) of individual planaria exposed to different 
test substances. Data are expressed as mean ± standard deviation (n = 3). Statistically 
significant differences are given as: **** represents p<0.0001, *** p=0.0005, while ** and 




6.3.3 Correlation Between Human Primary Irritation Index (PII) and Planaria 
Fluorescence Intensity (FI)  
Despite the dissimilar membrane structures, we sought to correlate the membrane damage 
caused to planaria by the irritants with literature data that has been used in predictions of human 
skin irritation. The Primary Irritation Index (PII) is from a patch test on albino rabbit skin and 
is a composite score of the number and severity of erythema / oedema to a test substance 
(Chakrabarti et al., 2018). The literature data available for PII was correlated with our 
fluorescence results, as shown in Figure 6.6. Test substances whose PII values were available 
in the literature (n=12) were plotted against our experimental fluorescence intensities (per cm2); 
due to catastrophic membrane damage (Figure 6.4), fluorescence values following treatment 
with BKC and carvacrol do not represent uptake of dye through a membrane and so were 
excluded.  Clearly our fluorescence intensities within the planaria increase with increasing 
values of the primary irritation index. The Pearson’s correlation (r) value (0.87) shows a 
statistically significant (p<0.005) positive correlation. This correlation suggests that this assay 
can serve as a rapid pre-screening tool to identify the likely category or irritation potential of 
compounds towards human skin. Though further study is merited using a broader library of 
compounds, the speed and simplicity of the assay provides an attractive alternative to tests 
using higher order vertebrates.   
 
Figure 6.6. Correlation between the Primary Irritation Index of compounds (PII) and the 




Our studies demonstrate planaria mobility or acute toxicity testing poorly discriminate between 
categories of skin irritants but may demonstrate materials that are either non-irritating or act as 
very strong skin irritants.  The planarian fluorescence assay is more discriminating with a direct 
correlation between fluorescence uptake into worms following short term exposure to irritants 
and literature reported irritation defined by their primary irritation index values. The 
fluorescence assay offers a rapid in vivo screening tool employing a model that is readily 
available and easy to maintain and which could act as a pre-screening method to inform 
subsequent sophisticated and costly assessments of skin irritants. Potentially this assay could 
be further extended to test irritation properties of various chemicals towards ocular, nasal and 
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Chapter 7. Toxicity Evaluation of the poly(AA-co-













Any formulation that is used topically requires testing for its irritation potential (Madan and 
Levitt, 2014). For this purpose, numerous methods had been used for irritation screening, 
ranging from in vivo methods such as the Draize test to in vitro methods using cell cultures 
such as Episkin or Epiderm. There have also been various attempts by researchers to develop 
lower animal models to replace the higher order in vivo models (Parasuraman, 2011). The 
planaria fluorescence assay (described in chapter 6) is one such model to predict the skin 
irritation potential of a compound  
p-menthane 3,8 diol (PMD) is a terpenoid and a naturally occurring insect repellent that is 
applied topically to repel insects (Drapeau et al., 2011). Polyacrylic acid (PAA) is an ionic 
polymer and is commonly employed in skin formulations, especially in hydrogels (Devine et 
al., 2006). Similarly, acrylic acid copolymers are widely used for drug delivery purpose (Ma et 
al., 2008). When testing the irritation potential of a compound towards the skin, acute toxicity 
testing is usually performed and essentially determines the effect of a single dose of a 
compound on a specific animal species. Studies have reported that PMD is safe to be applied 
on the skin at lower doses while at higher doses it did cause skin irritation whilst low molecular 
weight polyacrylic acid is described as a skin irritant (EPA safety document for PMD; 
polyacrylic safety www.polysciences.com). 
Planaria are a freshwater-living worms commonly used as a model in developmental and 
regeneration research (Gentile et al., 2011a). Planaria, are advanced invertebrates with some 
similarities in nervous system to the vertebrates. They are frequently used in 
neuropharmacology to predict the neurotoxicity of test substances (Hagstrom et al., 2016). 
Based upon their well-developed enzymatic system, they are also used to study 
organophosphorus pesticide toxicity (Hagstrom et al., 2018). They have also been used to study 
the cytotoxic, genotoxic and mutagenic effects of metals (Pra et al., 2005) as well as 
environmental toxicological studies (Li, 2008; Wu and Li, 2018). Moreover, planaria have a 
simple but well-characterised epidermal membrane (made of ciliated cells) that act as the first 
point of contact between the worm and a foreign substance (Azimzadeh and Basquin, 2016). 
In this work, we investigated the irritation potential of the copolymer poly (AA-co-APMD) 
compared with PAA and PMD alone, by using the planaria fluorescence assay. 
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7.2 Materials  
PMD was purchased from BOC sciences, USA. Benzalkonium chloride (BKC), sodium 
fluorescein and agarose were purchased from the Sigma-Aldrich, UK. PAA (Mw=5000 Da) 
was purchased from Polysciences, Germany and sodium hydroxide was from Fischer 
Scientific, UK. Instant ocean salt was from Aquarium Systems (UK).  
7.3 Test Organisms 
Planaria (Dugesia lugubris) were purchased from Blades Biological Ltd (Kent, UK). The 
animals were maintained in artificial pond water (APW) (0.5 g of instant ocean salt in 1L of 
Milli-Q water), prepared by the method of Cebrià and Newmark (2005) at room temperature. 
Animals were fed raw chicken (cut into small pieces), quantity sufficient for feeding planaria 
once a week. The pond water was changed every 48 h.  
7.4 Methods 
The protocol used was as described in chapter 6. Briefly a planarian was exposed to 0.1% (w/v) 
of the test substance for 1 min, followed by a washing with APW for a further 1 min. The 
planaria were then placed in a 0.1% (w/v) solution of sodium fluorescein in APW for 1 min. 
Finally, the planaria were washed with APW (15 mL) for 1 min to remove excess sodium 
fluorescein adsorbed to the outer worm surface. The test animal was then immobilised by 
embedding it in 2% agarose solution following the protocol of Shen et al. (2018) with minor 
modifications. In brief, a planarian was transferred onto a microscopic slide (VWR, UK), after 
which few drops of agarose solution were carefully added to cover the whole animal. The slide 
was immediately placed on ice leading to gelling of the agarose solution and immobilisation 
of the test animal. Fluorescence images of individual planaria were collected with a Leica 
MZ10F stereomicroscope (Leica Microsystems, UK) with Leica DFC3000G digital camera, 
1.6´ magnification with 160 ms exposure time (gain 2.6´), Gamma = 0.7 and wavelength=519 
nm (excitation wavelength). The negative controls were planaria treated only with sodium 
fluorescein in APW for water- soluble test compounds and sodium fluorescein in 1% DMSO 
solution (v/v) in APW for the poorly water-soluble test compounds. To quantify sodium 
fluorescein inside a planarian, the fluorescence of the whole animal was measured using 
ImageJ (version 1.8.0_112) software and the value obtained normalised by dividing by the area 
(cm2) of the individual planarian. All experiments were conducted in triplicate.  
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7.5 pH Study 
In this study the pH of the medium (APW) was either increased or decreased by adding either 
0.1 M HCl or NaOH. Briefly, APW was prepared by mixing 0.5g of instant ocean salt in 1L of 
Milli-Q water. The pH of the solution was measured by pH-meter (Thermo-Fischer, UK). To 
this 0.1M HCl or NaOH solution was added, and at each point, the pH of the solution was 
measured. 
7.6 Statistical Analysis 
Statistical significance for the fluorescence intensity test was determined using one-way 
analysis of variance (ANOVA), followed by Tukey’s test using Graphpad Prism software 
(version 7.0).  
7.7 Results and Discussions 
7.7.1 Fluorescence Study 
In this study, three test compounds were used namely PAA, PMD and the synthesised 
copolymer poly (AA-co-APMD). Benzalkonium chloride (BKC) was used as positive irritant 
control while APW with and without DMSO (1% v/v) was used as the negative control for 
water-insoluble and water-soluble compounds, respectively. The aim of this study was to 
evaluate the irritation potential of PMD alone, PAA alone and the irritation potential of the 
synthesised copolymer. 
As with the study described in chapter 6, the fluorescence intensity of planaria exposed to 
artificial pond water before immersion in the fluorescent dye was minimal and 
indistinguishable from background fluorescence showing that the planarian membranes were 
intact. In either negative control (APW with or without DMSO) the FI values of 2.6 and 2.5 
a.u. respectively were not significantly different showing that the addition of DMSO did not 
affect the worms membrane, which indeed is in accordance with chapter 6. With the positive 
control, BKC, FI was 52.6, again in good agreement with the earlier study and, together with 
the negative control data, shows that the assay is reproducible.     
A study conducted by US-EPA (the United States Environmental Protection Agency) for the 
registration of PMD as an insect repellent shows that PMD is quite safe to be used on the skin, 
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as it caused only slight erythema on rabbit skin when a concentrated solution was applied (EPA 
safety document for PMD); based upon this study it was expected that the fluorescence 
intensity (FI) of the planaria following exposure to PMD would be comparable to that of other 
non-irritants. The results indeed showed that the FI of planaria exposed to 0.1% (w/v) PMD 
was similar to that following exposure to PEG-400 (5 a.u.). However, as shown in the planarian 
assay development work, irritation is often related to concentration and the mild erythema 
caused in the rabbit assay is likely attributed to a greater concentration of PMD being applied. 
Similarly, according to the literature, low molecular weight PAA is a skin irritant while high 
molecular weight cross-linked PAA, such as Carbopol, has an excellent safety profile 
(polyacrylic safety www.polysciences.com). PAA (low molecular weight, i.e. 5000 Da), was 
found to be an irritant for the planaria, with FI of 14.6 comparable to para fluoro aniline (12.6 
a.u.), a moderate irritant. In the copolymer, i.e. poly(AA-co-APMD), the FI value fell to 7.5, 
indicating a   good safety profile and comparable to mild irritants in chapter 6 such as terpinyl 
acetate (8.1 a.u.). 
 
Figure 7.1. Exemplar fluorescent images of APW with fluorescein in DMSO (e), and after 
planaria being exposed to PAA (a), PMD (b), copolymer (c) and BKC (d). 
 194 
 
Figure 7.2. Fluorescence intensity (per cm2) of individual planaria exposed to different 
test substances. Data are expressed as mean ± standard deviation (n = 3).  
 
7.7.2 pH Study 
To explore further the cause of irritation by PAA in planaria, the influence of pH on the worms’ 
membrane was investigated. A series of solutions of artificial pond water were adjusted to pH: 
2.8, 3.2, 3.6, 4.2, 4.9, 5.5, 6.3, 7.3, 8.2, 9.1 and 10.2. The planaria were exposed to the differing 
solutions for 1 min and then washed and exposed to the fluorescence for a further 1 min as 
above.  The results showed that below pH 4.2 and above 8.2 there was a significant 
accumulation of sodium fluorescein within the planaria (hence indicating the toxicity). PAA 
has free carboxylic acid groups, and the presence of these cause a decrease in pH such that the 
pH of the PAA solution is 4.1. at which value there is significant damage seen to the planarian 
membrane.  This result is in good agreement with the literature where extreme pH changes 




























Figure 7.3. Fluorescence intensity (per cm2) of individual planaria exposed to different 




This study has shown that, in our planarian assay, PMD is a non-irritant whereas the polymer 
PAA is a moderate irritant, in agreement with the existing literature.  When prepared as a co-
polymer, the poly (AA-co-APMD) is a mild irritant.  This finding was expected and can be 
partially attributed to the pH changes seen when the worms are incubated with the free polymer 
which causes the solution pH to drop to a level where the worm membrane becomes damaged.  
On co-polymerisation, the free carboxylic acid content falls and hence the pH of the solution 
rises to nearer neutrality where membrane damage is minimal.  Though for sure, this (pH) may 
not be the only reason for the decrease in the irritation potential of the copolymer and there 
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8.1 General Conclusion 
Insect borne diseases are a significant cause of mortality around the world (Zeller et al., 2013). 
Infections like malaria, dengue fever and leishmaniasis are transmitted to humans by the bite 
of an insect. In order to prevent this, insect repellents are frequently used (Fradin and Day, 
2002). Various types of insect repellents are used for this purpose ranging from synthetic to 
natural insect repellents. Commonly used are DEET (N, N-diethyl-m-toluamide), p-menthane-
3,8-diol (PMD), picaridin, nepetalactone, neem oil and permethrin (Chen-Hussey et al., 2014). 
PMD is a naturally occurring insect repellent but can also be synthesised in the laboratory 
(Carroll and Loye, 2006; Yuasa et al., 2000). However, use of PMD has some drawbacks 
including rapid evaporation and potential absorption of the repellent into the systemic 
circulation raising concerns over its use in pregnant women and infants. Thus, there is a need 
for a strategy to overcome these problems. 
  
This PhD project focused on the development of a polymer-drug conjugate. The rationale for 
the synthesis of the conjugate was primarily to develop a system for prolonged drug release as 
compared to the conventional use of free PMD by exploiting the naturally occurring esterases 
enzymes on the skin, and secondly to minimise drug uptake into and absorption through the 
skin and hence reduce systemic PMD uptake as the molecular weight of the polymer would 
prevent (or certainly minimise) absorption. The first chapter provided an overview of skin as a 
potential site for drug delivery, described polymer-drug conjugates   and their advantages 
followed by a comprehensive discussion on the use of polymer-drug conjugates for drug 
delivery to diseased skin, e.g. eczema, wound healing, skin infections and cutaneous 
leishmaniasis. Most of these studies were promising in terms of efficacy and safety along with 
other parameters like the stability of the formulation and the drug loading. In some studies, 
issues that prevented the clinical translation of the conjugates were identified, which include 
difficulties with scaling up their synthesis followed by the disparity in the in vitro and in vivo 
results. 
 
The second chapter provided an overview of the general methods and materials that were used 
during this project. The third chapter described preliminary attempts to synthesise a polymer-
drug conjugate using high and low molecular weight hyaluronic and polyacrylic acid (PAA). 
Hyaluronic acid was chosen because of its excellent safety profile, the moisturising effect that 
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it has and the presence of suitable functional groups for the conjugation. Similarly, PAA was 
selected because of its good safety profile and the presence of suitable functional groups.  
Several methods followed by modifications in these methods were attempted to conjugate the 
polymers with PMD but failed to yield the desired results. Despite changing the polymer, 
polymer molecular weight, solvents and the drug itself, the desired polymer-drug conjugate 
could not be synthesised. The most probable reason for the unsuccessful reaction was steric 
hindrance of PMD and access to the reactive sites in the polymer themselves (as polymers are 
large molecules). This led to a change of approach, i.e. to develop a monomer drug conjugate 
and then subsequent polymerisation to form a polymer with the incorporated drug (PMD). 
 
The fourth chapter focused on the synthesis and characterisation of the polymer-drug conjugate 
using free radical polymerisation of AA and APMD which resulted in the formation of 
poly(AA-co-APMD) ester copolymer with low to medium molecular weight (depending upon 
the monomer ratios). The synthesis was then followed by characterisation to determine the 
properties of the copolymer, e.g. glass transition temperature (Tg), reactivity ratio of the 
monomers, molecular weight and drug loading on the copolymers. The reactivity ratio study 
revealed that the AA is much reactive than the APMD, probably due to the presence of bulky 
cyclohexane ring in the APMD. The properties of the copolymer were dependent upon the 
monomer ratios in the feed mixtures and consequently the content of APMD in the polymer. 
Higher content of APMD results in the formation of a turbid solution in water. Thermal analysis 
revealed greater thermal stability of the PMD in the copolymer as compared to the free drug 
(PMD) whilst the DSC study revealed a decrease in the Tg by the addition of APMD into 
polyacrylic acid, most probably due to the decrease in the rigidity of the polymer chain. Drug 
loading was calculated by two methods; a titration method and elemental analysis both gave 
comparable results which were in agreement with the reactivity ratio studies. 
 
The fifth chapter tested the hypothesis that esterases will hydrolyse the ester bond in the 
copolymer and thus will release the PMD over an extended period, and that the molecular 
weight of the copolymer will decrease the penetration and permeation of the PMD through the 
skin. For this purpose, porcine liver esterases (PLEs) were used to hydrolyse the ester bond in 
the copolymer. The results showed that the ester bond in the copolymer is susceptible to 
hydrolysis by PLEs. The amount of the parent compound (PMD) liberated from the control 
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experiments was approximately 45% of the loading. Thus, it was concluded that the hydrolysis 
of the copolymer was mostly if not purely enzymatic and no chemical hydrolysis and 
decomposition was involved, also evidence by the lack of PMD release in the absence of the 
enzyme. The amount of the drug released from the copolymer was below expectations the basis 
for which was investigated to test whether exhaustion of the enzymes or steric effects affected 
PMD release; molecular weight was shown to influence release whereas adding of 
new/additional enzymes did not have any effect on the amount of PMD released indicating that 
the enzymes had not been saturated. To assess the permeation and penetration profile of our 
copolymer and PMD alone (control), skin permeation and penetration experiments were 
undertaken by using Franz diffusion cell. The biggest challenge in this study was to develop a 
method to quantify the copolymer. For this purpose, the gel permeation chromatography (GPC) 
was used. It was found that, compared to PMD, copolymer only penetrated the upper epidermal 
layer and did not permeate the skin (pig ear), indicating that polymer-drug conjugation can be 
used to avoid or minimise permeation of the parent compound into the systemic circulation. 
Hence, potential side effects associated with PMD application can be avoided. 
 
The design of formulations that contact human tissues requires toxicological testing and, in 
particular, topically applied formulations require skin irritation testing. The classical test used 
to assess skin irritation of the compounds is the Draize test (Draize et al., 1944). Over time, 
due to ethical as well as scientific reasons, alternative methods have been sought using lower 
animal models (Callens et al., 2001). Chapter six reports a novel method to quickly screen out 
potential strong irritants by using planaria as a model, based upon the hypothesis that the 
greater the irritation potential of a compound then the greater will be the fluoresence 
accumulation inside the flatworm following short term exposure to irritants. Using reported 
irritation defined by their primary irritation index values, twelve test substances were 
evaluated, three each from strong-, moderate-, mild- or non-irritants, alongside controls of 1 
minute exposure to Artifical Pond Water with or without DMSO, and an untreated planarium 
to determine autofluorescnece. Autofluorescence was negligible and fluorescence uptake into 
the control planaria was minimal following short term exposure to the dye; uptake of 4 a.u./cm2 
from APW with DMSO indicates no substantive damage to the outer membrane. Following 
exposure to the non-irritants, fluorescence was not signficantly different to that of the control 
animals, with greatest intensity seen for PEG-400 exposure at 5 ± 2.3 a.u./cm2.  Data for the 
mild-irritants was also not signficiantly different to that of the controls, with benzyl alcohol 
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causing fluorescence of 4.6 ± 3.9 a.u./cm2 which rose to 10 ± 5.8 a.u./cm2 with tri-isobutyl 
phosphate.  The increasing trend in fluorescence intensity continued with the moderate irritants,  
ranging from decanol (9.5 ± 3.2a.u./cm2) to linalyl acetate (20 ± 3 a.u./cm2).  As a strong 
irritant, citronellal (18 ± 6.2 a.u./cm2) gave similar fluorescence to linalyl acetate but both  
benzalkonium chloride (53 ± 11.2 a.u./cm2) and carvacrol (48 ± 12.5 a.u./cm2) caused 
catastrophic damage to the membrane resulting in significantly higher fluorescence intensities 
than all other tests. It was concluded that the fluorescence assay offers a rapid in vivo screening 
tool employing a model that is readily available and easy to maintain and which could act as a 
pre-screening method to inform subsequent sophisticated and costly assessments of skin 
irritants. Potentially this assay could be further extended to test irritation potential of various 
chemicals towards ocular, nasal and vaginal mucosa.  
 
The last chapter of this thesis reported the evaluation of the toxicity of the copolymer poly(AA-
co-APMD), polyacrylic acid and PMD by using the planaria fluorescence assay. The study 
showed that the conjugation of the PMD into the copolymer significantly reduces the irritation 
of the PAA (alone). Moreover, this is as expected from the skin permeation data and most of 
the copolymer resided at the top layer of the skin, and thus we expect it to exhibit low irritation 
potential in vivo. In order to know the possible mechanism/cause of the irritation of the 
compounds towards planaria, the effect of pH and logP was studied, revealing that extremes of 
pH disrupted the planarian membrane while the logP values (available from the data) of 
different compounds does not have a significant relationship with its increasing or decreasing 
values.  
 
Overall, the aims of the project have been achieved through successful synthesis and 
characterisation of the copolymer despite the initial challenges faced. Moreover, it was proven 
that the PMD can be released from the copolymers by the eastreases and upon the application 
of the conjugated polymeric system significantly reduced the permeation of PMD through 
human skin. We were also able to develop a new model to predict the irritation potential of 
strong irritants towards the skin and based upon that model we successfully evaluated the 
irritation potential of our copolymer. 
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8.2. Future Work 
This section is broadly divided into two sub sections. First discusses the future work related to 
this particular study while the second considers broader future uses of polymer-drug conjugates 
as a drug delivery platform for skin diseases. 
8.2.1 Future Work Concerning this Project 
The study could not cover all the aspects that should be considered when translating a 
formulation further towards its regulatory approval and clinical application. 
  
      8.2.1.1. Optimising the Conjugate 
        Despite multiple attempts and modifications to the method or molecular weight or even 
to the drug carrier, it was not possible to produce an HA-PMD conjugate. However, this 
carrier (HA) has been successfully conjugated in literature reports (Chen et al., 2014; 
Huang and Huang,2018). HA is attractive as it is safe, widely used and is known to be a 
moisturising agent in cosmetic preparation. Studies also show it can penetrate the outer 
layers of the stratum corneum (but not through the tissue) (Essendoubi et al., 2016) and 
hence it may help to retain the conjugate on the skin surface for extended periods. It would 
be of value to further explore the reasons for the non-reactivity and seek alternative 
approaches for an HA-PMD system. 
 
       8.2.1.2. Drug Loading 
       Whilst drug loading is satisfactory in the pilot work, it remains at ~10% of the copolymer. 
having it higher for extended drug release may be beneficial. This could be either by 
changing the monomer, i.e. choosing methacrylic acid instead of acrylic acid or may be 
methacrylic anhydride etc 
 
       8.2.1.3. Synergistic Effect 
       Another area that could be possibly explored is the potential combination of repellents like 
DEET or blend with DEET or may be vanillin for multiple actions of repellency, for 
example it might help us to cover a broader range of coverage (protection from insect 
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bites) as compared to the PMD alone, as there are reports that inclusion of 5% vanillin 
increases the protection time up to 4.5 hours when used in conjunction with citronella oil 
(Songkro et al., 2012). 
 
        8.2.1.4. Formulation 
        Formulation of the conjugate is an essential step for the ultimate usage (in humans). Whilst 
the formulation involves challenges, the biggest of which is to prevent the hydrolysis of 
the ester bond during its long-term storage in the presence of excipients. Thus, requiring 
strict testing before being formulated. The formulation can be in the form of a topical 
spray or maybe a hydrogel. 
 
       8.2.1.5. In vivo Testing 
        Similarly, another study that could have been done is the in vivo study. However, this 
study was planned out (6g of copolymer batch was prepared) but could not have been 
done due to unforeseen circumstances. For this purpose, we suggest arm-in-cage study 
which is a standard method to evaluate the efficacy of any insect repellent formulation, 
involving the use of either human volunteers or the animals (rabbits), where a formulation 
is applied (typically on arms in humans) followed by the calculation of the number of 
mosquito bites usually up to 24 hours. In the end, the obtained data is compared with the 
control (Logan et al., 2010). 
 
8.2.2 Future Potential of Polymer-Drug Conjugates for Skin Drug Delivery 
Over the last two decades, the application of PDCs to diseases other than cancer has increased, 
including for topical delivery though this remains a relatively under researched area. As 
macromolecular constructs, passive diffusion through the intact stratum corneum barrier is not 
feasible and hence the focus is on targeting to the follicles or use in conditions where the skin 
barrier is damaged such as psoriasis or wound healing. Thus, opportunities exist for similar 
barrier dysfunctioning conditions such as atopic dermatitis, scabies or cutaneous leishmaniasis 
(Smith, 2007). 
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One opportunity is in treating cutaneous leishmaniasis (CL). There are two major problems 
associated with the use of current drug regimen for the treatment of CL; (1) they are 
administered in the form of cutaneous injections which are painful and (2) they have elevated 
toxicity and carry substantial side effects restricting their use (Croft et al., 2006). The features 
important for consideration to develop a PDC for CL are that as the outer protective barrier of 
the skin, i.e., SC is damaged so delivery should be feasible.  Secondly, the target site where the 
parasitized macrophages are located is accessible but requires site-specific delivery as is 
feasible with conjugates which can ideally be taken up by the Leishmania infected 
macrophages and release the drug within phagolysosomes. It has been reported that the 
macrophages infected with the Leishmania parasite require more glucose as energy source for 
their survival (Hassani and Olivier, 2013; Liu and Uzonna, 2012), therefore polymeric 
polysaccharides such as neoglycoproteins, xanthan and HA could be suitable polymers as these 
polysaccharides can be taken up by the receptor mediated endocytosis using mannose receptors 
on the macrophages. Moreover, Leishmania infected macrophages are rich in a protease 
enzyme called cathepsin, thus requiring a linker that is susceptible to proteases so can release 
the drug of choice within the parasite-phorous vacuole of macrophage. 
 
Scabies caused by Sarcoptes scabiei is another common skin infestation affecting more than 
200 million people worldwide, characterised by intense itching and discomfort for which there 
are various drawbacks associated with treatments.  For example, there are reports of 
neurotoxicity associated with the systemic absorption of topically administered lindane, whilst 
some literature shows the development of resistance against ivermectin in humans (Khalil et 
al., 2017). The main aspects that should be considered when designing a PDC system for 
topical therapy of scabies is to deliver the drug at the site of infestation, i.e. the lower SC of the 
skin (Morgan et al., 2013). The possible solution can be conjugating permethrin, ivermectin or 
lindane with polypeptides or hyaluronic acid (HA) that are proven to enhance the permeation 
of the drug through SC but at the same time preventing the systemic absorption as compared 
to the drug applied alone topically (Witting et al., 2015). 
 
During the last two decades the occurrence of the skin fungal infections has been increasing 
and are increasingly difficult to treat with a growing population of patients with co-morbidity. 
For fungal therapies, conventional formulations are widely used, irrespective of where the 
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fungal pathogen is residing within the skin, i.e., whether in the SC or deeper skin layers.  The 
treatment of deeply seated fungal infections such as invasive aspergillosis and candidiasis is 
problematic. Moreover, the application of ineffective formulations can provoke adverse effects 
including allergic reactions (Kumar et al., 2014). To avoid some of the above difficulties, one 
approach could be to use PDCs with an anti-fungal drug conjugated to a polypeptide or a low 
molecular weight HA, so that it can penetrate into the skin thus releasing the drug at the site of 
the infection.  This may result in avoidance of the side effects associated with the allergic 
reactions on skin. 
 
8.4. Significance of the Key Findings 
To the best of our knowledge, till this date, there is no published work relating to the use of 
PDCs on the intact skin to decrease the permeation of a compound. Thus, this work for the first 
time reports the use of PDC as a drug delivery system to decrease the permeation as well as 
extend the release of the drug, i.e. PMD. The findings in this thesis provides a mean to extend 
this technology, i.e. PDCs to other volatile compounds like perfumes, which can be beneficial 
not only to extend their efficacy (smell) but also to avoid any side effects associated with the 
permeation of volatile compounds as well as it can also be used to avoid any skin irritation that 
normally is associated with abrupt release of the drug once a formulation is applied onto the 
skin. 
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